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Human tissue and biobank research is of increasing importance for understanding the causes of widespread diseases and developing 
effective therapies. However, while the success of biobank research depends 
on the availability of a large number of samples and the consolidation of 
collections across country borders is very desirable from the perspective 
of researchers, the legal and ethical requirements for the procurement, 
storage and use of human tissue samples are rather heterogeneous across 
different countries. Moreover, the lack of comprehensive supranational 
regulation on human tissue and biobanking can be seen as posing a serious 
threat to transnational biomedical research. Against this background, it was 
one of the aims of the EU-funded Tiss.EU project (“Evaluation of Legislation 
and Related Guidelines on the Procurement, Storage and Transfer of Human 
Tissues and Cells in the European Union – an Evidence-Based Impact Analysis”) 
to analyse the ethical and legal regulation of human tissue and biobank 
research across the 27 European Member States plus Switzerland. The 
results of nine international workshops and three conferences are gathered 
in this volume. While the country reports evaluate the implementation of 
ethical and legal guidelines at a national level, point out their strengths and 
deficits, and, where required, create an evidence base for the revision of 
said legislation, the conference reports address more general ethical and 
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The Tiss.EU project – with full title “Evaluation of Legislation and Related Guide-
lines on the Procurement, Storage and Transfer of Human Tissues and Cells in the 
European Union - an Evidence-Based Impact Analysis” – was funded by the Eu-
ropean Commission in the 7th Framework Programme from April 2008 until 
March 2011. Within this project researchers from ten different European countries 
addressed questions of ethical and legal regulation regarding human tissue research. 
For this purpose, they analysed the respective legislation and guidelines in and 
across Europe, evaluating their implementation at a national level, their strengths 
and deficits, and, where required, created an evidence base for the revision of said 
legislation. This was made necessary by the lack of a comprehensive EU regulation 
on human tissue and biobanking, which poses a serious threat to transnational 
biomedical research. The legislation that exists so far covers mainly clinical applica-
tion. 
In order to achieve its goal, the Tiss.EU project organized nine international 
workshops and three International Status Conferences during its three year project 
period, providing a platform for leading experts in the field of human tissue and 
biobank research. This allowed for the gathering of information on the current 
legislation in the 27 EU member states plus Switzerland. The present volume col-
lects the revised reports on these events. Besides this, the documents, in their orig-
inal form, can also be found at the project’s website, www.tisseu.org. One of the 
aims of the Tiss.EU project was the establishment of an information portal freely 
accessible to interested scientists as well as the broader public. The website also 
hosts an extensive database of legal documents, ethical guidelines and scientific 
articles on human tissue and biobanking to facilitate further research in the field. It 
will be maintained beyond the project period. 
During its term, the Tiss.EU project also set up a network of experts in the 




multitude of disciplines, including ethicists, lawyers, physicians, policy makers and 
non-governmental institutions, from the whole of the European Union and Swit-
zerland.  
The organizational structure of the Tiss.EU project was two-layered: on the 
one hand, there was a consortium consisting of the coordinating institution in 
Goettingen (Germany) and the nine academic partners from different EU Member 
States, namely France, Germany, Hungary, Ireland, Italy, Lithuania, Sweden, The 
Netherlands and the United Kingdom. Each partner was assigned a country group 
of two to five EU countries, which reported on the current regulation on human 
tissue and biobank research in their respective countries.1 On the other hand, the 
partners were teamed up in groups of two to three to evaluate the leading ethical 
and legal issues for human tissue research that arose with regard to one of the 





                                                     
1 The country reports refer to a range of legal documents and guidelines on human tissue and    
biobank research. Insofar an English translation is available, these documents are accessible via the 
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The four focal themes2 were: 
1 Procurement, storage and transfer of tissues and cells for non-clinical research purposes  
Scandals in relation to the procurement and storage of human tissue have recently 
undermined public acceptance and trust in the respective research institutions, 
suggesting that if potential donors were to withhold their participation in research 
projects, important biomedical research may run the risk of decline. There is also a 
large discrepancy between the public perception of tissue storage issues and the 
views of medical professionals and researchers, pointing to a need for greater 
transparency. A particular problem is posed by the storage of human tissue that 
transcends clinical purposes and as such is not related to the treatment of an im-
mediate health threat. In cases as these, issues of consent and anonymization rise 
to the fore.  
 
                                                     
2 Cf. Beier, Katharina/Schnorrer, Silvia (2011): Ethical and Legal Aspects of Human Tissue and Biobank 
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2 Rights, interests and entitlements in human tissues and cells  
Among the main issues of this focal theme are questions about the ownership of 
tissue removed from the body, whether they affect source entitlement (for example 
when tumor cells are removed from a patient) or stakeholder interests (for example 
the parents’ interest when tissue is excised from their child post mortem). The 
focal theme also covers issues related to intellectual property rights and addresses 
questions related to the freedom of movement of goods and services within the 
EU. 
3 Anonymisation and pseudonymisation as means of privacy protection  
Standards of pseudonymisation and anonymization of tissue samples may come 
under close scrutiny these days, because many biomedical projects include research 
on the genetic dispositions of patients. This raises important questions touching on 
the subject of privacy and control of personal data. Who should have access to 
donors’ health information, for example? There is a risk that donors may be sub-
ject to disadvantage or discrimination on the basis of disease dispositions.  
4 Biobanking  
It is imperative that mutual ethical and legal standards for the extraction, storage 
and exchange of human cells and tissues be defined, though different standards 
will have to be applied to biobanks that focus on the research and treatment of 
specific diseases, and non-specific and national biobanks (such as the UK  
Biobank). The property problem that arises when tissues and cells are transferred 
from donors to research projects or national and international institutions also 
needs to be dealt with, as a joint ethical and legal regulatory framework is still miss-
ing. 
 
The information obtained through the Tiss.EU workshops and conferences led to 
the drafting of a final recommendation document which covers the most im-
portant issues raised in the course of the project. It is aimed not only at researchers 
in the field, but also at policy makers on a national or European level. The docu-
ment will be published in an international journal in order to reach a broader audi-
ence. 
As has been mentioned above, this volume contains the reports on all the 
workshops and conferences conducted during the Tiss.EU project’s three year 
period, arranged chronologically. The original reports have been slightly amended 
and brought up to date for this edition. With regard to content, the nine work-
shops held in Hanover, Budapest, Paris, Padova, Leiden, Stockholm, Dublin, Bir-
mingham and Vilnius focused on the different focal themes and compiled the 
country reports. The three International Status Conferences (all held in Goettin-
gen, Germany), meanwhile, addressed issues of ethical and legal aspects of human 
tissue research, privacy, confidentiality and personality rights in biobanking and 






final chapter of this volume summarizes the most important results gathered dur-
ing the course of the project with particular regard to the four focal themes.  
The editors wish to thank Katharina Lüttich and Tilman Gunz for their gener-
ous help in preparing the manuscript for publication. 
 
The Editors 
Göttingen, August 2011 
 
 
Ethical and Legal Aspects of  Research with Human 
Tissue in Europe 
First International Status Conference of the Tiss.EU Project 




The conference on ethical and legal aspects of research with human tissue in Eu-
rope was the kick-off meeting of the Tiss.EU project “Evaluation of Legislation 
and Related Guidelines on the Procurement, Storage and Transfer of Human Tis-
sues and Cells in the European Union − an Evidence-Based Impact Analysis”. The 
conference was organized by the project management team Dr Christian Lenk, 
Prof Claudia Wiesemann and Dr Katharina Beier in Göttingen and by the project 
partner Nils Hoppe from Hannover. About 45 people, speakers included, from all 
over Europe took part in this kick-off meeting that lasted from 26-28 June 2008. 
The conference made a first contribution to the overall project aim. In order to 
assess the impact made by European Union’s regulatory activities to date on re-
search in the member states (plus Switzerland) the project will gather and compare 
national legislative instruments and guidelines. To this end the call for papers re-
quested contributions from the following thematic areas: 
 ethical and legal regulations regarding the procurement, storage and trans-
fer of tissue and cells for research;  
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 rights and entitlements to tissue and cells;  
 anonymisation and pseudonymisation to protect privacy rights;  
 ethical and legal aspects of research with biobanks; 
 national regulations in the field of research with human tissue in individual 
EU member states. 
The selection of submitted papers was guided by the intention to cover a prefera-
ble host range of countries in order to get an overview about current ethical and 
legal standards for research with human tissue. On this basis 14 speakers from ten 
different countries have been invited to the Tiss.EU conference in Goettingen. 
Their contributions were assigned to three thematic blocks that naturally featured 
some overlaps. In particular, the first section was set up to grasp the ethical and 
legal challenges of biobanks in theoretical and conceptual terms. The contributions 
within this block provided the framework for the country reports that were at the 
centre stage of the second block “European approaches to human tissue research”. 
The last thematic block was chosen both to provide some future prospects and to 
identify remaining challenges for ethical and legal governance of biobanks.  
2 The contributions 
Part I: Ethical and legal challenges of human tissue research 
After an introduction to the Tiss.EU project given by Dr Christian Lenk and Nils 
Hoppe, the conference commenced with Michael Barilan from Tel Aviv University, 
Israel. His presentation was concerned with the ethics of using human tissues in 
biomedical contexts. In particular, he argued that human body parts that are de-
tached from a living body cannot be protected by natural human rights for the 
reason that a real-time link between personal will and a basic human interest of the 
embodied person is missing. Notwithstanding this, Barilan insisted that the ethics 
of human rights and dignity may bring important lessons to the ethics of using 
human tissues and remains: firstly, human tissues are never morally value-free, i.e. 
they may be used only for specific culturally valuable purposes and only in the 
absence of reasonable substitutes. Secondly, the appropriation of human remains 
requires some form of consent or endorsement as well, since the human body and 
body parts are never “found objects”, to be collected, manipulated and exploited at 
one’s own pleasure. Thirdly, dead bodies or tissues are nobody’s private affair, but 
are always of concern to humanity and to communal ways of respect. Although 
possession of human tissues and human remains may imply elements of property 
rights (e.g. legal rights to sell in exchange for money; legal immunity from dispos-
session) this does not override considerations of human dignity as a public value.  
Ethical and Legal Aspects of Research with Human Tissue in Europe 
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Austen Garwood-Gowers, a senior lecturer of law from Nottingham (UK), fo-
cused his presentation on the current human tissue discourse. He critically ob-
served that governments are often more concerned with tissue use promotion than 
with protecting the individual as an end. The discursive distortions range from the 
misuse of key terms and concepts to “red herrings” which suggest that the law 
allows more use than it in fact does, and “Trojan horses” which suggest that the 
law is achieving respect when it is not. By exploring the relevant issues both from a 
UK and more comparative and international perspective, Garwood-Gowers out-
laid certain tensions between overarching ethical and human rights norms and 
tissue specific discourse, law and practice. He specifically concluded that the exist-
ing international instruments are not applied properly to the field of human tissue 
research yet.  
In accordance with Garwood-Gowers’ observation of governments’ bias to-
wards the use of human tissue, the Director of the “Legal Pathways” Institute in 
Aerdenhout, The Netherlands, Jasper Bovenberg, was concerned with the issue of 
tissue samples and data shipment between countries. As this affects Europe’s abil-
ity to sustain its edge in biomedical research he pinpointed the legal challenges of 
tissue transfer by taking into account the different concerns of stakeholders and 
donors, but also acknowledged concerns couched at an institutional or national 
level. To overcome these concerns Bovenberg suggested thorough informed con-
sent procedures for donors and special sample transfer policies to reassure institu-
tional concerns. Further he recommended, as an answer to national concerns, the 
accomplishment of export controls and highlighted the importance of individual 
“Sample Transfer Agreements” for research projects to meet legal patchwork con-
cerns and to promote a “free movement of samples” in the EU Research Area.  
What the Kantian formula to treat human beings never merely as a means im-
plies in the context of human tissue research was the crucial question addressed by 
Rieke van der Graaf. The researcher from the University Medical Center in Utrecht, 
NL, argued that it includes both, an element of consent and an element of end-
sharing, and made clear that meeting the consent in the Kantian formula is some-
thing over and above asking informed consent. According to her analysis it plays a 
role at a more fundamental level, i.e. we have to ask whether people have sufficient 
reasons to consent to being used in this way. Van der Graaf’s advanced under-
standing of informed consent had several implications for biobank research. First-
ly, the form of consent in the Kantian formula should be regarded as foundational 
to the much-debated broad consent for biobank research. In line with the Kantian 
formula she argued that broad consent does not have to be problematic if partici-
pants have sufficient reasons to give their consent. Second, van der Graaf’s analysis 
shed new light on the issue of re-contacting donors. In particular, she argued that 
even when the donor would not give his or her actual informed consent, one can-
not say that the she is used merely as a means and hence wrongly enrolled. To 
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ensure end-sharing and sufficient reason to consent van der Graaf strongly em-
braced Winickoff’s & Winickoff’s “Charitable Trust Model”.1 
Leen Trommelmans, researcher at the renowned Centre for Biomedical Ethics 
and Law at the University of Leuven, Belgium was also concerned with the donor’s 
perspective. In particular, she focused on the donation of cells for human tissue 
engineered products (HTEPs). In accordance with the guideline on advanced 
therapy medicinal products (which covers HTEPs), Trommelmans argued that cell 
donors may have remaining interests in the donated cells, and may want to protect 
these interests. For the reason that at the moment the main element that orders the 
relationships between the parties in the cell transfer is the informed consent of the 
donor that is obtained before removal of these cells, she asked whether the existing 
provisions for informed consent are adapted to the context of tissue engineering 
and the interests of the donor. In addition, Trommelmans suggested some approa-
ches toward a well-suited informed consent procedure. In particular, she argued 
that the informed consent process in cell donation has de facto a double function: it 
should firstly provide cell donors with the necessary information to decide whether 
donation is in their best interest and/or doesn’t go against deep-seated worldviews. 
But the informed consent equally is instrumental in ordering the transfer of cells 
and defining its criteria. As one conclusion Trommelmans suggested that, as far as 
concerns informing the donor, the current regulation should also cover cell dona-
tion for TE applications that are not intended to be implanted in humans or used 
as extracorporeal applications but that do contain donated cells.  
Part II: European approaches to human tissue research 
Following these conceptual investigations on informed consent, Milena Bister’s talk 
on informed consent practices in Austria opened the second thematic block on 
“European approaches to Human Tissue Research” at the Tiss.EU conference. By 
this she contributed to the ongoing interdisciplinary analysis regarding the question 
of how to deal with informed consent in the mirror of tissue research and banking 
in the European Union. The sociologist presented her findings from a case study 
on the practice of informed consent to medical research on leftovers from surgery 
conducted from April 2005 to February 2007 at the Medical University and Gen-
eral Hospital of Vienna. Contrary to the Human Convention on Biomedicine Aus-
tria allows for “implicit agreement” of the silent patient through a hypothetic in-
terpretation of the contract of treatment between patients and doctors. This ena-
bles hospital staff members to use therapeutically unneeded bodily substances in 
order to fulfil the legally established institutional objectives of teaching and re-
searching. As a result of her investigation Bister suggested an understanding of 
                                                     
1 D. Winickoff/R. Winickoff, The Charitable Trust as a Model for Genomic Biobanks, 349 New 
England Journal of Medicine 12: 1180-1184 (18 September 2003). 
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informed consent as a “boundary object” (Star and Griesemer 1989)2 between 
medical professionals and donors. This means that informed consent as such 
might be better understood as an appropriate tool to satisfy divergent interests in 
the medical encounter than as a tool for patients’ empowerment. Bister argued that 
the different motives for both obtaining and giving consent she observed in her 
studies account for the contemporary unchallenged practice of informed consent. 
Bister’s interpretation of Austrian informed consent practices was followed by 
Bianka Dörr’s investigation on the Swiss legal and ethical situation for human tissue 
research. As to date there is no specific legislation on Federal level in Switzerland, 
but the very influential guideline on biobanking from the Swiss Academy of the 
Medical Sciences from 2006. By now, the Swiss authorities have recognized the 
need to take action in this field. As early as in 2006, first preliminary drafts of a 
Federal Law on Research with Humans (Humanforschungsgesetz) were presented. 
Against this background Dörr examined the present and prospective legal frame-
work for research on biological material and personal data in Switzerland. She 
ended with a ventilation of the question of the legal qualification of bodily sub-
stances under Swiss law and pointed at a new dualistic approach of property and 
personal rights. She concluded that the Swiss regulations are a first step forward 
towards finding a balance between the personal rights of the donors, the interests 
of research and the third party interests. 
 
Bianca Dörr:  Characterization of the Regulative Approach of the Swiss Acade-
my of the Medical Sciences (SAMS) 
 
The text of the guidelines is based on the premise that transparent rules strengthen 
trust in research in the long term and increase the readiness of potential donors to 
donate bodily substances. The biobank guidelines aim to consider both the present 
national and international framework and the essential principles of bioethics (au-
tonomy, welfare, justice). The guideline text is specially designed to balance indi-
vidual rights against research interests. It contains, therefore, provisions for the 
protection of the human dignity and privacy of the donor as well as for quality 
control in the operation of the biobank. All research projects which may directly 
affect the donor of biological material require the formal approval of the relevant 
ethics commission for clinical trials (SAMS 2006, 4.1). 
 
Source: Citation from manuscript text 
 
In the same vein Virginie Commin from the Centre National de la Recherche Scien-
tifique, Paris, investigated the French legal framework for human tissue research. 
                                                     
2 Star, S.L. and Griesemer, J.R. (1989): Institutional ecology ‚translations’ and boundary objects: 
amateurs and professionals in Berkeley’s Museum of Vertebrate Zoology, 1907-39. Social Studies of 
Science, 19, 387-420. 
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Although the French law does not name biobanks expressly, the legislator provid-
ed them recently with a relatively interconnected legal framework. Commin fo-
cused her analysis on the technical specific rules related to the activities of bio-
banks (on which conditions a biobank can be established, on which conditions 
samples can be given thereto) and pointed out that there is an application of the 
big principles of “French-style” bioethics: “non property” principle, informed 
consent and data confidentiality principles. According to Commin’s judgement the 
French legislator grasped and answered the main part of the questions raised and 
so paved the way for a sustained activity of biobanks in France. In spite of this 
dense legal framework, she made also clear that the French law did not succeed in 
covering all the questions arising from the practices of biobanks, notably the rights 
of the donors such as an on-going control on the use of biological material and 
associated data they gave for research purposes, as well as researchers’ right to 
access biobanks and current issues related to ownership. 
 
Commin & Noiville: Specific Legal Rules for Biobanking in France 
 
“No property” principle is expressed in a strong way by the Civil Code since 
it is incorporated three times and that these provisions are public order rules: 
“Human body, (and also its body parts and products) cannot  be subject matter of  
a property right” (article 16-1 paragraph 3 of the Civil code). 
 
Informed consent principle related to the collection of human body ele-
ments and products is provided by article L1211-2 of Health Public code. It is a 
sine qua non condition which is required prior to the collect of human body sample 
for a medical or scientific use. 
 
Data confidentiality principle is set out in Loi Informatique et Libertés (Act re-
lative to computers, files and liberties) of the 6 January 1978 and modified the 6 
August 2004. Schematically, this principle is organized around three actions that 
the researchers must comply with: an application for data access to the Commission 
Informatique et Libertés (CNIL), an independent administrative authority protecting 
privacy and personal data; information of the donor who can object to his data 
processing and finally data coding. 
 
Source: Citation from manuscript text 
 
Paola Parente from the Catholic University of the Sacred Heart, Rome, closed the 
first conference day with an overview about the ethical and legal aspects of the 
collection and storage of human biological material in her country. She pointed out 
that in Italy there is a lack of specific rules and regulations concerning this field of 
research, which also leaves the definition of biobanks to guidelines. However, bio-
banks have been studied by the National Committee for the Biosafety and Bio-
Ethical and Legal Aspects of Research with Human Tissue in Europe 
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technologies, which presented guidelines for biobanks’ setting and accreditation 
(2006). The Committee also endorses a uniform legislation on biobanks in the light 
of promoting a new way of solidarity between groups and generations based on the 
voluntary sharing of sample and information for a common resource. Notwith-
standing this, there is a need for deeper reflection on the limits of the intervention 
and manipulation of the human biological sample to guarantee human dignity and 
rights and, at the same time, the own needs of the research. Due to Parente this is 
particularly necessary because of the different ways of regulating privacy with dis-
similar standards of safety in each country. 
 
Spagnolo, Daloiso & Parente: Relevant Legal and Ethical Documents in Italy for 
Biobank Governance 
 
All relevant data concerning the drawing and storage of human biological sam-
ples in the Italian law have been evaluated in:  
1. the DPR 285/90 art 41 c. 2 concerning the Mortuary Policy Rules: “drawing 
and storage of human samples, from foetus too, should be allowed by the local 
authority …”;  
2. The Penal law, article n. 413: “Whoever makes a dissection on a cadaver or 
on its part even with scientific or didactic purpose when it is not allowed will be 
punished with imprisonment till 6 month and a fine of…”;  
3. The Constitution of the Italian Republic in the article 32: “The Republic 
safeguards the health as a citizen’s fundamental right and as social interest […] 
Nobody should be forced to accept a medical treatment […] and the law will never 
break human rights”;  
4. The Italian Code of Medical deontology (2006), Art.12, 20, 35, 40, 41. 
Furthermore, some main national organizations and foundations have drawn 
up specific guidelines: “Guideline for biobank setting and accreditation”, “Guide-
line for biobanks certification” by the National Committee for Biosafety and Bio-
technology (Ncbb) and “Biobanks and research on human samples” by the Na-
tional Committee for Bioethics (Ncb). 
 
Source: Citation from manuscript text 
 
Part III: Governing human tissue research – future perspectives 
As the first speaker of the second conference day, Bardhyl Cipi, Professor and Head 
of Department of Forensic Medicine and Medical Ethics Sector in Tirana, Albania, 
completed the second block of country reports by bringing in a South-East-
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European perspective. In his talk he admitted that problems of human tissues and 
cells have not yet been addressed in Albania. Consequently the biotechnical achie-
vements of developed countries could be used, or even misused in Albania, as 
already happened elsewhere − there were several medical scandals. As a concrete 
example Cipi referred to the trafficking of human organs that might also affect the 
handling of human tissue for research purposes. In his conclusion Cipi thus point-
ed out that the problems arising from the extraction of human tissue and cells, but 
also organ transplantation etc. should be known in Albania, but are not mirrored in 
proper legislation yet. 
The sociologist Susanne Weber from the renowned ESRC Centre for Genomics 
in Society at the University of Exeter offered a comparative analysis in a specific 
field of human tissue research. In particular, she investigated how the transposition 
of the EU tissue directives into the national regulatory frameworks of Germany 
and the UK are beginning to shape clinical research using autologous stem cells. 
According to Weber, autologous stem cells represent a particularly interesting case 
study for an analysis of the implementation of EU tissue regulation and the fram-
ing of clinical research, because – although autologous stem cells are considered 
ethically unproblematic – the integration of the EU Directive equally varies across 
countries. Whereas Germany has adopted a framework which predominantly treats 
autologous stem cells akin to medical products, the UK has implemented a two-
tier framework. As a sociologist Weber called for a close consideration of the ex-
changes between actors and systems of governance in defining and shaping regula-
tory practices and drawing legitimacy from them. She also took up the question of 
harmonisation and concluded that standardization is necessarily produced locally 
spreading out into broader biomedical networks of scientific, medical and norma-
tive exchange.  
Nadja Kanellopoulou, researcher at the Scottish University of Edinburgh, was the 
first speaker of the third thematic block, which was set up to focus on the chal-
lenges for biobank governance. Kanellopoulou discussed the normative assump-
tions and paradoxes in the regulation of the use of human biological material for 
the purposes of biobanking research in the UK. She pointed out that research 
initiatives, such as UK Biobank, operate as resources for the public good. Analysis 
of their guiding principles and policies for access and benefit sharing, however, 
reveal critical questions as to whether these reflect anxieties about research ac-
countability and use. According to Kanellopoulou these questions are linked to key 
“control dilemmas”, situated at the heart of the balance between participants’ pos-
sible entitlements and the public interest. As public concerns are affected by in-
creasing awareness of the value of human tissue in modern research, she asked 
how the documented shifts of tissue biovalue might affect public willingness to 
contribute to research. Above all, she critically examined current regulatory em-
phasis on altruism and genetic solidarity in the UK, in the light of emerging trends 
for reciprocal research models, and in pursuit of better criteria for responsible 
biobanking. Her deliberations led up to the crucial question whether it is sustaina-
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ble to regulate research on the basis that participants do not see value nor retain an 
interest in how research samples are used, or the information they contain. Kanel-
lopoulou concluded that there is a need for an optimal balance between such inter-
ests and considerations of social responsibility and moral obligation in research 
participation. Consequently the role of law will have to be placed in a broader so-
cial, ethical and economic context.  
David Hunter, lecturer in bioethics at the University of Ulster, Northern Ireland, 
focused on the rather institutional issue of Research Ethics Committee involve-
ment as it is foreseen in the UK Human Tissue Act (HTA) 2004. Given the fact 
that the HTA does not represent a principled approach but instead a pragmatic 
approach which balances off several different ethical considerations, Hunter noted 
that much of the more difficult decisions are left to the Research Ethics Commit-
tees (RECs). In particular, it is now the role of RECs to decide whether research 
can be carried out using human tissue where no consent was given for the use of 
this tissue in research. Likewise RECs are charged with approving of human tissue 
banks which then need no further ethical approval to carry out research solely 
using tissue from that bank. However, according to Hunter there has been little 
guidance so far in regards to the decisions these committees must make. For this 
reason he delineated these decisions and offered some philosophical guidance to 
RECs in making these decisions. 
Given the fact that pathologists are responsible for the selection and availabil-
ity of human tissue specimens for diverse academic purposes – an activity which 
has generally taken place in an ill-defined ethical and legal framework – the Ger-
man pathologist Christoph Brochhausen analyzed the German, British and European 
regulations regarding secondary use of human tissue. Whilst the Royal College of 
Pathologists in London made specific suggestions for the handling of tissue ar-
chived after therapeutical or diagnostical resection, in Germany several laws and 
regulations touch on the subject of archived tissue, but no specific regulations exist 
concerning the handling of already archived tissue. As Brochhausen pointed out, 
there is uncertainty about the feasibility of the academic use of surplus tissue. 
Against this background he concluded that adequate informed consent is needed 
for the secondary use of surplus tissue samples. In fact, pathologists should be 
pro-active in the discussion about the framework for the academic use of archival 
material. Based on the comparison of German, European and British regulations 
Brochhausen further suggested solutions for a formalized informed consent as 
concerns the additional use of human tissue samples. 
 
 




This detailed summary of conference talks is evidence of the complex examination 
of ethical and legal challenges of human tissue banking carried out at the first 
Tiss.EU conference. Notwithstanding this broad topical spectrum of the contribu-
tions, some overall results appear that should be highlighted here.  
First, it has to be noted that the notions of human dignity and respect as well 
as its practical implications need to be clarified in the field of human tissue re-
search. Conceptual suggestions as they were made by Barilan, Garwood-Gowers 
and van den Graaf pave the way towards an advanced understanding of the ethical 
implications of using bodily materials for research purposes. Their discussions 
made clear that in order to respect the human body as well as its removed parts, 
there have to be adequate rules and responsibilities. To meet this challenge Michael 
Barilan called for a stronger communitarian approach in deciding on human tissue 
usage. A “Charitable Trust Model” as has been envisioned by Rieke van der Graaf 
seems to be in line with this. A need for revisions can also be documented for the 
concept of informed consent in order to match the specific features of biobanking. 
Those contributions that dealt with the issue of informed consent revealed that not 
only the practices of informed consent vary from country to country, but that its 
functions are also interpreted differently. Whether broad or rather specific consent 
requirements should be valid or what kind of information needs to be given de-
pends on the stakeholders’ interests involved in human tissue research. In this 
context, the majority of speakers critically noted that the role of the donor is still 
underexposed and too much is overlooked from a rather institutional perspective. 
However, there was no consensus on the means of an increasing donor empow-
erment. In one of the discussions the Tiss.EU project partner Judit Sándor, former 
Head of the UNESCO Bioethics Section, also called for more cultural sensitivity in 
the understanding of informed consent practices, especially in those countries with 
different ethnicities.  
The country reports on the ethical and legal circumstances for human tissue 
research in different European countries that have been at the centre stage of the 
second block revealed immense variations concerning scope and level of biobank 
regulation. Whilst some countries as France or the UK passed already laws on 
human tissue use, others, like Albania, still miss authoritative rule. To bridge this 
regulative gap in Europe means to set a task besides harmonization requirements. 
Furthermore, based on the country reports one can hazard two guesses about the 
future development of tissue regulation: firstly it can be expected that the devel-
opment of tissue law necessarily interacts with existing ethical guidelines in this 
field, i.e. the so called soft law, and will also have to take societal discourses into 
account as they have been encouraged in the UK or Switzerland in order to match 
expressed concerns. Secondly, there is some evidence that as a consequence of 
critical assessments the current law on human tissue research will be subject to 
revision (e.g. in France). This fact strengthens the Tiss.EU project’s aim to provide 
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an overview on existing regulatory approaches as this might provide a valuable 
resource for comparison and improvement in the field of human tissue law.  
 
 
Rights and Entitlements in Human Tissue and 
Cells 
First International Workshop of the Tiss.EU Project 




The first international workshop within the Tiss.EU project was organized by the 
project partner Nils Hoppe from Hannover. The workshop’s main topic was one 
of the four Focal Themes of the Tiss.EU project, “Rights and Entitlements in 
Human Tissue and Cells” (Focal Theme B). In addition, the workshop’s regional 
focus was on the regulation of human tissue research in the countries of Austria, 
Switzerland and Germany. Due to this focus the academic background of the in-
vited speakers was mainly in law. The debate on legal aspects of human tissue us-
age was completed by contributions issuing matters of practical application of 
human tissue for research.  
2 The contributions 
The workshop started with a general introduction to the Tiss.EU project given by 
Christian Lenk as representative of the coordinating institution in Goettingen. In his 
presentation he gave a review on the most pressing ethical questions evoked by 
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human tissue research. Against this background, Nils Hoppe delineated the major 
legal challenges in this field. In particular, he called for a clarification regarding the 
following three aspects:  
 Firstly, the relationship between research and therapeutical applications of 
human tissue is highly controversial since only the latter is covered by an 
EU Directive (2004/23/EC) so far. However, an examination of this Di-
rective is expected to provide valuable insights for the pending regulation 
of human tissue research. 
 A second challenge concerns the legal status of tissue and cells. Whereas 
there is a far-reaching consent among the European countries that the 
human body cannot be conceived in terms of property (res extra commerci-
um), this does no longer hold true regarding its separated parts. As a mat-
ter of fact, technically processed tissue is considered a medicinical product 
in Germany. This amounts to questions such as whether research facilities 
can rightfully claim property rights on extracted tissues and cells and how 
such claims might be reconciled with the personal rights of donors to sus-
tain the disposal of their bodily materials. 
 Closely connected is the issue of commercialization, which needs to be 
distinguished from mere economization of human tissue usage. In this 
context Hoppe called attention to an obvious contradiction: Whereas the 
prohibition of commercialization regarding the human body precludes 
profits on the side of the donor, this is not equally true for researchers or 
other users of human tissue. 
In view of these challenges the British jurist José Miola (University of Leicester) 
stressed the need for an improved regulation of human tissue research. In particu-
lar, his talk was concerned with a comprehensive analysis regarding the consent 
provisions of the British Human Tissue Act. Miola related to several human tissue 
scandals in British hospitals that preceded the enactment of the Human Tissue Act 
in 2004. Since human tissues were used without asking for the donors’ consent, the 
Human Tissue Act was expected to serve as a punishment to medical misconduct 
and as such was strongly challenged by the medical profession. Due to this argu-
ment, the Human Tissue Act came about as compromise that encounters not only 
criticism from the research community being in favour of preferably unhampered 
research conditions, but also from those who insisted on stricter consent provi-
sions. According to Miola’s evaluation, the consent requirements of the Human 
Tissue Act remain unsatisfactory in several respects. Firstly, the medical profession 
has been successful in lobbying for a “general consent”-provision instead of the 
originally foreseen specific consent regulation. Secondly, the Code of Conduct 
which has been released by the Human Tissue Authority as “guidance” to the 
Human Tissue Act appears somewhat less strict: For example, a failure to follow 
its stated rules is not regarded a criminal offence. Thirdly, Miola called attention to 
legal loopholes like in the case of already existing tissue collections as there is still 




the possibility to use them without the consent of the donor. However, as “the 
proof of the pudding is in the eating”, Miola regarded it premature to conclude the 
failure of the Human Tissue Act at the present point of time, but rather argued for 
an ongoing review of the Act in terms of its adequacy in regulating human tissue 
research. 
Due to the regional focus of the workshop the jurists Jürgen Simon (University 
of Lüneburg), Bianka Dörr (University of Zurich) and Markus Kastelitz (University 
of Hannover) informed about the legal regulation of human tissue research in 
Germany, Switzerland and Austria, their contributions revealing some major con-
cordance. In contrast to Great Britain, human tissue research is subject to a rather 
fragmented jurisdiction in these three countries, comprising transplantation-, trans-
fusion-, drug- and funeral laws. According to Jürgen Simon, this necessarily leaves 
severe loopholes: Whereas the funeral laws of the German “Bundesländer” are 
pertinent to body parts of dead persons, the legal status of materials from living 
human beings remains unacknowledged. Another problem relates to bodily materi-
als removed in surgeries: as these may be transformed into systematic tissue collec-
tions they can no longer be declared simply as “waste.” According to Markus Kas-
telitz, the situation is not much clearer in Austria. Whereas one side argues that 
hospitals obtain a property right in tissues extracted in surgeries, the Austrian Su-
preme Court ruled out the possibility of taking tissues from dead persons without 
their former consent. The Austrian enactment of the EU tissue directive 
2004/23/EC does not provide for further clarification either. Restricted to thera-
peutic applications, it is by no means clear what it means for research in human 
tissue. Simon as well as Kastelitz thus argued for a comprehensive tissue research 
law that should furthermore include regulations for the usage of tissues from living 
donors. The Swiss draft for an all-encompassing research law even exceeds this 
requirement, but since the law will be enacted earliest in April 2009, an assessment 
whether human tissue research will be sufficiently regulated by the awaited “Hu-
manforschungsgesetz” is still outstanding. However, in view of the Human Tissue 
Act, according to Miola, it is at least doubtful whether a comprehensive law is per 
se superior to a fragmented regulation.  
Regarding the legal status of bodily materials, the three speakers widely agreed 
that the usage of human tissue is a matter beyond property law in their countries; 
yet as soon as tissue has been separated from the human body, the “source” of this 
material can claim a de facto property-right. According to that, it was stressed by 
Dörr that this dualism evokes the question how the transformation of human tis-
sue and cells into quasi-property can prevail without risking a substantial loss of 
personal rights. In spite of far-reaching concordances between Germany, Switzer-
land and Austria, the workshop also revealed some differences, for example in the 
transplantation laws. Whereas these regulative differences might affect the usage of 
tissue for therapeutic purposes, according to the participants’ unisonously voiced 
opinion there is nevertheless no such impact to be expected on the future regula-
tion of research with human tissue. 
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The need for a coherent regulation of human tissue research was also stressed 
by two contributions from a rather practical point of view. Michael Harder, who is 
the managing director of “corlife” – a private company that was founded as a spin-
off of Hannover Medical School in 2006 –, provided valuable insights into one 
among many possible applications of human tissue for research. “Corlife” special-
izes in implants for cardiovascular therapies based on tissue-engineered matrix 
composites. When integrated into the patient's body they become indistinguishable 
from the patient's own tissue. In his talk, Harder particularly focused on the pro-
duction of heart valve replacements by matrix transplants for the reason that the 
legal status of these very materials is unclear: they can neither be regarded as tissue 
nor organs. According to Harder, although these matrices are of human origin, 
they should be seen as medicinical products that by definition do not undergo 
industrial manipulation. However, as R&D activities are not covered by consent 
provisions in Germany yet, “Corlife” currently imports heart valves from the US in 
order to be “on the safe side”. Given the fact that the heart valve replacements are 
meant for the European market at the end of the day, several participants voiced 
their discontent with this practice. As a second matter of practical importance, Ralf 
Heyder (Referent of the German Association of University Hospitals) cautioned 
against the currently prevalent demonization of profit in the field of human tissue 
research. Bearing in mind that all kinds of tissue usage incur costs, profit should 
not be prima facie excluded; according to Heyder, there should rather be a thor-
ough distinction between legitimate manners of economization and illegitimate 
practices of commercialization. Whereas he considered it ethically ineligible to 
profit from the neediness of patients, it is by all means justified to use profit as an 
incentive to encourage ethically desired behaviour. In particular, Heyder recom-
mended a sufficiently implemented profit system to promote innovation and effi-
ciency. Against this background, he specifically argued for an adequate reimburse-
ment of hospitals undertaking transplantations as a means to overcome the short-
age of organs and tissues that results from the currently insufficient remuneration 
in Germany. 
The talk of the legal researcher Marcello Corrales (University of Hannover) on 
the European database directive highlighted that human tissue research is also 
challenging the present EU legislation. In particular, he pointed to the fact that 
genetic databases are not covered by the EU database directive yet. Starting from the 
premise that IP rights might be rightfully claimed for genetic databases too, this 
might not only pose obstacles to the researchers’ access to a certain database, but 
the “creative investor” of the database could even obtain a de facto-monopoly on 
certain data. In addition, Corrales highlighted the fact that the database directive 
might come into conflict with the individual’s right to access her personal data. 
 
 





In summary, the contributions and discussions at the workshop in Hannover rein-
forced the exigency to address the legal challenges of human tissue research thor-
oughly from an inter-European perspective. In particular, the country reports of 
this workshop revealed fundamental questions of human tissue research that are 
only partly answered by national or EU law. Accordingly, all speakers articulated 
their regret that human tissue research is not covered by an own legislation so far. 
Notwithstanding this, the three country reports pointed to important aspects of 
the current legislation on human tissue deserving further scrutiny. For example, in 
the case of Germany, Jürgen Simon called attention to the fact that funeral and 
pathology laws are even divergent between the federal legislations in the German 
counties. However, the existing concordances between the German, Austrian and 
Swiss legal approaches display a promising starting point for further legal adjust-
ments within the field. This prospect is additionally reinforced by the fact that even 
Switzerland as non-member state of the European Union takes pains to adjust its 
legislation to EU law in certain fields. In particular, the workshop revealed the 
following common features: 
 In compliance with the European Bioethics Convention (art. 21) all three 
countries regard the legal status of the living human body as res extra commerci-
um and follow the non-commercialisation principle of the human body and its 
parts.  
 Regarding separated body material all three countries acknowledge a property-
like right of the potential donor on these materials. After the separation, a 
transfer of property is possible with the donor’s consent.  
 The three countries stand in the tradition of the personality right and interpret 
the right of a person or this person’s relatives to control the further use of 
body material as related to the personality right or the “continued personality” 
of a deceased person.  
 In Germany and Austria, proposals have been brought forward that required 
consent is not necessary in case of research with anonymised tissue samples. 
However, most of the projects in the field of tissue research use pseudony-
mised samples.   
 There are similarities in the current national recommendations on biobanking 
of the three examined countries, for example the referral that donors who par-
ticipate in biobank research should be informed about findings with personal 
diagnostic or therapeutic relevance (Switzerland) or findings which are essen-
tial to life (Austria, Germany).  
The obvious differences between the British legal approach and the human tissue 
legislation in the three examined countries propel the Tiss.EU project’s aim to 
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further examine whether there are other clusters of countries following a similar 







Anonymisation and Pseudonymisation as Means of 
Privacy Protection 
 
Second International Workshop of the Tiss.EU Project 
Budapest, 6-8 April 2009 
 
Petra Bárd, Judit Sándor 
1 Introduction 
The second international workshop within the Tiss.EU project was organized by 
Judit Sándor and Petra Bárd from the Centre for Ethics and Law in Biomedicine 
(CELAB) at the Central European University (CEU), Budapest, Hungary. It 
focussed on one of the four Focal Themes of the Tiss.EU project by addressing 
questions of “Anonymisation and Pseudonymisation as Means of Privacy Protec-
tion” (Focal Theme C) in relatively unexplored jurisdictions of Central and Eastern 
Europe such as the Czech Republic, Hungary, Slovakia and Romania. Due to the 
interdisciplinary nature of the workshop’s subject, invited speakers represented a 
wide range of disciplines such as law, medicine, philosophy and information tech-
nology.  
The structure of the workshop followed a two-track approach: on the one 
hand speakers presented their countries’ regulatory framework and existing prac-
tices concerning anonymisation, and on the other scholars addressed various relat-
ed theoretical concerns and problems. Emphasis was put on the geographical 
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scope of the workshop: invited were not only experts to summarize the related 
legal rules in their own countries, but also scholars from Central Eastern European 
jurisdictions to address the theoretical issues.  
The substantive part of the workshop started with general presentations fram-
ing the issue of anonymisation and pseudonymisation.  
As a first speaker, Christian Lenk as representative of the coordinating institu-
tion University Medical Center Goettingen greeted the audience and emphasized 
the special importance of personal data and genetic data in ethics and law in his 
introductory remarks. In particular, he asked whether common standards of ano-
nymisation in medical research can be obtained and how the privacy of and control 
over medical data can be secured.  
Judit Sándor, CEU professor and Director of CELAB, representing the host in-
stitution of the workshop, gave a thorough analysis mapping anonymity issues. She 
made reference to different areas of life and illustrated her point on the importance 
and diverse nature of anonymity with examples from different branches of law. 
She also drew attention to a perceived relation between anonymity and altruism: 
according to this view, the ultimate form of altruism is the total absence of a per-
sonal relationship, like in the case of an organ donation between complete 
strangers, where the identity of the donor and recipient is hidden through anony-
misation. In the special case of biobanks, however, she was sceptical as to whether 
altruism can be presumed on the side of the gene donor, especially since biobanks 
are combinations of research and commercial enterprises. Sándor also emphasized 
the divergent functions and the lack of a uniform definition of anonymisation in 
both international instruments as well as Hungarian pieces of legislation.  
The keynote speech, delivered by Bernice S. Elger, professor at the University of 
Geneva, Switzerland, went into the clashing interests, the importance of bio-
banking and that of privacy protection. According to her, the ethical and legal 
framework for genetic research with human tissue is currently not well defined. In 
particular, she stressed that terminology varies widely concerning different degrees 
of anonymisation. The exact definition and understanding of anonymisation is 
important for sample donors, researchers and ethics commissions for several rea-
sons: it not only informs about the degree of protection and risks to confidentiali-
ty, but in most jurisdictions, it also influences the type of required consent to be 
obtained from sample donors. In the remainder of her presentation, Elger ex-
plored ethical, legal and practical problems related to anonymisation and pseudon-
ymisation. In particular, she argued that complete anonymity is difficult to obtain, 
which leads to the predominant use of linked anonymisation. Following Elger, 
anonymization does still not mean that researchers are free of obligations to obtain 
consent. Rather, consent should be as specific as possible; only for future research 
(provided a Research Ethics Committee’s approval) it might be acceptable to allow 
for general consent. In the end Elger strongly recommended to discuss the differ-
ent regulatory frameworks at an international level in order to pave the way for a 
better harmonization of standards. 




The second session opened with a presentation by Ants Nõmper, senior lecturer 
at the University of Tartu, Estonia, who presented his thoughts on autonomy by 
referring to the Estonian population databases. Estonia is of particular interest to 
researchers in the field of bioethics, and especially to those interested in biobank-
ing. As Nomper pointed out, Estonia has provided controversial innovations in 
this field. Firstly, in 2000, it adopted a regulation on population biobanks that gov-
erned the usage of medical and genetic data and tissue samples of volunteers. Vol-
unteers were asked to give an open consent that justified not only the collection of 
data and tissue samples but also an almost unlimited usage thereof in the future. In 
2007, Estonia abandoned the consent requirement altogether and established its e-
health project, in which participation is mandatory for each patient in Estonia, on 
the possibility of close access to data for third parties. Nomper’s presentation also 
shed some light on the considerations behind both innovations and provided an 
update regarding the progress of these projects. He concluded his presentation by 
suggesting that autonomy could be enhanced by better access control, more accu-
rate data and a higher level of data protection. 
Josef Kuře, Professor at the University Centre for Bioethics and Department of 
Medical Ethics, Masaryk University in Brno, Czech Republic, talked about the 
ethics of biobanking. According to Kure, biobanking represents not only new pos-
sibilities in health care but also new challenges for governance framework(s) on the 
level of both, ethical reflection and legal regulation. In his presentation, starting 
with the informed consent concept and its application for various forms of bi-
obanking, he provided a short overview of ethical aspects of biobanking. Amongst 
others, he argued that samples and data should be distinguished. Attention was 
also paid to concerns about some common research practices, including data avail-
ability, specific issues involving research without adequate consent, privacy, the 
commercialisation of biobank research and discrimination. In the end, Kure envi-
sioned some possible future scenarios. The understanding and safeguarding of pri-
vacy and confidentiality may remain the same, or may be slightly altered in the fu-
ture. Possible divergences may also take two directions: on the one hand we might 
move towards a strong privacy and confidentiality protection model, or towards 
abolishing privacy and confidentiality as we understand them today. 
2 Country Reports: Slovakia, Czech Republic, Hungary, 
Romania 
The first target jurisdiction to be addressed was Slovakia. Professor Jan Koller from 
the Central Tissue Bank, University Hospital Bratislava, addressed traceability re-
quirements and privacy protection in Slovakian tissue and cell establishments. Star-
ting his presentation with EU imperatives, Koller stated that since 2004, three 
European Directives (23/2004/EC, 17/2006/EC, 86/2006/EC) on setting stan-
dards of quality and safety for the donation, procurement, testing, processing, pre-
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servation, storage and distribution of human tissues and cells have been adopted 
by the European Parliament and Council and the European Commission. In addi-
tion to safety and quality measures for human tissues and cells for use in humans, 
the Directives contain requirements on protection of human rights and privacy, 
assurance of confidentiality of any health related information, full traceability of 
donations and distribution of tissues and cells as well. The EU Member States have 
been obliged to implement the Directives into their national regulations (Slovakia 
did so at the end of 2007). The Competent Authority for tissues and cells in Slova-
kia is the Ministry of Health. The donation and transplantation system in the 
country is coordinated centrally by the Slovak Center for Organ Transplantations 
(SCOT). Since the beginning of 2009, a new centralized computer information 
system has been established in the country in order to assure confidentiality and 
privacy protection as well as full traceability of organs, tissues and cells and related 
products.   
The SCOT uses a validated electronic system, the so-called Transplantation In-
formation System Slovakia (TISS) presented by Daniel Kuba from the Slovak Cen-
tre for Organ Transplantation and professor at the Slovak Medical University Bra-
tislava. Kuba first explained the organization and structure of the Transplant Net-
work in Slovakia. The initial requirements for TISS at the development phase were 
accessibility through web application; the existence of a national central infor-
mation system; organ procurement and transplantation data management; tissue 
and cells procurement, processing, storage, allocation and transplantation data 
management; the traceability and safety of recipients at the same time; whilst the 
legal requirement was the implementation of EU law and the adoption of relevant 
national pieces of laws. After giving an insight into the technical details of the sys-
tem, Kuba continued by stressing the importance of safety for both, the hardware 
and basic software level. He emphasized that traceability and privacy protection are 
the most important issues of safety in the transplantation chain. Although these 
two requirements might seem contradictory, efforts should be made to harmonize 
them. In his view the new information system could become a tool through which 
these two requirements can be reconciled. 
Lukáš Prudil, Associate Professor at the Department of Social Medicine and 
Health Care Administration, Masaryk University Brno, Czech Republic, presented 
a country analysis on the Czech Republic. Prudil addressed different aspects of 
human tissue and cell usage in the Czech Republic: in particular, he explained the 
legal background including its international aspects regarding the usage of tissues 
and cells for research purposes, usage of tissues and cells for purposes other than 
research (e.g. transplantation), research on human stem cells, creation of databases, 
and data protection issues. The Oviedo Convention, for example, has become part 
of the Czech Law by being incorporated into Act 96/2001. However, as Prudil 
explained, there is no unique legal document covering research and usage of hu-
man tissues and cells in the Czech Republic. Instead there is a diffuse legal regula-
tion in this field due to a missing conceptual approach and an unreasonable divi-




sion of competencies among state bodies. To find a real legal regulation of this 
issue is thus like solving a puzzle. However, according to Prudil, the most probable 
legal solution is conformity with international obligations. 
István Peták from the Hungarian Biotech Association, KPS Molecular Treat-
ment Solutions and the Semmelweis Medical University presented the Hungarian 
country analysis, wherein he emphasized the importance of a uniform regulatory 
framework. Concerning the recent Hungarian legislation on human tissue research, 
Act No XXI of 2008 on the “Protection of human genetic data, human genetic 
tests and research and biobanks”, which defines a biobank as a “collection of sam-
ples containing genetic samples and related genetic and personal identification data 
for the purposes of a human genetic study or human genetic research under this 
Act”, is of major importance. According to Petak, however, a number of questions 
remain open, for example whether storage of biological material without DNA or 
RNA for research purposes satisfies the definition of a biobank, or whether in-
formed consent for unforeseen research purposes is sufficient in a long-term per-
spective: can one ask for general consent, and if so, how general can the consent 
be, etc. Furthermore, he pointed to the review and authorisation practices by ethi-
cal committees, which can make up for the necessary and by nature incomplete 
donor consent. In Hungary, for non-invasive, non-interventional medical research 
studies either a local ethical committee or the Scientific and Research Ethics 
Committee (ETT-TUKEB) grants approval. The former decides on research pro-
jects done without genetic studies conducted by one single institute, whilst the 
latter decides if multiple institutes or registered biobanks are involved or if human 
genetic studies are carried out.  
Zoltán Alexin, senior lecturer at the University of Szeged, Department of Soft-
ware Engineering, addressed the specific topic of the workshop, anonymisation of 
health care data in Hungary. According to him, the essence of the private sphere is 
that no one can intrude into it against the data subject’s will. If an unwanted intru-
sion takes place, this violates not only the right to privacy, but also the right to 
human dignity that includes the right to self-determination and the right to full 
bodily and personal integrity. Furthermore, Alexin underlined that Hungary is con-
siderably late in implementing the internationally accepted ethical principles con-
cerning medical research involving human subjects. An ethical review and approval 
for invasive research projects are legally obligatory since 2002; for non-invasive 
research since March 2007. However, as he pointed out, even today, some research 
is still done without ethical review. In fact, any ethically approved retrospective 
database research can be done without informing the participants and without 
obtaining their consent. Within this legal framework an expressly progressive step 
was made by the adoption of the Act on the protection of personal genetic data, 
on human genetic examinations, research and biobanks in 2008. In his presenta-
tion, Alexin also discussed some elements and deficiencies of the Hungarian legal 
system in connection with the ethical and data protection rulings. In particular, he 
criticized the current anonymisation methods by contending that neither the 
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American HIPAA guideline nor pseuonymisation provides a secure method to 
cease the connection between the data and the data subject. For this reason he 
pointed to a solution proposed by Johannes Gehrke (Cornell University), who 
advised a slight distortion of data, which would ensure the anonymity of the data 
subjects.   
Ioana Berindan-Neagoe, Head of Functional Genomics Department, and Assis-
tant Professor of Immunology from the Cancer Institute “Ion Chiricuta” Cluj 
Napoca Romania, addressed the issue of tumour banks and their use in functional 
genomic studies in Romania. She referred to Law no. 677 of November 2001 for 
the protection of individuals regarding the processing of personal data and free 
movement of such data as this moulds the background for the Romanian regula-
tion concerning medicine and biomedicine and the international instruments rati-
fied by the Romanian legislator. Neagoe also listed Romanian pieces of legislation 
covering the field of human tissue research. Decree no. 1242/2007, amongst oth-
ers, deals with the approval of standards selection and the evaluation of donors’ 
(healthy or diseased) tissues and cells. Decree 1763/2007 lays down the technical 
requirements for donation, sampling, testing, processing, preservation, distribution, 
coding etc. These provisions are transposing the Directives 17/2006/EC, 
23/2004/EC, 86/2006/EC and 23/2004/EC into national law. The Romanian 
legislation makes sure that Romania participates in the establishment of a single 
European code, which will use a specific numerical code for identification of all 
human cells and tissues donated to the banks of cells and tissues, except for repro-
ductive cells donated between partners. Neagoe emphasized that the obtainment 
of tissues and cells is considered a donation act that is regulated by certain ethical 
principles such as avoiding discrimination and securing people’s confidence in 
research by assuring confidentiality to the patients.  
Continuing with the Romanian jurisdiction, Simona Zanfir, counsellor at the Le-
gal and Communication Department of the Romanian National Supervisory Au-
thority for Personal Data Processing, addressed the question of the processing of 
personal data regarding the state of health and human medical research in Roma-
nia. The presentation focused on the general aspects concerning the legal frame-
work for the processing of personal data in Romania, including certain information 
about the Romanian National Supervisory Authority for Personal Data Processing. 
The necessity of anonymisation was at the focus of her presentation. Due to the 
methodology of the National Institute for Statistics, confidentiality, access to med-
ical data, security of data basis and the necessity of anonymisation related to hu-
man medical research were the main issues. Zanfir discussed the practical aspects 
of the processing of data regarding the state of health and human medical research 
in Romania before she derived her conclusions. 





Professor Judit Sándor and CELAB researcher Petra Bárd summarized the findings 
of the workshop. Recognizing the scale of the problem, they addressed two im-
portant issues in the field of anonymization and pseudonymisation: privacy con-
cern and efficiency through standardization.  
 All presentations – implicitly or directly – dealt with both issues: privacy 
on the one hand and the question of how anonymisation should be real-
ized on the other hand, i.e. how to make the coding or pseudonymisation 
efficient enough so that researchers, donors, recipients and society in gen-
eral can benefit.  
 These issues, however, have to be preceded by a preliminary question: 
what is the goal of the given repository of genetic samples and data, i.e. 
what type of biobank are we dealing with? Theoretically, even in the ab-
sence of any information attached to a sample, the donor can be identified 
if a matching sample is taken from her/him. Therefore only (i) archaic 
samples, (ii) samples which underwent the pooling procedure or (iii) math-
ematically distorted data can be regarded as truly anonymous.  
 Total anonymity is not only hardly conceivable or practical; it is not even 
desired in the diagnostics context. Donors may have compelling reasons 
to claim access to the tissues in the future. Therefore many jurisdictions 
have opted for allowing doctors and/or researchers access to the code (the 
Slovak model, for instance, seems to be in line with this proposal), where-
as a number of scholars speak out for linkable anonymous samples where 
doctors do not have access to the code – a theoretical model that has been 
realised by the Romanian system.  
 Anonymity requirements as laid down by Hungarian law are particularly 
interesting, firstly through the example of reproduction, but also in rela-
tion to the recently adopted law on biobanks. While the laws and defini-
tions may be missing or contradictory, researchers, practitioners and 
scholars in the field seem to agree on the need for common ethical, legal 
and technical standards. 
Peculiar characteristics of the national pieces of legislation in the target countries 
include the following: 
 In the Czech Republic, extensive human subject research is executed, while a 
corresponding legal framework is missing. Rules applicable to biobanks, 
research conducted on cells and tissues, and anonymisation requirements 
cannot be found in a single legal document. There are however a number 
of general pieces of national legislation and international instruments gov-
erning the field. 
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 With regard to donation, there is a presumed refusal (i.e. a full written in-
formed consent is required), except for deceased donors, in which case 
consent is assumed.  
 Interestingly, according to the Act 227/2006, Ministry of Education ap-
proval (not Ministry of Health approval) is needed for stem cell research, 
which is a unique solution in Europe. 
 In the Czech Republic, surplus embryos are still being created and may be 
used for research purposes, without being coded like other tissues and 
cells.  
 Hungary had the first biotechnology association founded in 2002. The 
country has a solid record of attracting and conducting international clini-
cal trials, with over 250 performed each year, which is outstanding espe-
cially if seen in light of Hungary’s population. 
 Since 2002 there has been an ongoing legislative process which resulted in 
the Parliamentary Act XXI of 2008 on the protection of human genetic 
data and the regulation of human genetic studies, research and biobanks.  
 The law addresses the use of genetic information only in the very narrow 
biomedical sector: in the fields of genetic testing, screening and research. 
It restricts the use of genetic data only in this biomedical context; howev-
er, even given the lack of regulation on the broader use of genetic data, ac-
cording to the Act XXI of 2008, data processed for diagnostic or research 
purposes cannot be disseminated for the purposes of insurance. The Act 
applies to genetic sampling for human genetic study and human genetic 
research performed under the Act on the territory of the Republic of 
Hungary, the processing of genetic data irrespective of the place of sam-
pling, and to genetic testing and screening, human genetic research and bi-
obanks. 
 Genetic samples and data anonymised in accordance with the require-
ments of the Biobank Act even before its entry into force may be treated 
in line with the Act for human genetic research and study. One of the 
specificities of the Biobank Act is that it regulates three different levels of 
coding and anonymity: (i) encoded genetic sample or data, meaning the 
replacement of all personal identification data relating to the donor by a 
retained code; (ii) pseudonymous genetic sample or data, meaning encoded 
genetic samples or data that is provided to the person concerned together 
with the code replacing the personal identification data; (iii) anonymised 
genetic sample or data, meaning genetic sample or data where all personal 
identification data has been rendered inapt of identifying the person.  
 For the purposes of human genetic research only anonymised, encoded or 
pseudonymised genetic samples or data may be transmitted to third coun-




tries, and only on the condition that the law of the given country provides 
for data protection corresponding to that under the Biobank and the Data 
Protection Acts. In the course of transmitting encoded genetic samples 
and data to third countries, the code key necessary for personal identifica-
tion must not be relayed. 
 For the purposes of human genetic study, only encoded genetic samples 
may be transmitted to third countries. Genetic samples or data may enter 
the territory of Hungary only from a third country where the requirements 
laid down in the Hungarian law are ensured; this has to be verified by the 
health authority.  
 Review and authorisation by ethical committees can make up for the nec-
essary yet naturally incomplete donor consent. In Hungary, for non-
invasive, non-interventional medical research studies either a local ethical 
committee or the Scientific and Research Ethics Committee (ETT-
TUKEB) grants approval. The former decides on research projects that do 
not include genetic studies and are conducted by one single institute, while 
the latter rules in cases where multiple institutes or registered biobanks are 
involved and human genetic studies are done. 
 In Slovakia all European Union pieces of legislation have been transposed 
into national law. 
 Concerning donation in line with the Health Care Act, the service provider 
uses a unique numerical code assigned to the donor and to all the products 
connected to him/her which is derived from the uniform coding system. 
The SCOT (Slovak Centre for Organ Transplantation) uses a validated 
electronic system, the so-called Transplantation Information System Slo-
vakia (TISS).  
 In Romania, tissue and cells sample collection is considered as a donation 
act that has to satisfy a number of requirements. Romanian law provides 
for a general prohibition to process particular categories of data, including 
data regarding the state of health, as well as for exceptions for processing 
special data.  
 The National Supervisory Authority established in 2005 issues certain reg-
ulations on anonymisation, recommending the adoption of adequate secu-
rity measures on a technical and organizational level. Accordingly, data 
controllers must evaluate the potential risks for data processing, establish 
adequate security policies, inform and permanently train the employees, 
and establish the control on access to avoid unauthorised access from ad-
ministrative personnel or anyone else.  
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Judging from the workshop’s presentations on the regulation of human tissue re-
search in the Eastern European countries, at least some common tendencies can 
be derived:  
 All national legislations refer to the Oviedo Convention on Human Rights 
and Biomedicine.  
 International standards are considered far more important than in many 
long-time Member States of the Council of Europe. 
Despite the fact that all national legislations refer to the Oviedo Convention and 
adhere to European Union standards, Member States of this particular country 
group (Hungary being an exception) do not seem to take the lead upon their own 
initiative to go beyond the European minimum standards. 
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1 Introduction 
The third international workshop within the Tiss.EU project was organized by the 
project partners Christine Noiville, Florence Bellivier and Virginie Commin from Paris. It 
provided a major contribution to the fourth Focal Theme of the Tiss.EU project 
by addressing questions of “Biobanks for research purposes” (Focal Theme D). In 
addition, the workshop’s regional focus was on the regulation and practice of hu-
man tissue research in the countries of Spain, Portugal and France. The workshop 
was completed by a fourth country report on the UK. Due to the Tiss.EU’s coop-
erative structure regarding the examination of focal themes, the workshop was 
enriched with an additional presentation from the UK. The academic background 
of the invited speakers encompassed philosophy, law, political science, medical 
ethics and humanities, medicine, sociology, and natural sciences. 
The workshop started with a general introduction of the Tiss.EU project given 
by Nils Hoppe as a representative of the project management. In his presentation, 
he focused on the major legal issues in the field of human tissue research. Among 
others, he referred to property and consent issues in human tissue research by 
illustrating them with common law cases. In doing so, he pointed out that whilst 
these issues are highly controversial within society, jurisprudence in this area re-
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mains firmly rooted in the “no property principle”. Questions of consent to the 
removal and use of human body parts remain important conditions for the societal 
acceptability of biobank research.  
Following Hoppe, Christine Noiville and Florence Bellivier from the hosting institu-
tion in Paris presented the major issues to be discussed at this workshop. Besides 
the issues of consent and property they also stressed the need of an in-depth analy-
sis regarding the protection of confidentiality in the context of biobank research. 
In particular, a confidential treatment of health data that are derived from stored 
biological samples might be important to erase fears of discrimination or eugenics 
in the public.  
2 Country Reports 
2.1 Spain 
Starting the first section of country reports, the Spanish jurist Carlos Romeo Casabona 
(Professor at the University of Deusto, Bilbao) presented the Spanish Biomedical 
Research Act (Biomedical Research Act nr.14/2007, 03 July 2007), including spe-
cific provisions for research biobanks as well as the forthcoming Royal Decree. 
According to his assessment the Act displays a very complete legal device for the 
regulation of consent, privacy and property. As to the latter, he pointed out that 
access to biological samples for scientific use is not hindered by property rights. 
Also the regulation of consent is a really sophisticated one: on the one hand, the 
individual’s rights are protected by the requirement of two consents given separate-
ly for both, the obtainment of samples and the samples’ use for specific research 
purposes (article 60.1). However, if no consent is given or in the case of withdraw-
al, healthcare assistance is still guaranteed. On the other hand, the Spanish consent 
rule has been shaped to fit the biobanking practice. For example, specific rules 
apply when difficulties arise for obtaining consent on already collected samples 
that shall be used for purposes not covered by the initial consent (article 58.2): 
provided that (a) an ethics committee approves the research, that (b) research oc-
curs in the same institution and that (c) the obtainment of secondary consent im-
poses too much burden. Notwithstanding these comprehensive consent provi-
sions, according to Casabona it remains yet unclear whether the secondary use of 
samples has to be operated in the same health unit or if the law allows for a broad-
er interpretation of this point, though he thinks that the latter is true, by inferring 
that research interests prevail over stringent requirements.  
Regarding the issues of property and access, institutions running biobanks 
have a right of ownership but do not have any right of commercialization. The 
stored samples in a biobank shall rather be freely assigned to third parties who 
need them for biomedical research (art. 69.2).  Although cell lines in principle can 
be given for free as well, Casabona doubted that this provision is sustainable in 




practice. He thus expected this provision to be displaced by a for-payment regula-
tion in the future. 
2.2 United Kingdom 
In the following discussion Heather Widdows (Professor for Global Ethics at the 
University of Birmingham) agreed with her Spanish colleague on the importance of 
consent. Yet according to her, there is a specific “inadequacy of individual con-
sent” in the context of huge biobanks such as the population-based UK Biobank. 
Indeed, Widdows explained that the “key feature of genetic information is that it is 
typically information about a family, or even … about a larger community not just 
about an individual patient”1.  For this reason, the managers of UK Biobank rather 
relied on a “trust model” bearing on a broad consent rule: Whilst no specific in-
formation on particular research purposes needs to be given, individual consent is 
still maintained. Admitting that this implies a weakening of consent, Widdows sees 
this tendency however counterbalanced by a right of withdrawal guaranteed at 
different levels (e.g. no further contact, no further access, no further use). An addi-
tional ethical safeguard is attained by the Ethics and Governance Council that 
monitors the compliance with ethical provisions in order to ensure “the promotion 
of health throughout society” (Ethics and Governance Council  2007). As a reac-
tion to Widdows it was yet doubted by Nils Hoppe that this “trust consent goes 
very far” since there is no feedback of information.  
In her talk, Donna Dickenson (University of Bristol) approached the issue of 
property from a different perspective. By referring to recent law cases she pointed 
to a partial exception to Common Law (excised tissues as either waste or res nullius 
are no one’s thing). In the Bristol Sperm Donors case (2008), the judges stated that 
“a sperm donor was entitled with a property right on to his sperm but did not have 
a commercial interest”. However, she explained that at least on a “Lockean basis”, 
the act of an egg or sperm donation can be seen as creating a property right (inten-
tionality, risk and effort) since it is a real effort compared to the donation of saliva. 
In the same vein, the Catalona judgment (2007) – although subject to criticism – 
did at least recognise that separated tissue can be a rightful object of property 
rights. Following Dickenson, this distinguishes it from the Moore and Greenberg 
cases, which concerned patients’ claims to patent rights and profits, not to tissue 
samples as such. According to Dickenson it is “obvious that there is a value in 
excised tissues for research” due to its potential for scientific findings, the high 
costs for the biobanks’ maintenance and commercial interests at stake. However, 
as for the procession of different types of tissues the amount of work involved 
varies strongly, the Lockean notion of property is no longer tenable. Accordingly 
Donna Dickenson proposed a “sliding scale of property rights”, thereby taking the 
                                                     
1  See Brock DW (2001) Genetics and Confidentiality. The American Journal of Bioethics 1(3), pp. 34-35.  
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Common Law notion of property as a bundle of rights2 into account. According to 
this notion, property rights should be graduated according to the donors’ and bi-
obanks’ different scales of involvement.  
In the following presentation, her British colleague, Jane Kaye (University of 
Oxford), focused on privacy issues by adopting a prospective approach. In particu-
lar, she referred to international research networks where data sharing is so com-
plex that traditional privacy safeguards do not fit this practice. As a major problem 
she identified the continuous growth of these international networks. From her 
point of view, it will be impossible to control the transmission of individual data or 
to obtain new consent for every secondary use of already collected samples. In the 
same vein, “retracting data from different data sets” will make withdrawal impossi-
ble. The weakening of consent also impacts the protection of privacy. Provided 
that there will be a broad consent with “proxy decision making by Research Ethics 
Committees (RECs)” this could undermine the individual’s control over her per-
sonal information due to the fact that RECs have no “expertise in disclosure”, “no 
transparency in decision making (not publicly available)” and only an “uncertain 
legal authority”. According to Kaye, data sharing should thus firstly be regulated by 
reforming the RECs (i.e. putting them on a professional footing, equipping them 
adequately to carry on the role they have been entrusted with), and secondly by the 
establishment of “mechanisms” that allow individuals to “control their data” and 
to be “involved in active decision making”. Against this background she called for 
a strengthened national regulatory framework (Human Tissue Act, November 
2004) in order to take international research activities better into account. 
Although in the subsequent discussion most participants agreed on the fact 
that the monitoring of data confidentiality is weaker on account of intense and 
complex data flows within international research projects, some differences regard-
ing the consequences of this observation remained at the workshop. Whilst some 
discussants argued that a confidential treatment of data is provided anyway by a 
stringent anonymization process where coded data are not nominative anymore, 
others doubted that this is a sufficient means for the protection of confidentiality.  
2.3 France 
In her presentation on the French legal framework for biobanking, Fay Betsou (Bio-
banque de Picardie, France) underlined that in the biobank she is in charge of, data 
are always coded by the physician before they are transferred to the biobank. 
Moreover, an access code is required for using the biobank computers. Due to 
                                                     
2  “The theory of property rights held by the modern specialist tends both to dissolve the notion of 
ownership into a mere shadowy ‘bundle of rights’. Thus a thing can be owned by more than one 
person, in which case it becomes necessary to focus on the particular limited rights each of the co-
owners has with respect to the thing.” In: Clarke A/Kohler P (2005) Property law commentary and ma-
terials, Cambridge University Press, p.187. Applied to biobanks, it could entitle not only donors 
but also researchers and institutions hosting biobanks with a right to property on biological sam-
ples. 




these provisions, the breach of confidentiality is considerably reduced. Betsou yet 
admitted that there are still “legal grey zones” regarding the protection of confi-
dentiality. For example, a break of code through the physician might be required 
by a justice decision (criminal offence, paternity tests etc.). However, according to 
Betsou, Biobanque de Picardie complies with very stringent privacy requirements. 
In addition, the issues of consent and property are also taken into account. Ac-
cording to Betsou’s judgment, the legal requirements for consent and property 
issues are often in conflict with the requirement of biobanks which are dedicated 
to biological sample transfer. Against this background she argued for several revi-
sions. Firstly, consent to sample storage should be replaced by a “semi blanket” 
consent, as this would optimize access to biological collections not only for a single 
specific research purpose through a narrow consent as it is provided by 2004 Bio-
ethics Law3. Secondly, she argued that “in 99.9% of cases, patients do not exactly 
know what they have consented for”, despite detailed information provided to 
them. Betsou inferred from this that patients do not mind and trust in their physi-
cian (above all, they usually hope medical research and healthcare to be improved). 
After “three years of discussion” Biobanque de Picardie finally succeeded in ob-
taining the right to use this kind of broader consent (“semi-blanket” consent). As 
to the issue of property, Betsou critically remarked that the French law does not 
make a clear distinction between raw material which cannot be sold in virtue of the 
“no property” principle and transformed material which can be sold. Firstly, she 
criticized the lack of a binding definition regarding the labor that has to be invested 
for the storage and processing of samples. According to Betsou, this would be 
crucial for a biobank’s economic sustainability. It is difficult to charge for the real 
incurring costs of the samples given that the work and skill involved are not as-
sessed by common standards. Secondly, Betsou cautioned against the development 
of an “unequal market” in practice where prices for certain biological samples are 
higher than others, e.g rare disease samples of Banque Généthon are more expen-
sive than common disease samples because there is a “larger market” for the for-
mer ones.  
The following discussion took up the issue of the donors’ rights on their bio-
logical material. Christian Lenk (University of Goettingen) argued that the donation 
principle per se does not hinder a potential feedback of health-relevant information 
to the donor. Christine Noiville and Florence Bellivier agreed that donors’ rights are 
very important. However, they also pointed out that these entail certain dangers 
regarding the biobanks’ sustainability. In this light, they regard the Catalona case 
not as “bad case”, since there might be more risks for the scattering of collections 
if donors are granted a property right in their samples. On the other hand, they 
argued that the focus on donors’ property rights misses the point of the property 
issue that is relevant in the case of biobanks. In fact, the “no property” principle 
                                                     
3  Bioethics Acts, 29 July 1994, nr.94-653 for the protection of the human body (Civil Code) and 
Bioethics Act nr.94-654 for  the procurement and use of bodily elements (Public Health Code) 
amended by the Bioethics Act, 06 August 2004. 
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does not prevent human body parts of having a value for patients and research 
(e.g. for diagnostic tests, the production of cell lines etc.). Noiville and Bellivier 
thus called for a clarification of property rights in the French law. In particular, by 
taking into account that “property means exclusivity“, they raised the problem of 
access to biobanks, as for example hospitals tend to justify their restrictive access 
policies by claiming a right of ownership for their collections. According to Em-
manuelle Rial-Sebbag (Inserm, France) this is however no common feature. As a 
proof to her claim, she pointed out that unlike hospitals the French Medical Insti-
tute for Research (Inserm) is ready to share its collections (in compliance with 
OECD guidelines about biological and associated data sharing within Biological 
Resources Centers). According to Safa Saker (Banque Généthon, France) the same 
is true for the Banque Généthon as it works on an open access basis, i.e. research-
ers who create a collection are obliged to respect this open access policy due to the 
fact that their research projects are funded by Banque Généthon. 
2.4 Portugal 
The country report on Portugal was provided by Paula Lobato de Faria (Professor at 
the University of Lisbon). Since she had to cancel her participation on short notice, 
Lobato’s talk was presented by Virginie Commin instead. Portugal has a specific law 
on biobanks used for research purposes since 2005 (Act nr.12/2005, 26 January 
2005). The creation of a national DNA profile database for the purpose of civil 
and criminal identification is regulated by an Act from 2008. According to Loba-
to’s assessment, there are many similarities between Portugal and the countries of 
Spain and France. This is especially true for the regulation of consent which has to 
be given for a specific research purpose (narrow consent). In Portugal there is also 
a very stringent regulation of data confidentiality in place. In particular, it is re-
quired that health and genetic data in health information systems should be kept 
separately, e.g. through different levels of access. Compared to other countries, 
Portugal, however, adopted a very original position concerning the issue of proper-
ty. Indeed, it is clearly stated by the law that “the donor is the owner of his/her 
biological samples and associated data”. Interestingly enough in practice no prob-
lems, such as the scattering of biological collections, occurred so far. 
3 Results 
Although research biobanks tend to grow in number around the world, in the ab-
sence of a common European framework, many uncertainties remain. The exist-
ence of specific national legal provisions and guidelines provides only a weak rem-
edy to this fact. In particular, the storage of biological samples and associated data, 
the scientific use of biobanks as well as their respective mode of operation raises 




several issues (e.g. regarding procurement, storage, transfer, profiling, risk of racial 
discrimination etc.).  
Three of these issues have been chosen for being discussed in detail at this 
workshop: consent (1), privacy (2) and property/access issues (3). Since the ques-
tion of feedback emerged as a fourth issue during the workshop’s discussions, it 
will be embraced by this report as well (4). The country reports on the legal 
frameworks of Spain, Portugal, France as well as the UK have been provided 
against this particular background. In addition, it was the aim of the workshop to 
highlight some convergences and divergences between the domestic frameworks 
of these countries.  
As a preliminary result, the following features can be derived from the work-
shop’s presentations and discussions:  
 Whilst some countries have adopted specific rules on biobanks, others rely 
on general regulations on public health or biomedical research. In particu-
lar, Spain and Portugal have passed/are about passing specific regulations 
(Spain relies on the Biomedical Research Act 20074 and is about to adopt a 
Royal Decree on biobanks; Portugal relies on the Personal Genetic and 
Health Information Act 20055). In contrast, the UK and France regulate 
biobanks on the ground of general legal provisions (Civil Code and Public 
Health Code for France6; Human Tissue Act 2004 for UK). In addition, 
the UK Biobank operates on the basis of a specific and detailed Ethics and 
Governance Framework.7 For this reason, some of the countries are more 
equipped with accurate rules capable to face the major challenges of  
biobanking than others. 
 This distinction (specific biobank provision/general regulation) does not 
overlap with another important distinction in the field of biobanks, i.e. be-
tween countries running population biobanks (UK) and countries having a 
huge number of dispatched sample collections at their disposal. 
3.1 Consent issues 
Prior informed consent has become the thread of most national legislations. In-
deed, this ethical and legal mechanism is the cornerstone of donors’ decision to be 
involved in biobanking. However, given its individual dimension, individual con-
sent does not exhaust the communal aspects of this activity, particularly concern-
ing access and benefit sharing (see below). 
                                                     
4  Biomedical Research Act nr.14/2007, 03 July 2007. 
5  Act nr.12/2005, 26 January 2005. 
6  Bioethics Acts, 29 July 1994, nr.94-653 for the protection of the human body (Civil Code) and 
Bioethics Act nr.94-654 for  the procurement and use of bodily elements (Public Health Code) 
amended by Bioethics Act, 06 August 2004. 
7  UK Biobank Ethics and Governance Framework (EGC), version 3.0 (October 2007). 
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In the countries of Spain, France, Portugal and the UK there is an agreement 
on the fact that consent is mandatory, must be informed and that donors can re-
voke their consent at any time. Nevertheless, a review of the existing regulations 
tends to show that they do not capture all practical issues at stake. As a matter of 
fact, there may be much more decisive issues than the general but vague principle 
of consent. For example, if article 60.2 of the Spanish Biobanks Act provides for 
an extension of primary consent for further similar research, neither the law nor 
public agencies have clearly set up the meaning of “similarity” so far.  
More precisely, three weaknesses appear. Firstly, a gap remains between legisla-
tions which provide for an opt-in system and those which foresee an opt-out 
mechanism. Secondly, it is not always clear whether or why the legislator has pro-
vided for consent in specific circumstances – e.g. for wasted or abandoned biologi-
cal material, for deceased donors, etc. – or if he has provided for specific require-
ments when biomedical research includes particular risks – e.g. genetic research 
and discrimination risks, R&D and the risk of commercialisation. Lastly, questions 
remain regarding the exact withdrawal modalities. For example, in France, no legal 
provision specifies the way how donors can withdraw from biobanking, whereas 
other models like that promoted by UK Biobank establish comparatively clear and 
graduated withdrawal rules. 
3.1.1 Opt in/opt out and blanket consent specific consent 
In France, Spain, Portugal and the UK informed and express consent is obligatory 
before any extraction of samples. Nevertheless, some countries require only a “mi-
nor” consent when the sample is obtained in the context of healthcare/surgery 
(France). In this case, the patient is presumed to agree that cells and other tissues 
extracted for his own sake during surgery may be kept for research. Of course, 
even in this case, the patient is informed of the planned use of his specimen, giving 
him a chance for withdrawal (“opt-out” system8). Unlike France, Portugal requires 
a new consent by the donor if his biological material collected for medical or re-
search purposes will be used for research once again (“opt-in” system9). Contrary 
to the UK, the French legislator decided not to rely on any blanket consent. Do-
nors give their consent for a specific research program (cancer, diabetes, etc.) and 
if there is any change in the research agenda (for example, if samples collected for 
cancer research are to be used in another research like, say, asthma), they have to 
be informed of this alteration and may oppose to it. Nevertheless, the distinction 
between blanket/specific consent appears as a nuanced one: in practice, the French 
system is based on a semi-blanket system (e.g., a donor gives his samples for every 
type of cancer research). Spain currently provides for a specific and narrow con-
                                                     
8  Articles L.1235-2 and L.1241-5 of the public health code respectively related to surgical waste and 
fetal tissues. 
9  Article 18 of the Law nr.12/2005. 




sent (“specific research purposes”) but the forthcoming Royal Decree is expected 
to switch to a blanket consent system. Portugal still provides for a specific and 
narrow consent.10 
From a general point of view, two tendencies are striking here:  
 In certain circumstances, an increasing acceptance for the application of 
broader consent can be observed. 
 Express consent is generally required, except when impossible or difficult 
to obtain (see below). 
In anticipation of a prospective harmonization of EU law, it might be reasonable 
to distinguish between tissue donors who would give blanket consent and research 
participants consenting to a specific research purpose. EU law would probably 
benefit from the implementation of this distinction as it respects not only the do-
nors’ autonomy but fits the practice of research.  
3.1.2 Consent in specific circumstances/Secondary use 
Regarding specific circumstances, like the obtainment of foetal tissues or tissues 
from deceased donors, the consent requirements vary across the countries. In 
France, the Bioethics law (articles L1235-2 and L1241-5 of the Public Health 
Code) relates to surgical waste and foetal tissues and provides for an express con-
sent. On the contrary, as far as deceased donors are concerned, only a presumed 
consent is needed11. In Portugal, in case of dead or disabled persons, consent is 
given by family members of first line or legal representatives (art.18§4, §5)12. In the 
UK, the Human Tissue Act provides for a written consent (Part 1, 1.3) in case of 
deceased persons.13  
In a similar vein, domestic rules provide for specific requirements when re-
search tends to compromise confidentiality, for example genetic research. In 
France, when genetic research is envisioned, express consent is needed. Spain has 
adopted a similar rule, whereas neither Portugal14 nor the UK15 provide for any 
specific rule.  
                                                     
10  According to article 18§1, the donor must be informed of expressed research purpose under 
which the collection is made. 
11  See Rapport de l’ Académie Nationale de Médecine (ANM), Paris, 17 March 2009, available at 
http://www.academie-medecine.fr/detailPublication.cfm?idRub=26&idLigne=1550. 
12  In Spain, it seems that Law nr.14/2007 does not provide for any specific consent requirements. 
13  There are two consent modalities: consent is signed by the person in the presence of at least one 
witness who attests the signature or, consent is signed at the direction of the person concerned of 
at least one witness who attests the signature. 
14  If no particular requirement is provided for consent in case of genetic research, nevertheless Act 
nr. 12/2005 provides for a specific non-discrimination principle (art.11) as well as restricted access 
by other health units (art.6). 
15  UK Human Tissue Act, part.3, “Miscellaneous and general”. 
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As far as secondary use is concerned, France has adopted an opt-out system: 
donors must be informed of new uses and can oppose them, except in cases where 
it is impossible to contact them again. Spain provides for a quasi similar rule (art. 
58.2 and 58.2.2) with just two exceptions: Firstly, “similar research lines” allow the 
research to proceed without any new consent or information; secondly, when the 
new research is not similar or when the donor cannot be found, an ethics commit-
tee may allow the research to proceed but only after its general interest has been 
proven. In the silence of a general law, UK Biobank has set up a rule that encom-
passes secondary use by a blanket consent system.16 Portugal, in contrast, provides 
for a secondary consent if biological material collected for medical or research 
purposes is used for another research purpose (art.18§3).17  
3.2 Withdrawal 
All four countries allow for a donor’s withdrawal of consent, but regulations di-
verge concerning its concrete modalities (destruction? definitive anonymization?) 
and the consequences of withdrawal.  
In France, nothing is said about these two issues and practically, biobanks do 
not seem to face these problems. In Spain, however, according to article 60.3 
BMRA 2007, the material must be destroyed. Portugal also explicitly provides for 
biological sample destruction in case of a donor’s withdrawal or withdrawal by 
his/her family members if the donor himself is disabled or dead (art.18§3)18. Inter-
estingly enough, UK Biobank provides for three options: “no further contact”, “no 
further access”, “no further use”. “No further contact” means that UK Biobank 
will still have the permission to use information and samples as well as to obtain 
further information from health-relevant records, but will no longer contact the 
participant directly. “No further access” implies that UK Biobank will no longer 
contact the participant or obtain further information from health-relevant records 
in the future, but will still have the participants’ permission to use the information 
and samples provided previously. “No further use” means that “in addition to no 
longer contacting the participant or obtaining further information about them, any 
information or samples collected previously would no longer be available to resear-
chers”.19  
                                                     
16  UK Biobank EGC: “ Because it will be impossible to anticipate all future research uses, consent 
will be sought for research in general that is consistent with UK Biobank’s stated purpose (rather 
than for specific research)”, p.5. 
17  No ethical review board is required except if transfer relates to a certain population or the whole 
population – respectively National Council on Ethics review or the Parliament approval will be 
required (art.19§7). In case of death or disability, consent is given by family members of first line 
or legal representative (art.18§4, §5). 
18  But there is no clear answer about data destruction except a right of information of every citizen 
on his/her genetic data use, notably how it is stored and the storage period (art.6§9). 
19  UK Biobank EGC, point 3, p.9. 




Given these different modalities of withdrawal, its effects (anonymization? de-
struction?) need to be examined more thoroughly. Whilst obviously not all regula-
tions take up these questions directly, at least Spain provides for detailed rules as 
far as minors and disabled persons are concerned (BMRA 2007, art. 58.5) and also 
includes temporary provisions for samples collected before the Act entered into 
force (not to speak about the fundamental issue of information feedback).   
3.3 Privacy issues 
How and to what extent are personal data contained in biobanks preserved from 
external interference? What is the exact content of national legislations on this 
question? Is a homogeneous answer possible (going further than the stringent 
European harmonization in 1995 about personal data that includes health data20)?  
For the assurance of privacy, the four countries in the workshop’s focus have 
set up strict rules like the vast majority of EU countries: 
 First of all, biobanks must be declared or authorized in a way or another 
by an institution in charge of data confidentiality. 
 Secondly, as soon as data allow for the identification of individuals, they 
must be encoded (exceptions might be admitted in the case of specific re-
search projects). However, coding must occur in such a way that donors 
can still be found when they want to withdraw from research (except if 
one considers that irreversible anonymisation is an obstacle to withdraw-
al). Currently not all national legislations define clearly what coding/ 
anonymisation/pseudonymisation means.  
 Thirdly, rules have been enacted which forbid any commercial exploitation 
of identifying data as well as any transfer of data to employers or insurers. 
In case of violations, the law provides for criminal sanctions. 
 To conclude, all these rules are meant to efficiently prevent breaches of 
confidentiality. In fact, potential breaches of confidentiality relevant to 
health data associated to biological samples are rather similar to medical 
data: the police can break the code with the help of a clinician; or in case 
of infection traceability, it is also possible through the clinician to have ret-
rospective testing for an infectious agent to prove spouse contamination. 
But it is rather unlikely that it should be possible to access data for em-
ployers/the health insurance industry, or in case of paternity testing: on 
the one hand, these practices are forbidden or require at least a judicial au-
thority decision; on the other hand, data are coded, access to the computer 
requires a code, and/or only the clinician, not the biobank, can access 
nominative data (Fay Betsou). 
                                                     
20  Directive 95/46/EC 
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This is not to say that all participants of the workshop were on a similar line. Some 
insisted that biobanks may constitute a real threat to privacy for several reasons:  
 Biobanks accumulate huge quantities of personal and generally sensitive 
data which are meant to be shared with other research teams and to be 
kept for a long time.  
 From this perspective it was emphasized that even if legal and technical 
precautions may successfully prevent the invasion of privacy, there re-
mains the much broader question of health profiling21 or genetic discrimi-
nation. Real or imaginary risks such as the use of biobanks by the police 
(for other uses than public health interests22) have also been evoked. 
On the other hand it was stressed from a more positive point of view that the legal 
and technical precautions taken are sufficient to prevent the invasion of privacy. 
However, the defenders of this position admitted that there remain technical issues 
to be answered in this context. A more serious problem is linked to the develop-
ment of private companies (e.g. 23andMe, DeCodeMe, etc.) that offer genetic test-
ing. Concerns arise particularly from the fact that privacy protection is generally 
vague in this context. In addition, some companies transfer samples and data to 
research institutions on the basis of unclear confidentiality guarantees.    
3.4 Property and access issues 
Collections of samples and data have a value; but who creates this value and who 
can claim to hold some rights in the content of these collections? Is it the donors’ 
right or the right of the facilities’ hosting the biobank (e.g. hospitals)? Is it the re-
searchers’ right since they collect the samples for their own research or rather the 
firms’ right since they eventually develop new medicines? In fact, all the actors 
mentioned may rightfully claim some rights in the collection of samples and data, 
but the way how these rights could be shared is an open question so far. In par-
ticular, there is a need to clarify the issues of property and access in the field of 
biobanking. Property and access issues may thus be the most tricky questions as far 
as European harmonization is concerned since they are both, the cornerstone of 
patients’ interests and decisive for stakeholders involved in biobanking activities.  
                                                     
21  For example, SARS epidemic justified breach of confidentiality in health data such as public nam-
ing of SARS patients, and threats of severe legal penalties for non-compliance. 
22  For example, the police could access the Swedish Newborn registry (PKU) in order to search for 
Tsunami victims after the parliament’s amendment of the Biobanks in Medical Care Act. 




3.4.1 Whose property? 
According to most European legislations – except Portugal23 – the donor is not 
entitled to any property rights in his biological material since he/she gives his/her 
samples on an altruistic basis. That is clearly formulated by all national laws even if 
they recognize the possibility to compensate donors for the expenses incurred by 
their gift.  
For example, in France, raw biological material cannot be the subject matter of 
any property right according to the “no property principle”: “The human body, its 
elements and its products may not form the subject of an inheritance entitlement” 
(art. 16-1, paragraph 3 of the Civil Code) associated with the interdiction of lucra-
tive gain (art. 16-6 of the Civil Code). This means that human samples cannot be 
owned by donors. Spain has established a similar rule.  
Researchers, hospitals, patient organisations, biobanks: all stakeholders should 
get their own share. However, the participants of the workshop agreed that the 
legal conditions remain unclear in this respect. In particular, how much labor is 
needed to create a legitimate property right? Should property be recognized on the 
same basis, irrespective whether it is for brain slides or for mere cheek swab? Can 
institutions and/or researchers appeal to any property right on raw material for the 
sole reason that they collected and stored it for scientific use? And finally, which 
degree of transformation turns biological samples into commodified goods?24  
Apart from these two relatively consensual points, divergence became noticea-
ble on the question whether property is a relevant concept to embrace biobanking. 
Most participants argued for a property model that is in favor of the donor. This 
argumentation is based on the assumption that any other solution would be detri-
mental to the latter. The proponents of this perspective thus deplored the US 
Catalona decision as a set-back to patients’ rights and criticized the underlying gift 
metaphor. As a remedy they suggested a recourse to the common law concept of 
“bundle of rights” in order to elaborate models of property sharing.   
Other discussants, in accordance with most regulations and case law, argued 
that the property concept is not sufficiently adapted to biobanks and thus should 
be overcome. The complexity originates in the fact that the sample is an entity 
extra commercium which is supposed to fit a general interest (research, equal access 
etc). However, the status of samples might change in the course of the research 
process: The further we proceed in the transformation of a sample, the more its 
                                                     
23  Law nr.12/2005, art. 18 §2 states that the material stored in the biobank is “the property of the 
people from whom it was collected and after their death or incapacity it is the property of their 
family members.” Consequently, the dispute on whether DNA is a thing or still a part of the per-
son – according to Roman categories between thing/person – does no longer exist (see Lobato 
De Faria P. (2009) Ownership rights in biobanks for research. Do we need a new kind of “biolog-
ical property”? in: The Ethics of Research Biobanking, Part 2, Springer, pp. 263-276. 
24  According to certain biobanks, it seems that preservation and conditioning activities for research 
purposes are in essence a transformation insofar as this activity requires highly qualified professio-
nals and sophisticated machinery which drive up costs. 
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scientific value increases. As a matter of fact, even within flexible concepts such as 
the “bundle of rights” theory, property still implies the legal right of the owner to 
prevent others from accessing his property. In practice, this could lead to a closing 
and blocking of the precious resources gathered in biobanks. However, it is im-
portant that samples are not “kidnapped” by just a few, otherwise that could be 
detrimental to the whole research. For the proponents of this position, the crucial 
issue is not to recognize property rights on biobanks, but to organize access to 
their resources.  
3.4.2 Access issues 
Biobanks are a source of unique biological samples and a very important tool for 
research. For this reason, there is a fairly wide consensus on the fact that their 
content should be available to all researchers as freely as possible. For example, in 
Great Britain, UK Biobank has established a “stewardship model” even though, 
UK funding institutions are “the legal owner of the database and the sample col-
lection”, and promotes this as a way to manage the biobank according to collective 
interests. In Spain, the legislator has provided for a steady administrative manage-
ment of biobanks through the Biomedical Research Act (2007). The Spanish law 
also supports the idea of broad access to biobanks by researchers (equality criteria, 
no payment for the resource, except a compensation for costs). It even provides 
that stored samples shall be “assigned freely to third parties who need them for use 
in biomedical research” (art. 69-2). This provision applies to any researcher, public 
or private, provided that his research is not for profit. In France, an embargo sys-
tem is generally used by patient organisations’ biobanks. In this case, the use of 
biobank samples is reserved to a specific researcher for two or three years. This 
limitation ensures that the material is not blocked forever and can circulate 
throughout the whole research community. The Portuguese law on biobanks (art. 
16 §2) provides for free access to data arising from research in the human genome 
for the scientific community. One may yet wonder whether this provides equal 
access for industry and academics. Moreover, it seems that donors can consent to 
the transfer of a few samples25 solely if the physician has asked for the samples’ 
provision (art. 19§4).26 Even though donors are not aware of this right yet, it could 
give rise to many difficulties in practice, such as the scattering of biological sample 
collections.  
                                                     
25  Lucrative gain is forbidden according to article 18§8 which provides for no commercial use, non 
patent, no financial gain on rough biological material. 
26  Through an a contrario interpretation of art.19§17: transfer of numerous biological material or 
collections, cannot be made solely with their consent, a local ethical committee approval must be 
also respected. 




3.5 Feedback of information 
The question here is whether donors’ placement of samples in a biobank justifies 
the feedback of information to them. More precisely, two questions of unequal 
difficulty arise in this regard. First, when samples are mainly used for scientific 
research, does the donor have a right to be informed of the overall results of the 
research? Second, does he have the right to be informed of a health problem con-
cerning him personally that could have been identified during the sample analysis?  
Most states answer the first question positively: As they have given something 
of themselves, sample donors have the right to be informed regularly about the 
overall results of the research. However, the French law does not explicitly require 
this for research on biological material but only for clinical trials where participants 
are involved (Article 1122-1 of the Public Health Code), whereas UK Biobank 
requires it explicitly in its charter (point 4, “Ongoing engagement with participants 
and the public”27). The same is true for Spain and Portugal, even though the Por-
tuguese law solely provides for the donors’ right to be informed of the investiga-
tion abandonment or biobanks closure (art.19§15).  
The second much more delicate question is object of controversies and elicits 
more varied responses. As the field of medical discoveries continues to grow, so 
grows the need to protect individuals from too much interference into their per-
sonal lives. The potential discovery during genetic examinations that a child’s legal 
father is not his biological father is a standard example of ethical issues that is en-
gendered by the power of genetic information. In this, but also other imaginable 
cases the “right not to know” may collide with the right to know (about a family 
member or about a sexual partner, for example) (see Spain, art. 4.5, 2nd section 
BMRA 2007). A real-life illustration of this issue was given by Judith Sándor, who 
referred to a Hungarian case of a man who gave his sperm to two different hospi-
tals, specialized in assisted conception, in order to have a baby not only with his 
wife but also with his lover. By a curious coincidence, the physicians working with 
the respective sperm at the two distinct hospitals happened to meet at a confer-
ence. Whilst talking about a patient affected with a very rare disease, they had to 
realize that they were talking about the same patient. They wondered how to deal 
with the dilemma of two women longing for a baby. Were they obliged to inform 
them?  
In contrast, when the biobank’s aim is research, the question of possible feed-
back of information to the donor is not raised in terms of the “right not to know”, 
but in inverse terms: The question is whether the donor has the right to be in-
formed of a potential health problem that is incidentally identified during the re-
                                                     
27  UK Biobank EGC point 4, p.8: “Regular communication will be important to inform participants 
of general findings from research based on the resources and to encourage continued participa-
tion. UK Biobank will therefore, look for a variety of ways for communicating with (including lis-
tening to) participants, the general public, research users and the scientific community […].” 
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search. For the UK Biobank the response is negative28: Though donors receive an 
identification form stating their blood group, fat mass, etc. when their sample is 
banked, any feedback of more detailed personal information is ruled out from the 
very beginning. In contrast, a rather fuzzy regulation is applied in France: from a 
strictly legal perspective, the researchers working on a collection are not obliged to 
report any health problems identified during the research. Certainly, in a care rela-
tionship, that is when the person is the doctor’s patient, the doctor is required to 
provide information, except in emergencies, when it is impossible, or when the 
patient does not want to be informed. But in a research relationship, the research-
ers have no such duty of care. In France, it is difficult to imagine that they might 
be sued or prosecuted for non-assistance to a person in danger, for not providing 
the information. Although researchers certainly must not provide medical infor-
mation unrelated to their profession, nevertheless both efficacy and ethics call for 
legal rules that make research and medical activity more consistent in this field. 
Unlike France, Spain and Portugal explicitly provide for a donor’s right to be in-
formed of research results which might be relevant for his/her health. In Spain, 
there is a right to know one’s genetic data (art.59.1). Also in Portugal, the donor is 
entitled to know the entire clinical process. This is also true for family members 
the donor has indicated. Health professionals thus have a duty to provide infor-
mation on the risks of diseases (art.18§6)29.  
From a more general perspective, it can be stated that the Western European 
countries that have been at the centre of the workshop in Paris provide for fairly 
specific regulations regarding human tissue research. This fact becomes mostly 
striking if one compares the countries of Portugal, Spain, France and also the UK 
to the Eastern European countries or even the German speaking countries where 
human tissue research, if at all, is subject to a diversified field of laws, guidelines 
and statutes. However, this is not to say that the current regulations in these four 
countries are perfect or sufficient. The workshop rather identified several ques-
tions that require further elaboration and clarification. 
                                                     
28  UK Biobank EGC, point 3, p. 6-7: “UK Biobank will aim to ensure that participants understand 
that enrolment does not provide them with a health check […]. However the value of such feed-
back is questionable because the data would be communicated outside of a clinical setting and 
would not have been evaluated in the context of the full medical record. As a consequence, the 
significance of the observations might not be clear and UK Biobank would not be in position to 
interpret their implications fully. Further, it […] might even be harmful (including causing undue 
alarm and having potentially adverse effects on insurance and employment status), to provide in-
formation without prior counseling or support” (which UK Biobank will not be able to provide: 
as explained below). 
29  The results must be made by a physician specialized in genetics (art.19 §12). 
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The Second Status Conference of the Tiss.EU project focused on “Privacy, Confi-
dentiality and Personality Rights in Biobanking and Genetic Research with Human 
Tissue”. The conference was organized by the project coordinator Dr Christian 
Lenk, Dr Katharina Beier and Prof Claudia Wiesemann from the Department of 
Medical Ethics and History at the Medical Center Goettingen together with the 
project partner Dr Nils Hoppe from the University of Hannover. During the plan-
ning phase and at the conference, the organizers received also inputs from two 
other EU projects in this field: GeneBanC and Privileged.  
In order to do justice to the topical focus of the conference, the organizers ex-
plicitly invited several keynote speakers that are known as legal and ethical experts 
in this field. In addition, the conference benefited from the contributions that have 
been accepted due to a call for papers that was announced in the European re-
search community. The talks of all speakers were assigned to three thematic blocs 
at the conference that allowed for different perspectives on the issues of privacy, 
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confidentiality and personality rights. The first bloc was meant to provide for a 
definition of terms, such as privacy, integrity or confidentiality that were at the 
focus of the conference. After these rather theoretical contributions, the second 
part was dominated by the perspective of legal scientists who addressed issues and 
means of data protection in the field of human tissue banking. The third panel of 
the conference finally dealt with questions of application and particular models of 
biobank regulation. Almost 40 participants, speakers included, from all over Eu-
rope took part in the Second International Tiss.EU conference that lasted from 16-
18 July and was held at Goettingen University library.   
2 The contributions 
The conference started with a general introduction to the Tiss.EU project given by 
Christian Lenk as representative of the coordinating institution in Goettingen. He 
pointed to the rapid changes regarding the availability of health information. 
Whilst in the 19th century only sparse information of the individual and her health 
was existent, we are now facing an immense increase in health and data registries 
which is additionally spurred by the progress in information technologies. As this 
development is not merely beneficial but may also pose several challenges to law 
and biomedical ethics, Lenk specifically asked whether our traditional understand-
ing of privacy that dates back to the 19th century is applicable to the context of 
human tissue research. In particular he expressed doubts that privacy can be simply 
transferred to today’s information society. This might call for an adaption of the 
privacy concept in the light of new challenges and contexts of application.  
The presentations of the first panel directly reacted to this question. Regarding 
the ethical challenges of human tissue banking a seminal input was provided by the 
talk of David Townend from Maastricht, who is one of the coordinators of the EU 
funded project PRIVILEGED. By outlining the structure of this project, he par-
ticularly discussed the issues of informed consent and whether exemptions for 
research can ever be justified. Furthermore he took up the issue of data access as 
well as matters of commercialization and benefit sharing. Whilst there is no com-
mon regulation of these aspects so far, Townend also pointed out that our 
knowledge of peoples’ interests in genetic information and biobanking is currently 
only derived from piecemeal surveys. Despite their disparity regarding methods 
and research questions asked, these surveys reveal, however, concerns regarding 
genetic research as some common trend. As it is important that research takes 
peoples’ attitudes and fears seriously in this context, Townend strongly voted for a 
specific EU-wide survey. As to privacy, the analysis of existent surveys revealed, 
that privacy interests vary with contexts, historical experience and the respective 
notion of citizenship. In fact, people are mostly concerned about commercial uses 
and consequently interested in the organizational structure of biobanks and data-
bases. For a better understanding of the specific nature of a sample-data-complex, 




Townend suggested the analogy with “words”. Like a word that always contains a 
piece of information, the sample is a personal data which cannot be separated from 
it. Against this background Townend finally raised the question whether people’s 
specific interests, for example in privacy protection, are adequately mirrored by the 
existent law. In particular, he criticized that it is not very clear about the harms it 
aims to protect.  
Mats G. Hansson, Professor for Biomedical Ethics at the Centre for Research 
Ethics & Bioethics at the University of Uppsala, went deeper into the philosophi-
cal investigation of the privacy concept. He argued that whilst all languages have a 
word equivalent to “private”, the distinction between the public and the private 
realm varies between cultures, depending on ideology, cultural and economical 
conditions. Consequently, the distinction between the private and public sphere is 
an ongoing discussion in moral theory, law and constitutional theory. As to the 
definition of privacy in the Western countries, Hansson pointed to the prevalence 
of privacy as a negative notion of non-interference into one’s personal sphere. 
Since this is a rather one-sided notion, he voted for a more positive understanding 
of privacy. In particular, he referred to the notion of integrity. Instead of merely 
defending one’s personal sphere against others, integrity refers to the individual as 
agent or ruler of her social relationships. It can thus be seen as a property of the 
social agent who navigates the intersection between public and private spheres. 
Consequently, “respect for integrity” implies a social and political recognition of 
the individual agent. According to Mats Hansson, this more positive understanding 
of privacy needs to be taken into account by developing more democratic and 
transparent regulations of human tissue research as integrity enhancing mecha-
nisms. As to the practical implications of his view for human tissue research, 
Hansson stressed that people’s primary interest is not to be left alone, but rather to 
achieve certain goals together with others. For this reason it is necessary to balance 
consent against other interests, such as the interest of not being exposed to unac-
ceptable risk and the interest in scientific results. As a matter of fact, he regarded it 
acceptable to waive consent for the benefit of important research results that final-
ly may increase the welfare of all.   
In line with Mats Hansson’s argument, Georg Lauß, Researcher at the Life-
Science-Governance Platform at the Political Science Department at the University 
of Vienna, pointed to the difficulties of distinguishing between public and private 
sphere as in practice there are complex entanglements. Notwithstanding this, in the 
public debate usually a clear-cut distinction is drawn between the public’s interest 
in science and the individual’s right to privacy. Lauß challenged this distinction by 
claiming that in the field of genetic research personal and private interests very 
often overlap with what is regarded as the common good. However, the distinction 
what is regarded as private and therefore needs to be protected is a matter of polit-
ical power. In fact, it is always a particular constellation of interests that can suc-
cessfully claim the status of a common good. At the same time, each appeal to a 
common good provokes claims for privacy since some do not want to be part of 
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this “common” good. According to Lauß, references to the public are however 
misleading. This is due to the fact that research issues are discussed by experts 
rather than the alleged “public”. For this reason the lay public is rather a phantom 
than reality. 
The distinction of public and private sphere was also addressed by Lars Øystein 
Ursin, who works as a Post Doctoral Fellow at the Department of Philosophy at 
the Norwegian University of Science and Technology in Trondheim. In particular, 
he argued that the limit of private matters is determined by the respective social 
relations of a person. Privacy is thus to be defined in relational rather than in indi-
vidualistic terms; i.e. it depends on the relationships we enter and thus on a norma-
tive assessment of oneself and others whether the revelation of an information 
displays a violation of privacy or not. From this perspective, things loose their 
privacy status if people decide to leave their matters to the public. Against this 
background, Ursin cautioned against an understanding of peoples’ interests in 
terms of property since this ignores the relational aspect of privacy. By taking this 
relational approach to privacy seriously, he concluded that privacy not only com-
prises rights but also specific duties to keep certain things in the private realm. In 
the context of human tissue research there is consequently a need to define the 
exact duties of tissue researchers and biobanking institutions for the protection of 
privacy and confidentiality of the research participants. 
Judit Sándor, Professor and Director of the Centre for Ethics and Law in Bio-
medicine at the Central European University in Budapest, opened the second panel 
of the conference that comprised ethical and legal perspectives on human tissue 
research. In particular, she examined the implications of privacy for the realm of 
human tissue research. Thereby she pointed out that the “old” concept of privacy 
cannot easily be transferred to nowadays affairs. This is mirrored by several au-
thors who criticize privacy for not being an efficient concept given the vast 
amount of data that is said to invade privacy. Sándor cited Ruth Chadwick, who is 
in favour of an open consent model and argues to tell people in advance that full 
privacy cannot be guaranteed in the field of human tissue research. Against this 
background, Sándor described our understanding of privacy as strongly shaped by 
technology and its progress. However, although the processing of personal data in 
DNA-banking might imply several harms such as loss of control, unwanted obser-
vations or the misuse of data, these harms need to be balanced against certain posi-
tive effects, such as the improvement of security matters. Consequently, Sándor 
argued for a more nuanced assessment of privacy in genetics. In particular, privacy 
should be assessed on a specific project basis, as for example population based 
research poses only minimal risks to the participants. In addition, one should be 
aware of that fact that, for example, in the Personal Genome Project people volun-
tarily disclose their personal information to researchers. To prevent this by legal 
means may thus entail the risk of enforcing privacy by paternalism. Sándor finished 
her talk by concluding that privacy is still a very useful concept in shaping safe-
guards for human biobanks through a limited and culturally contextual right; in this 




regard, informational privacy is still an important concept. However, she also ad-
mitted that the cultural and historical dynamism that shapes our understanding of 
privacy makes it almost impossible to build legal harmonisation of biobanks.   
Martin Sebastian Haase, Senior Research Associate at the Institute of Legal In-
formatics at the University of Hannover, examined the personal character of data 
that result from genetic research from a legal perspective. He pictured data as “dy-
namite” as it can be misused in several ways. He thus analysed the provisions of 
the EU Data Protection Directive (95/46/EC) which applies to every processing 
of personal data. To this purpose he went into the particular wording of the Di-
rective. According to Haase there is a tendency to speak of data as personal data as 
soon as a set of data is unique. Data become unique if different factors are accu-
mulated in such a way that they allow for identification. Consequently, from this 
perspective it is argued that data from human tissue research (since they often are 
genetic data), are to be considered as personal data. However, according to Haase, 
one has to be aware of the fact that one piece of information can be personal in-
formation for different people due to hereditary connections amongst family 
members. Against this background the theory of “unique character of data” ap-
pears too formal to define personal data. For example, although human tissue as 
such is unique, Haase argued that it should not be classed as personal across the 
board. He rather suggested that the character of data should be determined by the 
sense and purpose of their collection. For example, whilst even incorrect data can 
be personal data this does not apply to group and statistical data. 
Kris Dierickx, Professor of Biomedical Ethics and coordinator of the Gene-
BanC project at the Centre for Biomedical Ethics and Law at the Catholic Univer-
sity in Leuven, explained the structure of the GeneBanC project to the audience. 
Its major aim is to provide for an analysis of the ethical, legal and governance is-
sues of three different types of biobanks: disease-related biobanks, population and 
forensic biobanks. In his talk, Dierickx first addressed the question whether har-
monisation is ever feasible in the field of biobanking. In particular he identified fife 
types of biobanking networks that can be seen as a first step into that direction. 
For the regulation of biobanking however, the diverging aims of different types of 
biobanks need to be taken into account. Against this background, Dierickx critical-
ly remarked the weak legal safeguards regarding the privacy and confidentiality of 
forensic data. In fact, when it comes to privacy, forensic DNA sampling does not 
rest under the same protection measures as clinical genetic sampling. Also the 
Council of Europe’s guidelines are only valid for samples, but not DNA profiles.  
José Miola, who works as a Senior Lecturer at the School of Law at the Univer-
sity of Leicester, addressed the problem of lacking trust in biobanks. Although 
privacy and confidentiality are concepts that are used by the courts, these two con-
cepts are often conflated. In particular, it is not clear what makes information con-
fidential. Whilst an English court has argued that the anonymization of medical 
information is an effective means to avoid invasions into privacy, and that patients 
have no right of ownership over their information, it remains yet questionable 
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whether this information can be used for any purpose without the source’s con-
sent. In fact, Miola argued that the issue is not about owning one’s information but 
to be able to control it. The court in his rule to the case of “Source Informatics”, 
however, took this control from the patients and gave it instead to the doctors, 
researchers and pharmacists. According to Miola, the anonymisation of infor-
mation neither removes the duty of confidence, nor, in the absent of consent, in 
itself provides a legal or ethical justification for its use. This assessment is also in 
line with European dicta. As a matter of fact, consent remains the key concept to 
protect the interest of donors. In particular, any consent gathered should be careful 
to include all possible uses of the information, including potential future uses.  
Marion Albers, who works as a professor of Public, Economic, Information, 
Health and Environmental Law at the Faculty of Law at the University of Augs-
burg, outlined the legal situation for using human tissue in Germany. Although 
tissue materials after separation from the body turn into an object according to 
German law, the person from whose body these materials stem has the right of 
control. Thus, for the collection and processing of data the concept of informa-
tional self-determination is central to the German legislation. After the German 
Constitutional Court’s rule on the population census, the right to informational 
self-determination even displaced the notion of privacy. The court’s decision in 
this case includes that everyone has a right to determine the collecting, processing, 
alteration, transfer and also dissemination of his personal data. However, as Mari-
on Albers noted, the concepts of property, privacy and informational self-
determination imply a rather individualistic view. From this perspective the ques-
tion how individual data control can be accomplished within complex systems is 
neglected. In particular, this approach ignores the social context of data. In fact, 
the German Constitutional Court has recently extended the sphere of privacy. As 
to the privacy of a person, the court did not argue with a distinction between pub-
lic and private sphere, but referred to the fact that certain things are regarded as 
private since their disclosure might lead to embarrassment or discomfort for a 
person. Consequently in certain places and situations the individual can reasonably 
expect to be free from observation. In line with Lars Ursin, Albers stressed that 
the protection of privacy can only be explained in relation to others and is thus to 
be regarded as a relational and contextual right. According to her, it is thus not the 
meaning of personality rights to protect the freedom of behaviour or expression, 
which are covered by other rights. In fact, personality rights should not be under-
stood as rights of isolated human beings, but rather refer to individuals within 
relationships. Due to Albers, personality rights are a reaction to the protection 
requirements of individuals in sociality, that is, individuals acting in certain social 
contexts. She thus invited for a rethinking of individual rights. In particular, per-
sonality rights and the freedom of science should be elaborated as relational and 
context-oriented rights. Marion Albers concluded her talk by outlining some con-
sequences for the field of biobanking: firstly she stressed that informed consent 
should not to be regarded as waiver of important obligations towards tissue do-




nors. For this reason, she rejected blanket consent as it has no relationship to the 
research project concerned. Secondly, she pointed out that the general law in Ger-
many treats privacy still in a conventional way by disregarding the social contexts 
of individual actions. In fact, there are several questions in the field of genetic data 
banking that cannot be solved by reference to the concept of informational self-
determination and rather call for the elaboration of new and/or additional tools of 
protection. 
Paul Chummar, who works as a Senior Lecturer and Senior Research Fellow at 
the Catholic University of Eastern Africa in Nairobi, Kenya, and has his discipli-
nary background in Medical Anthropology, addressed the field of human tissue 
research from a more general perspective. He started his talk by the critique that 
the holistic perspective on ethical questions is increasingly lost of sight in medical 
ethics and recommended the perspective of Medical Anthropology as a remedy to 
this trend he observed in the discussion on human tissue research. His critique was 
particularly directed against a partial understanding of the person in this field 
which is mirrored by respective partial rights regarding the person’s control over 
research. Chummar yet conceded that there are no coherent, universal principles 
any longer that can be applied to medical research. Notwithstanding this, solidarity, 
the avoidance of exploitation and the protection of the vulnerable retain an im-
portant appeal in the field of human tissue research. For their accomplishment, 
however, one cannot simply refer to the law, but it is rather the society itself that is 
required to establish the principles of humanity and fairness amongst its members. 
Given that the technological development will not be stopped, it is our task to 
promote the morally correct use of these techniques. By taking the proposed per-
son-oriented approach seriously, Chummar argued for an intensified dialogue be-
tween different disciplines in order to establish more common ground in the field 
of human tissue research. 
Claudio Tamburrini, Research Associate at the Centre for Health Care Ethics at 
Stockholm University addressed the question of what is wrong with the forensic 
use of already existing genetic medical databases. In the course of his talk he par-
ticularly aimed to refute the objection from privacy that is usually raised against the 
application of medical data for forensic purposes. As a guiding question for his 
investigation he asked whether it would be justified to hand over samples from 
medical biobanks for forensic uses even without the consent of the donors. To 
answer this question, Tamburrini first examined the deeper meaning of privacy and 
argued in line with former speakers that it needs to be seen as a means that helps 
people navigate their social relationships. Thereby privacy acts as a shield that of-
fers protection in several ways: e.g. from interference and pressure from others 
having access to one’s personal sphere. However, Tamburrini stressed the fact that 
the right to privacy is different regarding its strength of protection. Whilst in the 
context of medical treatment it is a non-overridable right of patients, this is not 
equally true for the context of tissue research. In fact, the donor’s right to privacy 
appears overridable by other competing, absolute claims, which displays a highly 
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relevant observation for forensic databases. Against this background Tamburrini 
raised the question whether it would be justified to match samples from a crime 
scene with existing samples from a medical biobank. He thereby admitted that it 
would be irrational to risk the public’s trust for the clarification of minor crimes. 
For serious crimes, however, he argued in favour of a forensic use of medical da-
tabases. As a justification he pointed out that confidentiality is only one aspect of 
privacy that is worth being  protected, whilst there are other facets of privacy that 
are negatively affected by crime. For this reason he regarded it justified to sacrifice 
confidentiality in certain cases in order to protect other aspects of privacy as there 
are the physical and psychological integrity of an individual for future autonomous 
actions. In the remainder of his talk Tamburrini refuted several objections that are 
often raised against the forensic use of existing medical databases. As to the objec-
tion from social discrimination, he argued that this can be met by building up 
comprehensive registers that avoid any biases towards certain people or groups. 
Secondly, he addressed the objection from wrongful conviction by stating that this 
is also not a powerful one due to the general existence of judicial error. Although 
we know that wrongful convictions occur, nobody ever argues to abolish the crim-
inal system itself. Consequently, no serious argument against forensic databanking 
can be derived from this objection that, according to Tamburrini, is an ideological 
one. Concerning the objection from authority’s misuse, he finally argued that this 
focuses on the wrong thing. In fact, if misuses occur, the failure lies not in forensic 
databanking itself, but in the lack of appropriate democratic control mechanisms. 
Tamburrini concluded his talk by stressing that privacy should not be used as an 
objection to forensic usages of medical databanks. Since it is not an absolute right, 
restrictions of privacy are both possible and necessary. For this reason it is much 
more useful to clarify which aspects of privacy are concerned and whose privacy 
shall be protected in a particular case.  
Christina Schröder, who works as group leader of the Biobank Network at 
Fraunhofer IBMT in Potsdam, revealed insights into a particular privacy regime, 
the Central Research Infrastructure for Molecular Pathology (CRIP). In her talk 
she made clear that the protection of privacy is not only in the interest of donors, 
but also that the operators of biobanks do not want to disclose their information 
due to scientific and economic competition. The CRIP privacy regime was devel-
oped alongside with the Genome Research Network and is based on a public-
private partnership. In particular, it is constituted by a database contract that regu-
lates the workflow for data and transfer and is signed by all pathologists and part-
ners in the network in equal terms. All partners are provided with a software that 
allows the extraction of research relevant data from existing records. These data 
are then imported to the IBMT database that is open for enquiries from registered 
users. If there is an enquiry of a researcher, this is returned to the respective part-
ner institution which then has to decide whether it hands the samples to the re-
searcher or not. This system enables a very quick identification of samples that are 
relevant to a study. As to the protection of privacy, Schröder emphasized that 




partner biobanks cannot look into each other’s sample collections. Furthermore, 
the data that are collected at the database are structured in cases. Consequently, 
researchers cannot go for individual patients, but only for certain groups of diseas-
es. Finally, the access to the database is restricted to scientists that need to register 
personally to the system. Schröder concluded her presentation by pointing out that 
the German TMF concept (Telematic platform for medical networks of research) 
of genetic data protection serves as a model for the CRIP data protection regime, 
which may thus become a model for other biobanking networks as well.  
3 Results 
After these twelve extremely rich and sophisticated talks, Christian Lenk undertook 
the task of summarizing the major findings that emerged during the three days of 
discussion.  
 Firstly, the talks and discussions revealed obvious difficulties in defining 
the concepts of privacy and confidentiality unambiguously in the context 
of human tissue and genetic databanking. 
 This cannot only be explained by different philosophical, legal and 
national traditions. In addition, several speakers convincingly articulated 
their doubts that the traditional notion of privacy can simply be 
transferred to the field of electronic data processing and genetic research 
biobanks.  
 Given this development, some speakers expressed their sympathy for a 
liberalisation of biobank research. If privacy cannot be guaranteed in this 
field, this may speak for the establishment of open consent rules. 
 However, as to the protection of privacy there seems to be no 
homogeneous development. In fact, the presentations provided examples 
of both: the strengthening of the private sphere of the individual, but also 
the weakening of the individual’s rights. 
 However, the presentations reached a consensus that the definition of 
privacy depends not only on the individual and the nature of data collec-
ted, but is also closely related to the surrounding culture, societal 
relationships and the specific context of communication of information. 
If privacy is not an individualistic, but rather relational concept that 
consists of rights and corresponding duties (this was most clearly stated 
by Lars Ursin), it will be a future task to define the duties of tissue 
researchers and operators of biobanks towards the individual donors.  
 Concerning the violation of privacy, several presentations emphasized 
that potential harms are not only to be found on an individual level as 
concrete harms, but they also affect the social level by engendering an 
 Katharina Beier 
 
60 
atmosphere of surveillance and social control that liberal democratic 
societies should avoid. 
 Whilst the concerns towards the Personal Genome Project are by all 
means justified, one has to be aware of the fact that this is not the 
standard case of biobank research. The challenges in this context arise 
from the extension of the sphere where data is communicated, shared and 
distributed. According to Lenk, one particularly has to think of 
distributions from the patient-physician relationship to the local medical 
hospital, to national networks and finally to international networks inside 
and outside the EU. 
 Given that privacy and confidentiality are typically located in the patient-
physician relationship it appears as a future task to examine how these 
concepts can reasonably be applied to other spheres. 
 Lenk critically remarked that the instruments for the protection of privacy 
that have been mentioned at this conference are still rather traditional 
ones, such as data protection, anonymization, confidentiality and 
informed consent (might it be broad or more specific). Consequently 
there is a need to think of an adequate adaption of already existing ethical 
and legal instruments in the field of human tissue research instead of 
inventing completely new concepts and methods for the protection of 
privacy and confidentiality. 
 In the final discussion it was also mentioned that the idea of benefit 
sharing should take a much more prominent stance in the discussion 
about human tissue research. In particular, it was argued to divert some 
of the revenues from biobank research to Third World Countries. Whilst 
so far contributions consist mainly of taxes and foreign aid, there is also 
good reason to think of support in terms of biobank research results, as 
there are improved medical care and new drugs to severe illnesses.   
In terms of the Tiss.EU projects’ overall aims, the conference made a major con-
tribution to all four focal themes. It was obvious that the topic of privacy, confi-
dentiality and personality rights has many overlaps with other ethical and legal 
issues, such as informed consent, rights and entitlements in human tissue and cells, 
and last but not least also to anonymization and pseudonymization. The confer-
ence deepened already existing cooperations with several researchers, but estab-
lished also new contacts in the wider European research community. In particular, 
all speakers agreed to join the network of experts that is to be established and con-
tinuously enlarged in the course of the Tiss.EU project.  
 
Procurement, Storage and Transfer of  Tissues and 
Cells for on- linical Purposes in a Legal and 
Ethical Perspective 
Fourth International Workshop of the Tiss.EU Project 
Padua, 24-26 September 2009 
 
Alessandra Bernardi, Luciana Caenazzo, Renzo Pegoraro 
1 Introduction 
The Fourth International Workshop within the Tiss.EU project was organized by 
Renzo Pegoraro, Fabrizio Turoldo, Luciana Caenazzo, Alessandra Bernardi and 
Marco Agostini, from Fondazione Lanza of Padua (Italy), in cooperation with the 
University of Padua. The workshop was prepared in close collaboration with two 
partners of the Tiss.EU project, Dublin City University (Ireland) and University of 
Vilnius (Lithuania). About 30 persons, speakers included, participated at the work-
shop from 24-26 September 2009.  
The main focus of the workshop was one of the four Focal Themes of the 
Tiss.EU project, “Procurement, storage and transfer of tissues and cells for non-
clinical research purposes” (Focal Theme A) in Mediterranean Europe. Due to the 
interdisciplinary nature of the workshop’s subject, invited speakers represented a 
wide range of disciplines, such as Ethics, Law, Medicine, Philosophy, Sociology 
and Biosciences (Genetics and Biology). In order to explore the topic, the work-
shop was divided into four steps: 
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1) introduction to the state of the art of the focal theme from a scientific, le-
gal and ethical point of view (see presentations given by Angelo Rosolen, 
Alexander Schuster and Eugenijus Gefenas); 
2) country reports by experts from Cyprus, Greece, Malta, Slovenia and Italy 
on relevant laws and ethical guidelines which regulate the procurement and 
retention of human tissues and cells at the national level and description of 
the impact of current EU legislation and related guidelines on biomedical 
research in each country; 
3) presentation of contributions on ethical and legal issues concerning foren-
sic DNA databases and the forensic use of DNA biobanks; 
4) public session recovering basic information for the general public as well 
as specific aspects (e.g. type of consent and data protection) and perspec-
tives of the focal theme (e.g. a sociological comment on public perceptions 
of the involvement in research biobanks). 
2 The contributions 
2.1. The state of the art 
This first layer served to define the state of the art of the focal theme A, consider-
ing different aspects of the topic. From a scientific point of view, the following 
points were clarified by Angelo Rosolen (University of Padua) and shared with work-
shop participants:  
 Biobanks are invaluable tools for biomedical research. 
 There are two major types of biobanks: population-based biobanks and 
disease-oriented biobanks. Population-based biobanks are needed for epi-
demiological studies and for studies of environmental and genetic factors 
and human health. Disease-oriented biobanks are most meaningful if or-
ganized in the context of clinical trials and/or multicentric groups with 
some specified objectives and priorities defined upfront.  
 Biotechnology developments heavily influence the type, setting and scope 
of a biobank. 
 The establishment of a biobank must rely on sufficient and continuous 
availability of resources. 
The second contribution by Marco Agostini (University of Padua) was on the Euro-
pean Networks that collect human biospecimens annotated with essential clinical 
data and properly consented for broad investigational use. In fact, the shortage of 
standardized, high-quality biospecimens is widely recognized as a significant road-
block (especially in cancer research). The mission of several different EU networks 
(e.g. Tubafrost, BBRI, Conticanet, EuroBioBank , CNIO Tumour Bank Network,  
Confederation of Cancer Biobanks) is to guide, coordinate and develop the Insti-




tute’s biospecimen resources and capabilities and ensure that human biospecimens 
for research are of the highest quality. This is accomplished through the develop-
ment of a common biorepository infrastructure that promotes resource sharing 
and team science, in order to facilitate multi-institutional, high throughput genomic 
and proteomic studies. 
From a legal perspective, the aim was to offer an outlook of the current situa-
tion in European law in the area of procurement, storage and transfer of human 
tissues and cells. The main difficulties to achieve this goal have been recognized as 
the scarcity of a national legal regulation and as the fast development of the matter 
spread over different legal systems and levels. 
Alexander Schuster (University of Trento) gave an overall view of the EU Tissue 
Directive (Directive 2004/23/EC), deepening in particular the principle of volun-
tary and unpaid donations through the cited Directive, the Oviedo Convention, the 
EU Charter CoE Rec (2006)4 and the Directive 02/98/CE. In his speech, Schuster 
also dealt with need, characteristics and actual models of consent. Furthermore he 
underlined that criteria for accreditation and authorisation of biobanks appear still 
uncertain. A relevant document is the 2007 OECD Best Practice Guidelines for 
Biological Resource Centres. However some countries – e.g. Italy – refer to those 
standards without clarifying them extensively and make a merge of several sources 
(OECD, CoE Rec (2006)4, CE Dir. 04/23). 
From an ethical point of view, Eugenijus Gefenas (Vilnius University) identified 
two scenarios: the research on retrospective collections of human biological sam-
ples and in contrast the research on prospective ones, dividing the latter into col-
lections for specific research purposes (biobanks) or secondary uses (“research 
storage” of residual tissues). The case of samples taken for a specific non-research 
purpose (e.g. therapeutic, diagnostic or previous research interventions) can later 
become scientifically interesting. Gefenas explained that re-contacting and obtain-
ing specific consent is thought to be the best policy from the ethical perspective, 
but depending on the circumstances it may be impracticable for a number of rea-
sons. He suggested that in cases where re-contacting is not acceptable, it may be 
possible to use samples without consent (public interest may override autonomy 
requirements) and suggested that Research Ethics Committees (RECs) may under 
certain conditions decide whether the secondary use of human biological speci-
mens for research purposes can be exempted from consent requirements. On the 
other hand, Gefenas discussed different levels of consent (from specific to blanket) 
for prospective collections. At the end, he underlined that discussions on consent 
focus on themes of procurement and use of biological material for research pur-
poses but little attention is given to issues related to storage and transfer which also 
introduce possible logistic challenges (for instance regarding the growing length of 
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3 Country reports 
3.1 What are the provisions regarding the procurement, storage and 
transfer of tissue and cells for research purposes in your country? 
Greece: The collection and processing of sensitive data require prior authorization 
by the Data Protection Authority. There are exceptions, such as data collection 
from physicians that are bound by confidentiality, but they do not apply to  
biobanks. 
Cyprus: From the legal point of view, Cyprus does not have any laws that regulate 
the question, but regarding the ethical position, the Cyprus National Bioethics 
Committee (CyNBC) has published its “Opinion on the Establishment and Use of 
Biobanks and Registries of Human Biological Samples for Research Purposes”. 
The CyNBC’ s statement distinguishes between “biobank” and “biobanking” and 
“sample collection” or “sample databasing”. 
Biobanks by definition, contain human biological samples and/or substances 
with or without personal data and other relevant information. The state must legal-
ly recognize the purpose and role of the biobank, the principles and procedures 
governing the collection and provision of the samples/data by researchers, and the 
transparency/dissemination of the research results originating from biobank sam-
ples/data. The state must also assure free and informed consent from the individu-
als donating samples/data. In particular, they must know that their samples will be 
placed in the biobank, that samples are collected to support several present and 
future research projects both within and outside the country, that researchers from 
both Cyprus and abroad can access the samples/data of the biobank by following 
established procedures. Finally, the establishment and operation of the biobank 
should be reported to the Data Protection Commissioner. Consistent quality as-
surance procedures must be guaranteed, with a process of official accreditation of 
the biobank. 
Sample Collections or Sample Databases by definition contain human biological 
samples and/or substances with or without personal data and other relevant in-
formation. They fall under the responsibility of a person and/or organization/ 
establishment/institution and are collected for specific research projects. Free and 
informed consent can be either be “closed” or “open”, the establishment and op-
eration of the biobank should be notified to the Data Protection Commissioner. 
Malta: Malta is still bound by EU legislation. The Human Blood and Transplants Act, 
that incorporates the EU Directive 2004/23/EC (published as Bill No. 62 in the 
Government Gazette, No. 17886, 28/2/2006), sets standards of quality and safety 
for the donation, procurement, testing, processing, preservation, storage and dis-
tribution of human tissues and cells, including “haematopoietic peripheral blood, 
umbilical-cord (blood) and bone marrow stem cells, reproductive cells (eggs, 
sperm), foetal tissues and cells and adult and embryonic stem cells”. This Directive 




only applies to research on human tissues and cells when applied to the human 
body (i.e. in vitro research is excluded). 
Slovenia: Slovenia recently passed The Act on quality and safety of human tissues and cells 
intended for medical treatment (Act on Human Tissues) (UL RS 61/07).The first insti-
tution responsible for performing the Act on Human Tissues is the Agency for 
Medicinal Products and Medical Devices (Agency) of the Republic of Slovenia, 
established on 01 January 2007. Some legal provisions regarding biomedical re-
search are also included in actual Penal Code (UL RS 95/04). The Act on Human 
Tissues is compatible with requirements and obligations of OC, Directive 
2004/23/EC of the European Parliament and the Council of Europe (31 March 
2004) on setting standards of quality and safety for the donation, procurement, 
testing, processing, preservation, storage and distribution of human tissues and 
cells, the Commission Directive 2006/17/EC (8 February 2006), which imple-
ments the Directive 2004/23/EC and the Commission Directive 2006/86/EC (24 
October 2006) implementing Directive 2004/23/EC. 
Italy: There are two reference Acts (the Council of Europe’s “Recommendation on 
research on biological materials of human origin” and the National Committee for 
Biosafety and Biotechnologies Guidelines for the Institution and Accreditation of 
Biobanks) that contain the following provisions: specific information and consent 
or dissent of the donor, non-profit purposes of the donation, exclusion of donor’s 
remuneration, prohibition to interfere with the private life and prohibition against 
engaging in personal discrimination for participation in research or the knowledge 
of data derived from conserved samples, right to access and control the personal 
data of the party concerned, evaluation of the scientific pertinence and ethical ac-
ceptability of the research project by an independent commission. On the basis of 
the Authorisation of the Guarantor of Privacy of 22 February 2007 it is furthermore re-
quired that when the genetic data management cannot take place without identifi-
cation of the patient, specific measures must be adopted for keeping data separate-
ly from the very beginning of the collection. Except when such measures are not 
possible or require a disproportionate effort, the storage of genetic data and bio-
logical samples for research purposes can be carried out until the analyses are 
completed or the goals of the research project are achieved. The origin of the sam-
ple should be specified in addition to the measures taken to guarantee that the 
donor has given his/her consent, and genetic data and biological samples should 
be identified using codes or other means and be decoded only when necessary. In 
case that the database also contains information regarding genealogy or the health 
status of individuals, appropriate technical measures must be taken to secure the 
separation of this information (genealogy or the health status of individuals) from 
genetic and other personal data.  
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3.2 Does your Country have a discrete tissue law? 
Greece: There is no tailor-made legislation on tissue, but the Constitution contains 
some fundamental principles such as the Protection of Dignity and Privacy, Pro-
tection of Health and Genetic Identity (Art 5), Protection of Public Health is an 
obligation of the state (Art 21). 
Cyprus: There is no discrete tissue law.  
Malta: There is no specific mention of the use of tissues in research in Maltese 
legislation. There is however a Human Blood and Transplants Act, and it is envisaged 
that the EU Directive 2004/23/EC will be incorporated into this Act. 
Slovenia: Yes, it has a discrete law (Act on Human Tissues, 2007). 
Italy: There is no specific legislation, but some reference Acts and guidelines: 
“Guidelines for the Institution and Accreditation of Biobanks” (National Commit-
tee for Biosafety and Biotechnology, 2006), the Italian National Bioethics Commit-
tee’s document on “Biobanks and research on human biological material” (2006), 
the Decree of Ministry of Economic Development which establishes the proce-
dure for the institution of organisms deputed to certification of biobanks as bio-
logical resource centres (2006), the “Guidelines for Genetic Biobanks” of the Ital-
ian Society of Human Genetics and  Telethon Foundation, 2003, the Authorisation 
of the Guarantor of Privacy of 22 February 2007. 
3.3 Who is allowed to procure, store or transfer tissue and cells? 
Greece: In Greece it is not defined who can procure, store and transfer tissues and 
cells but according to the conditions of consent, access is only granted to named 
persons. 
Cyprus (CyNBC Recommendations): 
 Biobanks – Any organization, university, institute or other legal establish-
ment, private or governmental, which obtains approval by the CyNBC, 
obtains the permission of the Government (Ministry of Health) and noti-
fies the establishment of the biobank to the Data Protection Commission-
er. 
 Sample collections or sample databases – Any legal entity which obtains approv-
al by the CyNBC and notifies the establishment of the collection/database 
to the Data Protection Commissioner. 
Malta: In Malta it is not defined who can procure, store and transfer tissues and 
cells but according to the conditions of consent, access is granted only to named 
persons. 
Slovenia: The Agency and the donor centers are allowed for the procurement, storage 
and transfer of tissue and cells. Article 10 of the Act on Human Tissues provides the 




conditions for traceability in both directions (from donor to user and back) with 
strict adherence to personal data protection (necessary double-blind marking of 
each part of tissue, cells or product).  
Italy: In Italy it is not defined who can procure, store and transfer tissues and cells 
but according to the conditions of consent, access is granted only to named per-
sons. 
3.4 What type of consent is required in order to do research in human 
tissue and cells? 
Greece: The collection of biological material without consent is unconstitutional. 
Physicians also need the patients’ consent for any medical intervention. The Data 
Protection Act requires that consent is “freely given, explicit and specific indication 
of will”; also the subjects should receive “information as to the purpose of pro-
cessing”, “the data or data categories being processed”, “the recipient or categories 
of recipients of personal data as well as the name, trade name and address of the 
controller and his/her representative, if any”; such consent may be revoked at any 
time without retroactive effect. 
Cyprus (CyNBC Recommendations): 
 Biobanks – In general: individuals must provide their consent freely after 
having been informed that their samples/data will be stored for research 
purposes and that their samples/data may end up in different research 
teams in different parts of the world. They are given the opportunity to 
declare whether they would like to be informed of any research result that 
may directly or indirectly affect their health; they are also told what would 
happen to their samples/data in case the biobank closes down; finally they 
are informed that they have the right, at any given time, to withdraw their 
sample/data. The consent form is approved by the CyNBC or its Ethics 
Review Committees.  
 Sample Collections or Sample Databases – In general: individuals must provide 
their consent freely after they have been informed that their samples/data 
will be stored for research purposes. Possible options comprise a “closed 
consent” (meaning that any tissue or DNA obtained from the patient will 
be analysed and then destroyed. Specifically the patient gives his/her con-
sent for a blood/tissue sample to be taken for testing related only to a 
specific condition, and that sample and any DNA extracted from it will be 
destroyed once the results of the testing are available) being very specific 
about the project’s content and procedures and duration; or an “open 
consent” (meaning that samples of tissue or DNA obtained from a patient 
may be stored indefinitely or will be used in research relating to specific 
conditions) which allows that samples/data can be used also for other fu-
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ture research programs provided they are approved by the CyNBC and its 
established Ethics Review Committee. Donors are given the opportunity 
to declare whether they would like to be informed of any research result 
that may directly or indirectly affect their health, and they are also told 
what will happen to their samples/data in case that the collection/database 
closes down. They are informed that they have the right, at any given time, 
to withdraw their sample/data. The consent form is approved by the 
CyNBC or its Ethics Review Committees.  
Malta: There are no specific laws yet on what type of consent is required in order 
to do research on human tissue and cells. However, Malta will most probably 
adopt the broad consent, which is currently being practiced. 
Slovenia: Slovenia does not have a specific legal regulation related to informed 
consent (IC). However, The Law on Patient’s Rights (2008) has defined some re-
quirements about information and full consent. In principle, full IC is required, 
except in those cases where the obtainment of consent would involve unreasona-
ble efforts or the risk of undue invasion of privacy is minimized.  
Italy: In accordance with the Authorisation of the Guarantor of Privacy of 22 February 
2007, informed written consent of the patient is necessary to store biological sam-
ples and to manage genetic data, unless the data are used entirely for statistical or 
research purposes foreseen by law. For different research purposes informed con-
sent has to be obtained anew, but not if biological samples and genetic data are 
anonymized, if it is impossible to inform the patient despite reasonable efforts and 
if the research program (approved by the Ethics Committee) is authorized by the 
Guarantor according to article 90 of the Data Protection Code. The consent given 
by the patient can be freely withdrawn every time. 
3.5 What are the provisions for the secondary use of samples (i.e. research 
endeavors diverging from the originally foreseen purpose)? 
Greece: Data can be processed for purposes that where included in the infor-
mation given prior to the donor’s consent. Data can be lawfully processed for 
research and scientific purposes on the condition that it is anonymised. Public 
authorities can access data without an individual’s consent but need to follow the 
authorisation of the Data Protection Authority. 
Cyprus (CyNBC Recommendations): For all samples collected after 2004, all re-
searchers must ask the donors of samples to declare whether they provide either a 
“closed” or an “open” consent. Samples collected legally before 2004 can be used 
for research, provided the research activity is approved by the CyNBC and that the 
samples are anonymized.    




Malta: The Data Protection Act protects the individual insofar as any samples ob-
tained can only be used for the intended purposes for which the informed consent 
was obtained. There is also a time limit how long samples can be stored. Article 8, 
following the EU Directive 2004/23/EC, allows for an exemption when data is 
processed for historical, statistical or scientific purposes. However, the term “sci-
entific purposes”, as in the EU counterpart, remains unclear. Many would interpret 
this as meaning that once data is anonymised and no results which may identify 
individuals are obtained, the procurement, storage and use of these tissues is al-
lowed. However, recital 26 of the same Directive makes this doubtful. 
Slovenia: Article 33 of the Act on Human Tissues provides the link between the insti-
tutional units which regulate the use of tissues and cells and the “third person” 
(secondary user, research institution as for example the Biological Institute of Slo-
venia).  
Italy: On the basis of the Authorisation of the Guarantor of Privacy of 22 February 2007, 
the storage of genetic data and biological samples for research purposes can be 
carried out until the analyses are completed or the goals of the research project are 
achieved. For different research purposes informed consent has to be obtained 
anew. 
3.6 Does your country have a regulation on forensic DNA Databases? 
Greece: The Penal Code regulates the analysis of DNA (Art. 200A) deriving from 
biological material collected by suspects of criminal offences. Biological materials 
should be destroyed after DNA analysis. DNA fingerprint should be destroyed if 
they do not match with a crime scene or be kept until the end of the trial, in case 
that the result is positive (and then destroyed after the trial). The current legislation 
does not allow the creation of forensic genetic fingerprint data bases.  
Cyprus: Cyprus does not have a law for the regulation of forensic DNA databases. 
It does, however, maintain a National Forensic Database which is governed by the 
Data Protection Law (2001) and the Police Establishment Law. Basically, the genetic 
profiles of all individuals who are sentenced to imprisonment are entered into the 
forensic database. The genetic profiles remain there until their record is removed 
based on the Police Establishment Law (i.e. depending on the crime committed). 
Genetic profiles originating from unidentified crime scene stain samples are stored 
in the forensic database.     
Malta: There are no legal provisions on forensic databases. The Traffic Regulation 
Ordinance allows police officers to take breath and urine samples on pain of being 
found guilty of an offence if one refuses. By contrast, any use of blood samples for 
purposes of identifying DNA must have the consent of the individual.  
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Slovenia: Slovenia has a regulation on forensic DNA databases since 2008 (infor-
mal since 2001, when the EU countries agreed on the use of a common set of 
DNA-markers).1  
Italy: Italy ratified the Prum Treaty with the Law n.85 (30 June 2009) into national 
law. It regulates the establishment of DNA databases and introduces modifications 
of the Code of Penal Procedure in relation to measures which may infringe indi-
viduals’ rights of freedom of the person. 
4 Forensic uses of samples and data 
The session was kicked off by Pamela Tozzo (University of Padua) with a lecture on 
“Biobanks for medical research: does the Italian context safeguard minors?”. The 
background was that genetic research on biological material from minors can yield 
valuable information, which can improve our understanding of genetic-
environmental interactions that could not be fully understood if only adults partic-
ipate, as well as the development and genesis of early-onset genetic disorders. In 
this context, the major ethical concerns on biobanks are related to consent, priva-
cy, confidentiality, commercialization, and the right to be or not be informed. 
Moreover, research on paediatric data raises specific governance and ethical ques-
tions with regard to consent and privacy, which are not well deepened in the de-
bate on adults’ samples collection and storage. The talk analyzed different Europe-
an guidelines and position papers devoted to these themes, with particular refer-
ence to the Italian context, focusing on what is mentioned in each document on 
the ethical and legal requirements that guarantee minors’ rights. 
Subsequently, Renzo Pegoraro presented the work of Petra Bard (CEU Center for 
Ethics and Law in Biomedicine, Budapest) entitled “The fight against terrorism: 
European data protection and the establishment of a surveillance society”. The 
presentation started with an introduction into the positive developments of foren-
sic sciences on the one hand, and a warning against the dangers of measures in-
truding into privacy on the other, which are sometimes touching the borders be-
tween what is permissible and what is not from a human rights perspective. The 
role, benefits and dangers of genetic biobanks in the forensic context have been 
outlined. After having shown that the fear of crime is deepening in contemporary 
liberal societies – leading to the development of a “preventive state” (i.e. a state 
perceiving all citizens as suspects) – DNA collection, storage and analysis were 
singled out as means in the fight against real and perceived dangers of serious 
crimes and terrorism. The presentation of Petra Bard outlined a theoretically viable 
model with due regard to a perhaps not so utopian population-wide forensic data-
base. This part was followed by an analysis of forensic genetics in the European 
                                                     
1 The database is directed by the Ministry of Interior, Central Police Administration, Center for 
Forensic Investigation (http://www.policija.si/index.php/generalna-policijska-uprava). 




Union. Finally, special emphasis was given to the principle of availability intro-
duced by the Hague programme of 2004, and the exchange of forensic DNA data 
amongst the member states. 
The following speaker, Nils Hoppe (University of Hannover), focused his 
presentation (“Only problems, no solutions: reflections on some of the more an-
noying discrepancies in the discussion of commodification”) on the fallacy of the 
primacy of law, the misguided notion of wanting to shackle technology, the abuse 
of language and law and the despotism of the principles of autonomy. In particu-
lar, he criticised that in the vast majority of academic discussions in relation to 
commodification, the language being used is either not suited for this purpose or 
simply wrong. It is supposed to convey elements of altruism and altruistic giving 
where no such altruistic elements are present. Hoppe first suggested that we ought 
to critically question whether regulation is necessary in the first place, further on 
levelling the bulk of his criticism at the fact that, despite deploying property law 
principles when dealing with human tissue, we shy away from calling it property. 
This, he claimed, is not a deficiency in the law but a terminological uneasiness on 
the part of the public. Finally, he strongly criticised that the current regime disen-
franchises the individual whilst underpinning commercialisation of the human 
body through industry – which seems to be precisely the outcome which is deemed 
most undesirable.  
Claudio Tamburrini (Stockholm University) presented the lecture “Forensic bi-
obanks and privacy trade-offs: who should bear the burden?” He adopted an utili-
tarian point of view regarding forensic DNA biobanks. Tamburrini argued that a 
widely held critique against forensic biobanks is that they violate donors’ privacy. 
In his view, it is both unfair (we would be using donors merely as means to solve 
crimes) and counterproductive (people might become reluctant to contribute their 
samples in the future) to disregard donors’ rights in order to fight crimes. On the 
other hand, he added that this traditional objection to forensic biobanking affects 
only one aspect of the notion of privacy. In particular, this objection does not take 
properly into account the fact that the right to privacy, although an absolute one, 
can sometimes rightfully be overridden by other, more important considerations 
such as serious crime prevention. Accordingly, the privacy-based criticism against 
forensic uses of biobanks cannot be considered as a decisive reason to ban this 
practice. 
5 Public session 
The public session started with an introduction into the Tiss.EU project by the 
coordinator, Christian Lenk. Lenk’s presentation focused on the research objectives, 
on the essential questions in the areas of ethics and law, on the connections be-
tween theoretical issues and practical research, on the necessity of harmonisation 
of public values and research policies in the European Union and finally on the 
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cooperation among different countries, universities, disciplines, science and poli-
tics. 
The second talk was given by Mirella Filocamo, who works at the IRRCS G. 
Gaslini, a paediatric institute in Genova, and at the Telethon Foundation. Filoca-
mo’s presentation was an exhaustive outline of the main characteristics of  
biobanks and of implied scientific, legal and ethical issues. Filocamo started with a 
definition of biobanks, sketching their goals, peculiarities, and typologies. He also 
discussed the provenience of samples, research applications, beneficiaries, re-
quirements, guidelines, certification criteria, sample quality, data management, 
sample registration, data registration and services such as storage and distribution. 
The second part of Filocamo’s presentation focused on the ethical and legal issues 
implied in biobanks, such as confidentiality, privacy, correct use of samples, in-
formed consent and avoidance of discrimination. Finally, in the third part, Filoca-
mo talked about his personal experiences at the Gaslini Insitute and at the Tele-
thon Foundation. 
Corinna Porteri from the Bioethics Unit of “IRCCS Fatebenefratelli” of Brescia, 
offered an overview of the ethical issues related to biobanks for non-clinical pur-
poses. The main topics of her presentation were: 1) information and informed 
consent procedures; 2) protection of confidentiality; 3) return of results to the 
subjects; 4) access to samples and data; 5) commercial exploitation and benefit 
sharing; 6) public participation and trust. 
Carlo Petrini, chair of the Bioethics Unity at the “Istituto Superiore di Sanità” in 
Rome, reflected on several ethical issues in genetic research. Regarding the transfer 
of tissues and data protection, Petrini argued that the protection of privacy inter-
ests must be balanced against the interest in advancing research.  He particularly 
focused his attention on the following ethical issues: individuality and respect for 
autonomy, recognition and respect for difference, the multivariable nature and 
expression of genetic information, mutual exchange through consultation and 
communication, protection from discrimination and stigmatization, security, ac-
countability, equity, citizenship and universality. 
The last presentation by Federico Neresini (Department of Sociology, University 
of Padua) focused on the sociological aspects of biobanking. In Neresini’s opinion, 
biobanks can be perceived as an example of the mutual constitution of scientific 
and social dimensions, because they collect, purify and conserve biological materi-
al. This material, which seems to stem from an environment external to that of 
science, is made available for scientific research by reorganising the environment 
according to its needs. From this view, two main consequences have been dis-
cussed. Firstly, the contradictory character which emerges: on the one hand, the 
“pieces of ourselves” which are conserved in a biobank must be made independent 
from the donor; on the other hand, the organic material is always part of someone, 
and its value depends on the maintenance of a link with its original owner. Second-
ly, biobanks are culturally legitimated because they produce scientific knowledge 
which is useful for curing a body, which is a precious but fragile material support 




for individual identity. All these elements can contribute to an explanation why 
people are willing to become donors even if they are aware that they cannot direct-
ly benefit from the advancement of science which biobanks could prompt. This 
conclusion reaffirms the importance of an attentive evaluation of autonomy of 
sample donors and protection of their privacy and the need for a shared legislation 
on this matter. 
This session provided an opportunity for stressing the importance of an inter-
disciplinary approach by allowing the participation of various health care profes-
sionals as well as other experts of the ethical debate on biobanks. The participation 
of health care professionals and the public was particularly welcomed in order to 
realize a broad disseminating of the results of the Tiss.EU project. 
6 Results 
In summary, the workshop in Padua offered an introduction to the most crucial 
scientific aspects of the Focal theme A and provided valuable insights into the 
state of the art of the European legislation in the area of procurement, storage and 
transfer of human tissues and cells for non-clinical purposes. Despite major diffi-
culties in the process of harmonization of Biolaw at the European and internation-
al level, such as the lack or the variety of national regulation and the rapid devel-
opment of biological knowledge, supranational instruments have been indicated as 
a tool for scientific community and civil society.  
The ethical issues in Focal Theme A are closely connected to the issues of the 
other three Focal Themes when related to non-clinical research. The issues that 
have been identified as most specific to “procurement, storage and transfer” con-
cern the autonomy of sample donors and the protection of their privacy. In partic-
ular, speakers and participants discussed the types of consent (specific or broad) 
and the types of data security (coded materials, linked anonymised materials, un-
linked anonymised materials). The major question was whether strategies of sof-
tening standard criteria can be defined (e.g. allowing to broaden consent and to 
waive consent/recontacting requirements under certain circumstances). Other 
possible ethical problems in Focal Theme A concern the justice-benefits rate, the 
commodification of the human body, issues regarding specific types of tissues and 
cells (e.g. embryonic tissues), perspectives from various cultures, research on vul-
nerable populations, balancing interests of individuals and society. 
The country reports offered the possibility to discuss the main similarities and 
differences between national legislations and ethical guidelines as well as the appli-
cation of EU legislation in the respective country group. The participating coun-
tries show different levels of development concerning the legislation in the respec-
tive Focal Theme. In particular, Slovenia is the most developed state in this respect 
(i.e. it has a discrete law and other reference Acts). Greece and Italy demonstrate 
an intermediate state of development (no “tailor-made” legislation but they make 
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reference to the national Constitution, Guidelines or other Acts). Malta is the 
country that seems to be most bound by EU legislation, having no specific laws for 
managing the topic. Finally, Cyprus as well does not have any particular laws to 
regulate the procurement, storage and transfer of tissues and cells for research 
purposes but the Cyprus National Bioethics Committee (CyNBC) has published its 
“Opinion on the Establishment and Use of Biobanks and Registries of Human 
Biological Samples for Research Purposes”. In fact, the CyNBC is playing a key 
role in the national organization of sample collections and biobanks. Despite the 
small size of the country, this national approach appears very interesting and might 
be useful for other countries as well. Concerning the regulation on forensic DNA 
databases the country group situation appears homogenous: Slovenia, Cyprus and 
Italy have specific laws, Greece has reference Acts but no tailor-made legislation, 
Malta does not make any legal provisions for this topic. 
The workshop in Padua also promoted a public session in order to encourage 
the public debate on questions of procurement, storage and transfer of tissues and 
cells for research purposes. In fact, the social perception and exchange of experi-
ences could help to figure out which ethical and legal standards should be applied 
in the harmonization process of European regulations. From the workshop’s 
presentations and discussions the following aspects of the Focal Theme A have 
been identified:  
 Clinicians and clinical researchers routinely obtain human biological sam-
ples and often store them for future research (sample collections) with in-
ternal procedures on quality and confidentiality, mainly consistent with the 
EU guidelines.  
 Existing tailor-made and reference laws permit to deal with several issues 
of the Focal theme in a national context, but ethical dilemmas (e.g. how to 
guarantee autonomy of sample donors and the protection of their privacy) 
remain partially unsolved. For instance, the country reports suggest that 
the patients’ consent for research should always be required by law but 
there is no agreement on the type of consent to be obtained (one-time 
general, specific consent, blanket consent).  
 The country reports proposed some original solutions to cope with the 
Focal Theme A. The Cyprus’s experience in particular deserves to be men-
tioned. Cyprus does not have any laws to regulate the procurement and 
storage of human tissues but the Cyprus National Bioethics Committee 
(CyNBC) has published its opinion on the establishment and use of  
biobanks and registries of human biological samples for research purposes 
and is playing an active role in the process of organization of sample col-
lections and local biobanks. 
 A discrepancy between the public perception of the tissue storage issues 
and that of the medical professionals and researchers seems to exist, but 
the workshop’s participants agree that it can be managed giving independ-




ent and comprehensive information and elaborating shared recommenda-
tions for future EU policy decisions. 
 The necessity of having a specific session of forensic aspects of DNA da-
tabases arises first of all from the fact that advances in DNA technology 
and the discovery of DNA polymorphisms have facilitated the creation of 
DNA databases for the purpose of criminal investigation, followed by a 
considerable range of possibilities for criminal investigations. 
It turned out as a main aspect of the Focal Theme A that apparently in some 
countries of the Mediterranean area the interests of the Penal Law overcome 
the individual right of giving informed consent regarding the procurement, 
storage and transfer of biological sample for judicial purposes. 
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1 Introduction 
The fifth Tiss.EU International Workshop, organized by the Legal Pathways Insti-
tute for Health and Bio-Law, took place in Leiden, the Netherlands, 9-11 Decem-
ber 2009. More than 25 participants and speakers from all over Europe engaged in 
discussions on Rights and Entitlements in Human Tissue and Cells in the BENELUX 
Countries. 
The core of the workshop, the country reports on Belgium, the Netherlands 
and Luxembourg, was preceded by a scientific session where workshop partici-
pants had to analyze various sorts of tissue, learn about PCR, and perform extrac-
tion and processing of DNA (headed by Dr Carin Cruizen, University of Utrecht). 
Following this session an invited speaker, Natasja Klioueva LLM MSc (Nether-
lands Brain Bank/Brain Net Europe), addressed the importance of brain tissue 
banking for research into neuropsychiatric diseases and issues encountered with 
such tissue collections, including the right of access, use and stakeholder interests. 
She stressed the need for transformation of the “private” tissue collections into 
professionalized research biobanks. 
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In the country reports, the legal experts from Belgium (Herman Nys of Leuven 
University), Luxembourg (Mike Schwebag of the Luxembourg Ministry of Health) 
and the Netherlands (Jasper Bovenberg of the Legal Pathways Institute for Health and 
Bio-Law) gave a review of the laws and regulations of their respective countries 
regarding the rights and entitlements in human tissue and cells, or, notably, the lack 
thereof. In order to put their overview into a context, the experts were asked to 
consider a series of legal issues and questions for their respective jurisdictions 
raised by a real life case scenario concerning the development of human skin mod-
els. The scenario was specifically prepared for the workshop by A. El Ghabzouri, a 
prize winning dermatology researcher of the Leiden University. 
The last day of the meeting was kick-started with Arnaud d’Agostini’s presenta-
tion of the government funded $200 million research enterprise - Integrated  
Biobank for Luxembourg (IBBL) initiative, comprising three complementary pro-
jects in collaboration with high profile US research institutions. The legal issues 
triggered by the IBBL were subject to subsequent Moot Medical Ethical Review 
Boards (a role playing game). Assuming the role of a Medical Ethical Review 
Board, three different groups of the workshop participants had to discuss and 
agree on draft language in the research protocol, in particular: ownership of tissue, 
control of use, tissue of mentally incompetent participants, feedback, cross-border 
flow, creation of and research on cell lines, IP and benefit-sharing. 
In the final presentation given by Sven Bostyn, a Belgian patent attorney affili-
ated with the University of Amsterdam, the focus shifted from the traditional 
rights and entitlements in tissue, such as consent and feedback, to the IP-rights. 
Bostyn eloquently guided the participants through the intricacies of morality em-
bryonic stem cells research and the European patent law by providing a thorough 
analysis of European and US patent case law. 
The objective of the meeting was that legal experts from Belgium, Luxem-
bourg and the Netherlands present a “country report” on the laws and regulations of 
their respective countries regarding rights and entitlements in human tissue and 
cells. The experts were expected to list the various types of tissues in a matrix and 
then briefly go over the associated legislation and self-regulation. 
  




2 Country Reports 
2.1 Country Report: Belgium (Herman Nys, University of Leuven)  
Legal rules: 
 Law of 19th December 2008 regulating the procurement and the use of 
human bodily material for medical application in humans or for scientific 
research (entered into force on 01 December 2009). The law also imple-
ments the Directive 2004/23/EC. 
Basic principles of the law: 
 Removal from a deceased source: opting out rules of Organ Donation 
Law 1986 are applicable (art.12) 
 Removal from a living source: informed and written consent of the donor 
or legal representative in case of a minor or incapacitated donor is required 
(art.10) 
 Primary use: articles 10 and 12 
 Secondary use not for scientific research: 
 Informed consent of the source, unless asking consent is not appro-
priate/impossible, in which case a positive advice of EC university 
hospital is required (art.20 §1) 
 Every secondary use has to be approved by an EC licensed minister 
(art.21) 
 Secondary use for scientific purposes: 
 consent of the source is presumed after written information on the 
use and no opposition by source or legal representative before any use 
is made (art.20 §2) 
 Positive advice of EC is required (art.21) 
 Removal of human material is a legal monopoly of a physician in a hospi-
tal (art.4 §1) 
 No benefits may be offered in exchange for the patient’s donation of hu-
man material (art.6 §1) 
 All human material has to be transferred to a bank for human substances, 
which has the legal monopoly for the allocation of human material to us-
ers (art.2, 24). A bank for human substances has to be operated by a hos-
pital and has to be a not-for-profit legal person (art.7) 
 The removal of human material without specific preventive, therapeutic or 
scientific objective (art.8) is prohibited 
 The law contains a prohibition of removal and storage for so called de-
layed autologous or allogeneic use for a specified recipient (umbilical cord 
blood) except if the recipient suffers from a serious illness and sufficient 
material is preserved for use in other persons (art.8) 
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 Right of the donor to be informed of any serious information on health 
status discovered during processing or use of human material (art.11) 
 Material exported from Belgium and imported to Belgium is governed by a 
Royal Decree 29 September 2009, art.18 §1 and §2 
 
Conclusions: 
A new law, which regulates the removal of tissue from living and deceased per-
sons, has entered into force in 2009. It contains specific instructions to transfer all 
tissue to a monopolist bank for human substances, which is designated to allocate 
the transferred tissue to the users. The law also contains specific prohibitions such 
as removal without legitimate purpose and umbilical cord blood banking for a 
specific recipient. 
 
2.2 Country Report: Luxembourg (Mike Schwebag, Ministry of Health of 
Luxemburg) 
Relevant existing acts: 
 Act on autopsy, cadavers (Loi modifiée du 17 novembre 1958 concernant 
l’autopsie, le moulage, ainsi gue l’utilisation de cadavres humains dans un 
intérêt scientifique ou thérapeutique) 
 Act on blood (Loi du 15 mars 1979 portant réglementation de la transfu-
sion sanguine) 
 Act on removal of human substances (Loi du 25 novembre 1982 réglant le 
prélèvement de substances d'origine humaine) governs mainly organ transplan-
tation on living donors (med) and cadavers: removal of human substances, including 
research 
 Act on tissue and cells with human application (Loi du 1er août 2007 rela-
tive aux tissus et cellules humains destinés à des applications humaines jo 
DIR 2004/23/Œ) governs tissue and cells with application to human body (human 
use) 
 Control over research (on tissue) 
1) Biomedical research including intervention on a human being: Materi-
al collected for purposes of research or for double purposes 
 Consent has to be given 
 Consenting may authorize future use of material 
 Ethics review board (CNER) / Health Department 
2) Use of material lawfully collected at an earlier stage: no clear frame-
work at the moment, Oviedo Convention (art. 22) 
  




Important bioethics acts are imminent to be adopted: 
 Proposed act on ratification of the Oviedo Convention, including additional proto-
cols on cloning, on transplantation of organs and tissue and on biomedical 
research 
Status: Pending in parliamentary process (2006/Parl. Doc. 5528). Generic 
ethical standards for both research and medicine (includes changes to ex-
isting legislation) 
 Proposed act on biomedical research 
Status: Pending in parliamentary process (2006/Parl. Doc. 5552). Frame-
work for biomedical research (proposed: must include intervention on a human be-
ing) 
 Act on medically assisted procreation (no details on status and scope) 
Conclusions: 
 Very limited legal framework, but major “bioethics” texts pending 
 At current state, some domains have no clear regulatory answer 
 Status of waste material removed on non-research grounds is unclear 
 
2.3 Country Report: Netherlands (Jasper Bovenberg of the Legal Pathways 
Institute for Health and Bio-Law) 
Mapping the Dutch legal landscape requires a preliminary identification of (i) the 
various types of tissue that may become available (e.g. garnets, blood, bone etc), (ii) 
the various uses to which they can be put (e.g. clinical, therapeutic, industrial, re-
search etc) and (iii) the various sources of tissue or contexts in which tissue be-
comes available (e.g. adult volunteers, surgical patients, deceased persons etc.). 
Complicating matters is the fact that the same tissue type may be used for different 
purposes, or that tissue obtained from one and the same source may become avail-
able in different contexts, thus subject to different legal regime. 
This highly contextualized nature of the availability of tissue is reflected in the 
many different, divergent and sometimes even conflicting rights and entitlements 
in cells and tissue such as: 
 Environmental laws on medical waste 
 Public health laws 
 Archive status 
 Data protection laws 
 Constitutional rights to bodily integrity and privacy 
 Doctor-patient laws 
 Property rights (civil code) 
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In addition to specific tissue legislation on garnets, embryos, fetal tissue and blood, 
generic legislation applies across the spectrum of tissues. 
 
                         Generic Tissue Legislation (The Netherlands) 
Context/source Legislation Tissue type Use of Tissue 




(skin, fat, bone, muscle, 
arteries, veins, etc. 
Storage and research;  
Production of tissue 
products on basis of consent 
Living Donor Act on Organ   
Donation 
Organs and all sorts of  
tissue 
Storage and research 
Living Donor Act on Blood  
Donation 
Blood Transfusion, storage, 
research, production 
Post mortem donor Act on Cadavers All sorts of tissue, corpse Storage, training and research 
Post mortem donor Act on Organ  
Donation 
All sorts of tissue Storage, processing,  
preparation for              
transplantation, 
transplantation related   
research 
 
One crucial aspect of rights in cells in tissues is the right to control the use of the 
tissue in research. The Dutch legal framework grants the donor the following 
rights in this respect: 
 
                           Control over research on tissue (The Netherlands) 
Tissue type Control by Type of control Conditions 
Sperm Donor Explicit consent METC approval 
Ova Donor Explicit consent  
Fetal tissue Mother Explicit consent  
Blood Donor Opt out  
Surgical waste (skin, 
fat, bone, muscle, 
arteries, veins) 
Patient Opt out for anony-
mous and coded 




Approval scientific committee in 
certain cases  












 The Netherlands have a detailed legal framework for use of specific 
tissue (sperms, ova, fetal tissue etc.) 
 This framework incompletely addresses research use 
 The Netherlands have a generic framework for research on tissue be-
coming available in specific contexts (hospital, post mortem donation) 




 Both frameworks are complemented by civil code and penal code 
 Both frameworks are fragmented, overlap, and do not provide an-
swers to detailed questions 
 Cross border tissue flows are not problematic 
 Much is left to informed consent 
3 National legal contexts applied to a case study 
Ghalbzouri’s case: Building skin and other tissue models 
In order to put their schematic overview of national laws and regulations into 
context and to highlight pertinent issues, they will each use their overview to ad-
dress the various legal issues and questions raised by the same real life case scenar-
io. The case scenario was presented by a researcher of the Leiden University Medi-
cal School, Dr. A. El Ghabzouri. The case and the questions it has triggered for 
Ghabzouri and his team can be summarized as follows: 
Ghalbzouri’s prize winning research pertains to the development of human 
skin models that could serve as alternatives for the use of animals for testing cos-
metics, chemicals and pharmaceuticals. The demand for such alternative models is 
growing, as the European Union is committed to curtail  animal testing, but, on the 
other hand, keeps stepping up the number of products that require pre-marketing 
testing on animals (e.g. REACH).  
Ghalbzouri’s and similar forms of human tissue engineering require large quantities 
of human skin. So while his work may be good news for rabbits, mice and guinea 
pigs, he faces a number of issues regarding the rights and entitlements of humans 
(donors, laboratories, scientists, medical ethical review boards, funding agencies, 
industry) in their tissue and cells. In the case of Ghalbzouri: where and how can he 
legitimately procure, store, engineer and market the human tissue he needs for 
building his skin and other tissue models?  
The experts were asked to pay particular attention to the following aspects: 
 The issue of the legitimacy of the procurement and engineering of the human skin by 
researchers such as Dr. Ghalbzouri (academic) or others, e.g. L’Oréal (indus-
try). Potential sources for the human skin they need are leftover tissue from 
cosmetic surgery (e.g. breast reductions) or foreskin removed during circumci-
sion. Can the researchers lawfully obtain the human skin they need? From whom? Under 
which conditions?  
 Must consent from skin donors be explicit and informed opt-in? Or can it be 
informed opt-out? And is implicit opt-out a possibility? 
 The issue of rights of the skin donor. Is her right exclusively “binary”, i.e. can 
she only say “yes” or “no”? Or can she subject her donation to certain conditions? 
For example, can she stipulate that the skin may only be used for not-for-
profit research or that the skin may not be exported, in whatever form? 
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 The issue of ownership of the donated skin. Will ownership be transferred from 
the donor to Dr Ghalbzouri or his employer or to L’Oreal? Does ownership 
vest in the removed tissue in the first place?  
 As the skin is being preserved, processed and engineered into a “model”, at 
what stage does the law stop calling it “human skin” for purposes of determin-
ing ownership? How does tissue engineering affect ownership? 
 The issue of feedback. Any donated skin is likely to be screened or even geno-
typed by the researchers. Do donors have a right to receive any feedback of 
the findings or results of such screenings or genotyping? 
 “Droit de retour”. A healthy donor (e.g. young boy after circumcision) may be-
come a patient over time. Will he have any residual rights in his donated tis-
sue? Can technological developments such as growing stem cells from healthy 
skin give rise to rights to return or use of once donated material? Or does the 
law provide for an irrevocable donation?  
 The issue of export? Can Ghalbzouri lawfully obtain human skins from Bel-
gium? From Luxembourg? Do any import or export regimes apply? 
 “Non-commerciality”. Does the donor have a valid and enforceable claim for a 
profit share in the event the researchers (academic of industrial) are granted a 
patent or otherwise succeed in marketing their model?  
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The legal experts provided a detailed sketch of their national legal regimes for pro-
curement, storage, use and transfer of human cells and tissues. The speakers paid 
particular attention to new legislation and regulations of their respective countries 
as well as documents which are currently in development. The national regimes 
presented by the experts appear to be fragmented, comprising rules and norms 
originating from different legal fields. The regulations frequently resemble tangled 
conglobulations rather than a set of clear instructions and limitations. When ap-
plied to a real-life scenario, the differences and gaps in the national legislative re-
gimes of Belgium, Luxembourg and the Netherlands reveal themselves. It becomes 
clear that the gaps create uncertainties both for the donor (the source of the tissue) 
as well as persons or entities obtaining cells and tissues. The uncertainties are par-
ticularly evident where non-diagnostic and/or non-therapeutic applications of the 
tissue are concerned. Ownership of the tissue, control by and feedback to the do-
nor, commercial interests and benefit-sharing as well as cross-border flow require 
more attention from the law and policy makers. 
 
 
Anonymisation and Pseudonymisation as a Means 
of  Privacy Protection 
Sixth International Workshop of the Tiss.EU Project 




The Sixth International Workshop within the Tiss.EU project was organized by 
Claudio Tamburrini from the Centre of Health Care Ethics (Stockholm University) 
in close cooperation with the partners from the Central European University who 
are engaged in the same Focal Theme, “Anonymisation and pseudonymisation as 
a means of privacy protection” (Focal Theme C). In addition to this topic, the 
workshop dealt with the regulation of human tissue research in the Nordic coun-
tries (Sweden, Finland and Denmark).  
The Stockholm Workshop combined three different approaches: a (mainly) 
descriptive, a normative and a more practically-oriented one. In accordance with 
this structure, “the state of the art” regarding privacy issues related to biobanking 
in Sweden, Finland and Denmark was first presented by researchers from these 
three Nordic countries. Although this part of the workshop was intended to be 
mainly descriptive, important ethical and policy issues were addressed as well, by 
the speakers and during the discussions following their presentations. In between 
the country reports, a couple of more theoretically-oriented papers were presented 
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by bio-ethicists affiliated to the Centre for Healthcare Ethics. In particular, this 
part of the workshop addressed the philosophical foundations of the notion of 
privacy and the underlying ethics of granting donors the right to withdraw from a 
project. Finally, in the third part of the workshop, a more practically-oriented 
discussion on privacy was carried out, specifically about possible forensic and 
police investigative applications of biobank repositories, but also about sports-
men’s right to privacy in the context of anti-doping controls.  
2 Reports 
2.1 Sweden 
In her presentation “Anonymisation and Pseudonymisation – Concepts and Legal 
Standards in Swedish Biobanking”, Elisabeth Rynning (Faculty of Law, Uppsala 
University) underlined that the key issues in the Swedish biobank legislation (cur-
rently under revision) concern the terminology applied (how we define the con-
cepts and how we distinguish between them); how the choice of policy may affect 
different stake holders such as patients and research subjects, researchers and 
society; and what the legal implications of anonymisation or pseudonymisation 
are. In addition to this, regulators also need to address the fact that the status of 
tissue samples may change, not only from pseudonymised to anonymised, but also 
from anonymised to re-identifiable, by new scientific developments and changes 
in society.  
Unfortunately, there is wide variety of definitions and criteria used to explain 
these concepts, in national as well as international hard law and soft law docu-
ments. In the European context, some Members States – including Sweden – 
focus on the fact that pseudonymised data can always be identified, at least by the 
person holding the code key, and are thereby never anonymous. 
Pseudonymisation is achieved by exchanging all direct personal identifiers – 
such as name, address, social security number etc. – for indirect ones, such as a 
randomly picked number, linked to the sample/data by a code key. However, it 
must not be forgotten that samples/data can also be clearly identifiable without 
any direct identifiers or code keys if sufficient associated data are accessible, e.g. 
information on the time and place where the sample was collected, and various 
features of the donor. Even internal information such as DNA can be used for 
identification.  
In spite of the regulations laid down by the Swedish Personal Data Act 
(1998:204), the legal situation is not clear. Furthermore, there is no guidance as to 
what the wide identifiability concept of the Personal Data Act may imply with 
regard to biological materials and DNA. 
So what difference does it make in practice if samples and data are anony-
mised or pseudonymised? Despite the remaining risk of future re-identification, it 




would seem clear that anonymisation offers better protection of informational 
privacy. However, protecting autonomy becomes more problematic when the 
individual concerned loses control over the use of the sample/data and many legal 
safeguards cease to apply. Feed-back and other exchanges of individual data are 
no longer possible in the case of anonymisation. This means that both anonymisa-
tion and pseudonymisation have their advantages and drawbacks, from a privacy 
perspective.  
Under Swedish law, no special privacy regulation will apply to samples and da-
ta that have been rendered anonymous. Such materials and data fall outside the 
scope of the Personal Data Act and the Biobanks Act, as well as the Act on Ethics 
Review. 
With regard to research involving pseudonymised tissue samples and associat-
ed data, ethics review is mandatory and a specified, informed consent will normal-
ly be required. For new research on samples and data already collected, the Ethics 
Review Board may allow an exemption from this requirement. The donor will 
always have the right to withdraw, but in such cases the sample does not neces-
sarily need to be destroyed, since the Swedish Biobank Act also grants the bio-
bank administrator the choice to have it anonymised.  
The Swedish Biobanks in Medical Care Act does not cover all collections of 
identifiable human tissue samples, but limits its scope to such samples that have 
been collected within the activities of a health care provider, be it for health care 
purposes, research or other medical purposes. This means that tissues collected 
e.g. directly by research institutions or pharmaceutical companies will not be cov-
ered as a rule. This is one of the issues to be addressed in the ongoing revision. 
When the Biobanks Act does apply, pseudonymisation is a standard procedure 
adopted to protect privacy while still ensuring traceability. A coding system is thus 
required and the code keys must be kept safe and separate.  
The Biobanks Act also lays down certain restrictions on international transfer. 
Although research cooperation across borders, for example, is not prohibited, it is 
required that samples sent abroad are anonymised or pseudonymised, and after 
they have been used for the purposes intended, the samples must be returned or 
destroyed. In this context it has also been discussed whether it would be accepta-
ble to have the samples anonymised instead of destroyed, since the Biobanks Act 
would then no longer apply.  
In his talk “Biobanks: how do we protect donors’ privacy?”, Anders Brinne 
(Head of IT at Karolinska Institute Biobank) presented the services offered by KI 
Biobank to medical research studies, during the sample collection process from 
integration of a new study through sample handling and storage, to withdrawal of 
samples in different formats. Maintaining traceability from each stored sample 
back to individual donors is vital in biobanking, not only to ensure long-term 
usability of biobanked samples, but also in order to follow Swedish legislation, 
which stipulates the donor’s right to demand his/her samples to be discarded or 
de-identified. KI Biobank information that may allow identifying individual do-
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nors is used solely for identification purposes, at the time when the sample is col-
lected or when there is a request for it to be discarded. Identifiable donor infor-
mation is never used in internal biobanking sample management processes, in 
reports or in routine communication with customers or research groups. Strong 
safeguards are maintained at KI Biobank to ensure that identifiable donor infor-
mation is obtained and stored securely. All identifiable donor information sent to 
the biobank is encrypted and stored in a dedicated system, accessible only by staff 
with sufficient privileges. The KI-Biobank continuously improves quality and 
security in the information management and stays up-to-date with information 
security technology to ensure donor privacy. 
2.2 Finland 
In Finland, population statistics have been conducted for centuries, for instance 
by the Church (since 1500). The unique personal identification numbers, intro-
duced in 1964, and early computerised registers combined with patient records 
and biological samples provide a rich and versatile source for public health re-
search and longitudinal population studies. The legal framework for research us-
ing registries, patient records and biological samples is very complex, as it consists 
of several acts and decrees given at different times. The interpretation of the acts 
has also varied, and genetic research in particular has no special provisions. In her 
presentation entitled “Finland, the promised land of health registries – Law and 
practise of Finnish biobank research”, Sirpa Soini (Finish National Institute for 
Health and Welfare and the Faculty of Law, University of Helsinki) presented an 
outline of the national legislation. The Act on the Status and the Rights of Patients 
(785/1992) provides the basic rules for patient records. Under §12, health care 
units and health care professionals who are practising their profession inde-
pendently shall keep patient documents (as well as the samples containing biologi-
cal material collected in connection with organ examination and treatment) for as 
long as it takes to arrange and provide care and treatment for a patient, investigate 
possible claims for compensation related to care, and carry out scientific research. 
Other acts set the conditions for delivery of such data and samples for scientific 
research. 
In principle, all health information, whether in patient records or national reg-
istries, are handled as sensitive data, but delivery of such a data for scientific re-
search is exempted under certain conditions set in the other acts even without 
consent of the data subject. There are no provisions stipulating the feedback of 
the research to the individuals involved. Due to the incoherent legislation, an 
explicit Biobank Act has been demanded for a long time. A draft proposal was at 
last announced for a public hearing in March 2010. The proposal is scheduled to 
be submitted to the Parliament in spring 2010, and to come into force in 2011. 
Ideally, the Biobank Act is envisaged to foster effective use of both old and new 
sample collections in research and in activities aimed at furthering development 




and innovations relevant to health care. A broader consent will be introduced for 
future collections. Nevertheless, some issues are still open, and thus their outcome 
is uncertain.  
The National Institute for Health and Welfare (THL, formed after the merger 
of the National Public Health Institute (KTL) and the National Research and 
Development Center (Stakes)) has been collecting samples for epidemiological 
studies for decades. The Act governing the Institute contains specific provisions 
of collecting and using samples and data. To carry out the research and investiga-
tion tasks assigned to THL in the law, THL may gather and process personal data 
and blood and tissue samples. THL also functions as a statistical authority and 
maintains seven statutory health registries which can be used for research. The 
registries are confidential and governed by the Act on National Health Registries 
(556/1989). However, delivery of personal data from these registries for research 
is possible under certain conditions set by the law. The data ombudsman shall in 
that case be heard. The Act explicitly prohibits the use and delivery of the infor-
mation contained in the national health registries for decision-making concerning 
the data subject. Similar provision is in the draft Biobank Act. THL is authorised 
to give permission for register research. If the research setting is about to use 
patient records as well, then the permission of the Ministry of Health and Social 
Affairs will be needed in addition according to the Act on the Status and Rights of 
Patients (585/1986). 
In his talk on “Privacy Issues in the Finnish Biobank Legislation”, Lasse Lehto-
nen (Dept. of Law, University of Helsinki) stated that, at present, it is the Act on 
the Use of Organs and Tissues for Medical Purposes (101/2001) that defines the 
use of organs, tissues and samples for medical and other purposes (such as re-
search) in Finland. If the sample has been collected for treatment and diagnosis 
and then used for research purposes, it can be used for research without a new 
consent of the sample donor, if the consent is impossible to obtain because of the 
large number of samples, their age or for another comparable reason, or because 
the person has died. If these samples have been collected for research purposes 
they can be used for another research purpose only with the consent of the re-
search participant or his/her legal representative. Only if the person has died may 
the National Supervisory Authority for Welfare and Health give permission for 
the further use of these samples. This has raised the question if the purpose 
should be close or similar to the primary purpose, so that the original consent 
could be interpreted to be valid. The Ministry of Welfare and Health is currently 
preparing a new Act on Biobanks to solve the issues raised by old sample collec-
tions. 
In Finland, genetic data is considered to be medical data and as such falls un-
der the provisions for the protection of sensitive personal data. In Lehtonen’s 
view, and despite the fact that there has been some criticism for the automatic 
inclusion of all genetic data as sensitive medical data, the issue of genetic privacy 
has not stimulated vivid discussions in Finland. Only the possibility of employers 
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and insurance companies to carry out genetic testing has raised major concerns, 
and Finland now has a legislation that bans this type of genetic testing. Concern-
ing the issue of whether samples are considered as data in Finland, the Finnish 
Data Protection Act does not specifically mention biological samples. However, 
the data protection legislation applies to patient registries that include identifiable 
data on biological samples. Furthermore, the Finnish Tissue Act  (101/2001, §20) 
states that biological samples can be used for research with the authorization of 
the health care unit  in question, if no personal data is processed. 
Regarding the question of restricting basic individual rights, the aim of the re-
striction needs to be compatible with the principles of the Finnish legal system 
and it must also comply with the international obligations of the Finnish state. 
Thus, e.g. genetic privacy can be broken in paternal disputes, since it is required 
by an important social aim (the best interest of the child). Similarly, medical confi-
dentiality can be broken in cases of dangerous contagious diseases to protect the 
safety and health of third parties.   
According to the Finnish Act on Personal Data, an express consent is re-
quired for the processing of sensitive data. Processing sensitive data without the 
consent of the data subject is a crime according to the Finnish criminal code. 
However, data processing for health care purposes, when professional secrecy is 
guaranteed, does not require the express consent of the data subject. There is also 
a research exemption in the legislation: processing personal data for research pur-
poses does not require the consent of the data subject (Finnish Act on Personal 
Data §12, item 6). This notwithstanding, medical research requires the informed 
consent of the study subject on the basis of the Act on Medical Research. In addi-
tion to that, Tissue Act (101/2001, §20) requires that, when the purpose of use of 
the samples is changed, the consent of the patient should be obtained. The 
abovementioned research exemption does not cover commercial utilization of 
data (e.g. pharmaceutical trials). 
2.3 Denmark 
Mette Hartlev, from the Faculty of Law, University of Copenhagen, explained in 
her paper “Balancing of privacy and other interests in Danish Biobank regulation” 
that the only population-based biobank in Denmark is the PKU-registry, where 
samples from all newborns have been stored since 1982. Most other biobanks are 
located in the health care services. However, there is also a collection of tissue 
samples kept by the national police as part of a forensic DNA-register.  
There are a number of different stakeholders which have various interests in 
regards to the storage and use of tissue samples in biobanks, and these interests 
are not necessarily compatible with each other. The tissue donor will normally 
have a strong privacy interest as tissue samples contain very sensible information 
about the donor. Furthermore, donors might also have an interest in controlling 
or influencing the use of tissue samples for various purposes. This could be la-




belled as an autonomy interest. Some tissue donors, for example, might not want 
to contribute to a specific kind of research or may not want samples to be used by 
the police or disclosed to family members. Most tissue samples have been collect-
ed in connection with diagnostics and treatment, and there could be weighty diag-
nostic arguments for keeping the samples in a biobank – at least for a period of 
time.  
However, the main purpose of storing the samples is research, and there is 
consequently a very strong research interest in storing and having access to tissue 
samples for scientific purposes. This is also in the interest of society and for pub-
lic health purposes. Private companies – such as pharmaceutical companies – 
could also have an economic interest in establishing and using biobanks. Further-
more, the police services could have a forensic interest in getting access to tissue 
samples. Finally, in families with a history of genetic disorders, family members 
might – for diagnostic purposes – be interested in having access to tissue samples 
from other family members. Although the donor’s interest in respect for privacy 
and autonomy must be balanced against other interests, it is also important not to 
overestimate the conflict between the interests of the donor and other stakehold-
ers. Many tissue donors will be positive towards the use of tissue samples for re-
search purposes or to help family members. Furthermore, creating trust in bio-
medicine is of immense importance from the perspective of research, society and 
industry, and respect for donors’ privacy and autonomy rights is a way to create 
trust. The legal regulation of biobanks provides a framework for this assessment, 
and reflects the importance attached to the different interests.  
Compared to other Nordic countries, there is no single Act regulating  
biobanks in Denmark. Hence the regulatory framework includes a number of 
provisions in various Acts. The most important acts are the Health Act (2005), the 
Act on Processing of Personal Data (2000), and the Act on Biomedical Research 
(2003). Most tissue samples are collected in connection with diagnosis and treat-
ment of patients in the health care services. Collection of tissue samples in con-
nection with patient care is primarily regulated in the Act on Health which in-
cludes provisions on informed consent to medical intervention. Tissue samples 
collected exclusively for research purposes are covered by the Act on Biomedical 
Research which also requires an explicit informed consent of the donor.  
Storage of tissue samples is not specifically regulated in the Act on Health, 
and it is not demanded that the patient gives explicit consent to the storage of 
tissue samples obtained in connection with diagnosis and care. In the same vein, 
the Act on Processing of Personal Data does not require an informed consent to 
the storage of tissue samples for research, medical or forensic purposes. However, 
the Act on Health provides tissue donors with a right to retrieve and/or require 
the destruction of tissue samples obtained in connection with medical treatment. 
In regard to tissue samples obtained directly from a research participant, informed 
consent is necessary to comply with the Act on Biomedical Research. All in all it 
seems that the Danish regulation is more concerned with other interests than 
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donor privacy in regards to storage of tissue samples. However, donors still have 
some influence through the right to retrieve and demand the destruction of the 
samples. 
In her talk “Biobanks in Denmark as a research resource” (based on a co-
written paper with Sanne Ellegaard Jörgensen), Lisbeth Knudsen (Department of 
Public Health, University of Copenhagen) presented an account of the different 
biobanks existing in Denmark. They provide human samples and data for studies 
on for instance prenatal exposures and later development (Danish National Birth 
Cohort), lifestyle exposures and cancer risk (Danish Cancer and Nutrition Co-
hort), longitudinal studies with repeated sampling (Copenhagen Prospective Study 
on Asthma in Childhood), ex-vivo studies with placental tissue from human 
births. In her presentation she described informed consent, access to data, data 
protection, feedback to study persons and incentives to participate related to re-
search projects. In general, there is no requirement for explicit consent regarding 
the storage of tissue samples gathered within health care. Donors are, however, 
granted the right to withdraw by the Act on Health, which gives them the possi-
bility of retrieving or requiring the destruction of tissue samples gathered in con-
nection with medical treatment. Regarding tissue samples directly obtained from a 
research participant, informed consent is necessary to comply with the Act on 
Biomedical Research. To sum up, Knudsen pointed out that although consent and 
withdrawal procedures are not as clearly stated as one may wish them to be, do-
nors still have some influence through the right to retrieve and demand the de-
struction of the samples. 
Finally Knudsen presented a European human bio-monitoring program re-
garding environmental exposures of children and their mothers with participation 
from most EU countries. 
3 The philosophical and ethical foundations of privacy 
What is anonymisation? What is the rationale of anonymisation and the right to 
withdraw consent? What is the relationship between these two notions? These were 
the questions addressed by Niklas Juth and Gert Helgersson from the Department of 
Learning, Informatics, Management and Ethics at Karolinska Institute, in their talk 
on “Anonymisation and the right to withdraw consent”. They distinguished four 
meanings of anonymity of biological samples in a biobank:  
1) There is no identifying information (name, address etc) directly associated 
with the sample(s), but researchers have access to a code linking the sam-
ple(s) with such information (sometimes called coded samples),  
2) There is no identifying information (name, address etc) directly associated 
with the sample(s), but there is a code linking the sample(s) with such in-
formation to which the researchers do not have direct access, but some-




one else does (as in e.g. LifeGene, where special administrative personnel 
have the code, sometimes called reversibly anonymised (linked) samples), 
3) There is no identifying information (name, address etc) directly associated 
with the sample(s), and there is no code linking the sample(s) with such 
information (sometimes called irreversibly anonymised (unlinked) samples). The 
term Juth and Helgersson used when there is no such code due to the 
fact that it has been “deleted” or destroyed was “anonymisation through 
de-identification”, and this type of anonymisation was the focus of their 
talk,  
4) The biobank has no identifying material, since the sample has been dis-
carded or destroyed (except perhaps registers showing that the person in 
question once had samples within the biobank so that the person will not 
be contacted again), what they called the “destroying-option”. The Swe-
dish Biobank Act (chapter 3 §6) states that withdrawing consent should 
lead to 3) or 4). It is then up to the biobank in question to choose which 
policy to implement among these two. 
Anonymisation understood as de-identification may be sufficient to protect indi-
viduals’ privacy, since it prevents researchers and others to link the biobank in-
formation to any specific individuals. However, it may be insufficient to protect 
autonomy: if someone starts to object to certain research made in a biobank to 
which they have contributed and therefore decides that he or she no longer wants 
to contribute to the research, de-identification may not be enough, since some 
research can also be performed on de-identified material (for instance research 
aimed at investigating the prevalence of biological markers in a population). In 
this case, the “destroying-option” is the only guarantee that a person makes no 
contribution to further research.  
If we move to the definition and justification of a right to withdraw, we will 
notice that anonymisation is a way of implementing the right to withdraw your 
consent to participate. So which type of anonymisation is to be preferred? This 
depends partly on why the right to withdrawal is important to be respected, that is 
the reason or rationale for the right to withdrawal. If the primary reason is to 
avoid possible harms, then anonymisation through de-identification will take us a 
long way. However, as regards respect for autonomy, de-identification falls short 
when compared to the “destroying-option”. And on both solutions, we fail to 
respect those who want to opt-out of further participation altogether, since only 
the “destroying-option” will satisfy this demand. So for those who would defend 
research interests over the autonomy of donors, anonymisation through de-
identification goes too far, whereas those who would have it the other way 
around, i.e. defending the autonomy of donors over research interest, anonymisa-
tion through de-identification does not go far enough. So what to do in the light 
of this? In this regard, Juth and Helgersson maintained that anonymisation 
through de-identification is not satisfactory, unless it is complemented by other 
options for withdrawal. Since there is no evidence yet to suggest that research 
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interest would be compromised to a significantly larger extent by also allowing 
complete withdrawal and anonymisation through the “destroying-option”, they 
suggested that this option as well should be offered by biobanks. If participants 
are aware from the outset that this option exists, with no strings attached, they 
may be more at ease to participate to start with, which could even have a positive 
effect on participation rates.  
It is a contested question what kind of right the right to privacy is, and there 
are various different rationales behind this putative right. Each of them, if taken 
seriously, gives different answers to practical questions related to biobanks. In his 
presentation “Why Should We Respect the Privacy of Donors of Biological Mate-
rial?” Torbjörn Tännsjö (Centre for Healthcare Ethics, Stockholm University) dis-
cussed four basic moral outlooks upon which the right to privacy might be found-
ed. These are: (a) an ethics of honour granting the individual the right to control 
his or her public image, (b) a libertarian moral rights theory conceiving of our 
right to privacy as an aspect of our self-ownership, (c) an idea about the intrinsic 
value of autonomy granting us a narrow right to privacy and, finally, (d) utilitarian-
ism. Starting from these different moral approaches, Tännsjö particularly asked 
what conclusions we can draw from each of these views with regard to the follow-
ing four practical questions:  
1) Broad or narrow consent: Do we need to be specific when we ask the 
donor for consent, or is it sufficient to ask for a broad consent, to all fu-
ture uses? Here Tännsjö also discussed the related question of whether 
the donor should have a right to withdraw his/her consent.  
2) Implicit or explicit consent: Is it necessary to ask the donor for consent, 
or is it perhaps sufficient that there is a possibility for the donor to opt 
out of the system if he or she wants to (thereby assuming that everyone 
who does not say otherwise does consent)?  
3) Forensic uses: Should biological material be available for forensic uses? 
Should special banks be established for this purpose? Would it be objec-
tionable to construct a biobank to be used for forensic purposes, where 
everyone had to participate (donate)?  
4) Spare genetic material: What are we to say about the use of spare genetic 
material which has been involuntarily left behind by a “donor”? Is it 
morally unobjectionable to send it to a lab for genetic analysis if we hap-
pen to get hold of it? May for instance a hair dresser send hair from a cli-
ent to a genetic laboratory, have it diagnosed, and then the result pub-
lished? 
Tännsjö pointed out that although some overlapping consensus between these 
views on the above outlined issues can be reached, there is also radical and fun-
damental disagreement. In the present context, the disagreement between the 
moral rights view and utilitarianism is most important. Tännsjö illustrated this 
point by asking what would be wrong with taking efforts to ascertain the genetic 
characteristics of people using biological material that – as in the hair-dresser’s 




example – was left behind by some person. He emphasized that, although many 
of us might tend to argue that allowing this practice would amount to a violation 
of the individual’s right to privacy, there are heavy practical (consequentialist) 
reasons not to forbid these kinds of “genetic investigations”, mainly on the 
grounds that they cannot be stopped and that the costs of enforcing such a prohi-
bition will be too high. Who, for instance, is going to be made legally accountable 
for the findings? The hair-dresser? The laboratory who performed the analysis? 
Or perhaps the customer himself, who acted negligently by not seeing to it that no 
biological traces were left behind? 
4 Practical applications 
In his paper “The use of bio-bank samples in forensic applications” (co-written 
with Kerstin Montelius), Bertil Lindblom (Department of Forensic Genetics and 
Forensic Toxicology, National Board of Forensic Medicine, University of Linkö-
ping, Sweden) underlined that biobank samples can be and actually have been 
used in forensic applications but probably to a much lower intensity than ex-
pected. In just a couple of cases, samples from the Swedish PKU-biobank have 
been used for the search of suspects in criminal investigations by DNA compari-
sons. One of these cases was the investigation after the murder of the former 
Swedish foreign minister Anna Lind. Stored samples from pathological investiga-
tions have in some cases also been used after decision by the court to solve ques-
tioned family relations. This has been done a few times a year in cases where for 
example an alleged father has died.  
For the identification of deceased Swedish citizens after the Tsunami 2004 in 
Thailand a temporary law was issued in which it was stated that samples from the 
PKU-biobank could be used for the identification process. Identification of dead 
bodies is performed in different ways and by using different techniques. The main 
methods are comparisons of DNA profiles and comparisons of dental infor-
mation or fingerprints. In addition, physical evidence and personal properties can 
give information, but this is just added as secondary information. Visual identifica-
tion is not a valid way to identify deceased persons in mass disasters like after the 
Tsunami in Asia 2004. The process of identifying a missing person is based on 
information concerning the missing person so called ante mortem (AM) infor-
mation. For DNA comparisons, the DNA information can be obtained from 
analysis of a self-sample taken before the disaster or analyses of samples taken 
from close relatives (parents, children or siblings). Similar information must also 
be collected from the dead bodies, so-called post mortem (PM) information. PM 
samples for DNA analysis must be taken and stored in a way that they can be 
analyzed for DNA polymorphism. Degradation and contamination can heavily 
destroy the possibilities for a successful investigation. With DNA information 
from AM samples and PM samples, a comparison (matching) can be made. De-
 Claudio Tamburrini 
 
100 
pending on whether the AM information originates from a self-sample or from 
close relatives, the evaluation will be based on a direct comparison between the 
PM and AM profiles or a kinship analysis.   
Ulrika von Döbeln, who is the director of the Swedish PKU-biobank and also 
works at the Centre for Inherited Metabolic Diseases at Karolinska University 
Hospital, presented a vivid view of the process that led to the handing over of 
data about Foreign Minister Anna Lindh’s suspected murderer to the police. In 
her presentation “PKU-biobank and crime: what can and what cannot be done”, 
she established the starting point for neonatal screening for PKU in Sweden to 
1965. Since then, blood spotted on filter paper (DBS, dried blood spots) is sent 
from all newborns in the country to one centralised laboratory, the PKU laborato-
ry. Gradually, more disorders have been included in the neonatal screening pro-
gramme. Samples have been saved since January 1975 comprising the youngest 
3.5 million people of the 9 million population. In accordance to the Swedish Bio-
bank Law implemented in 2003, they are saved for an unlimited time. The sam-
ples are used routinely in medicine for verification of congenital CMV-infections 
by determination of CMV-DNA and for research projects mainly based on DNA 
studies. An issue with the PKU-biobank is the limited amount of blood in the 
samples, 100-200 cubic millilitres (uL) per person, but also the manual organisa-
tion of the bank and the fact that the samples have been taken before the infants 
have been given their social security number.  
When the Swedish Foreign Minister was killed in 2003, the Swedish prosecu-
tion authority requested a sample from the suspected murderer from the PKU-
biobank. It was sent to the Department of Forensic Genetics for DNA-profiling 
and comparison of traces found at the crime scene. Some weeks later the PKU-
biobank became famous through a vivid discussion among experts and the media 
of “what can and what cannot be done” with biobank samples. About 2000 peo-
ple requested destruction of their PKU-samples as a consequence. The Biobank 
Law is presently being revised. Hopefully, the revised biobank law will provide 
more distinct rules for the treatment of biobank samples. Von Döbeln made it 
clear that the issue of making biobanks available to prosecutors and police investi-
gators lacks practical relevance at present. Due to the great amount of samples 
and the way in which they are stored it is practically impossible to get a matching, 
unless one already has the identity of the person whose samples one sets out to 
control.  
In his presentation “WADA’s anti-doping policy and athletes’ right to priva-
cy”, Claudio Tamburrini (Centre for Healthcare Ethics, Stockholm University) dis-
cussed the World Anti-Doping Agency’s (WADA) Anti-doping Code, according 
to which athletes are regularly tested for forbidden doping substances in connec-
tion with sport competitions. Their samples are stored for long time, in case new 
doping detection techniques are developed in the future that might allow for the 
identification of forbidden substances not detectable at present. As WADA’s 
ambition is not only to have clean competitions, but also clean athletes, different 




measures need to be implemented to facilitate testing in-between competitions as 
well. One of them is making sportspersons fill a form to keep doping controllers 
informed about their whereabouts, so that they can reach the athletes and make 
them undergo unannounced tests.  
WADA’s anti-doping policy has been widely criticized for violating athletes’ 
right to privacy. However, this debate is often carried out as if it was crystal clear 
what kind of right this supposed athletes’ right to privacy is. This is far from being 
the case. So, Tamburrini underlined, it seems as if we need, if not a definition, at 
least a characterization of what this presumed right to privacy might be thought to 
cover. As a preliminary conclusion he suggested to perceive of the right of privacy 
not as a single right, but rather as a cluster of rights, each one designed to protect 
different areas of our lives, and each one derived in its turn from other, more 
fundamental rights. A further conclusion he advanced as a consequence of this 
conceptual analysis was that violating athletes’ right to privacy cannot be con-
doned by any of the moral-philosophical approaches traditionally discussed in 
connection with privacy.  
5 Results 
 In general, it can be said that all three Scandinavian countries reported in 
the workshop have a long history of keeping records. The unique person-
al identification numbers and early computerised registers combined with 
patient records and biological samples provide a rich source for public 
health research.  
 Although the Nordic countries in general and Finland, Denmark and 
Sweden in particular cooperate and consult each other in order to adopt 
uniform legislation based on a common interpretation of European law, 
there are clear differences among these countries. To begin with, they dif-
fer in whether biological samples are covered by the definition of person-
al data in the laws implementing EC Data Protection Directive 
95/46/EC. This also gives rise to differences regarding whether consent 
for new and different uses is required as well as the options implemented 
to make withdrawal possible. 
 In spite of the different regulations laid down in all three countries, the 
legal situation is not clear yet. Under Swedish law, for instance, no special 
privacy regulation will apply to samples and data that have been rendered 
anonymous. Such materials and data fall outside the scope of the Personal 
Data Act, the Biobanks Act, as well as the Act on Ethics Review. Since 
there are no legal safeguards against unethical research on anonymous 
samples or data, the only available means of privacy protection seems to 
be the possible requirement to respect prior restrictions made by the per-
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son concerned. Whether or not such a requirement is actually recognised 
under Swedish Law, however, is not clear. 
 In Finland all health information, whether in patient records or national 
registries, is in principle handled as sensitive data, but delivery of such da-
ta for scientific research is exempted under certain conditions set in the 
other acts (even without consent of the data subject). There are no provi-
sions stipulating the feedback of the research to the individuals involved. 
 In Denmark, compared to other Nordic countries, there is no single act 
regulating biobanks. Storage of tissue samples is not specifically regulated 
in the Act on Health, and it is not demanded that the patient gives explicit 
consent to the storage of tissue samples obtained in connection with di-
agnosis and care. In the same vein, the Act on Processing of Personal Da-
ta does not require an informed consent to the storage of tissue samples 
for research, medical or forensic purposes. Thus it seems that the Danish 
regulation is more concerned with other interests than donor privacy. 
However, the Act on Health provides tissue donors with a right to re-
trieve and/or require the destruction of tissue samples obtained in con-
nection with medical treatment, and this gives donor some influence on 
the storage of such samples. In regards to tissue samples obtained directly 
from a research participant, informed consent is necessary to comply with 
the Act on Biomedical Research.  
 Regarding international transfer of biobank samples, cooperation across 
borders is not prohibited in the three Nordic countries, but it is required 
that the samples are anonymised or pseudonymised. After they have been 
used for the purpose intended, the samples must be returned or de-
stroyed.  
 There are strong practical (consequentialist) reasons not to forbid people 
to obtain knowledge about other people’s genetic constitution, even 
against their will, mainly on the grounds that the prohibition would be 
difficult to uphold and the costs of enforcing it too high. However, 
whether or not these reasons also are conclusive was left as an open ques-
tion by the workshop participants. 
 Anonymisation through de-identification does not seem satisfactory, un-
less it is complemented by other options for withdrawal. In that regard, 
the option of destroying the samples is to recommend and should be of-
fered by biobanks. This might lead to participants being more at ease to 
donate their samples to biobanks. 
 Biobank samples can and actually have been used in forensic applications 
but probably to a much lower intensity than expected. 




 There are at present rather few possibilities of using biobank material for 
police investigations, other than for matching a sample gathered at the 
crime scene with an already identified suspect.  
 The kind of violation of athletes’ right to privacy related to the implemen-
tation of the World Anti-Doping Agency´s (WADA) anti-doping policy 
cannot be condoned by any of the moral-philosophical approaches tradi-
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1 Introduction 
The second international workshop in the transfer, storage and procurement focal 
theme was organised by Bert Gordijn, Shiofra Murphy and Elizabeth Yuko from the 
Institute of Ethics at Dublin City University. In addition to the Ireland country 
report, the workshop also addressed various issues falling under the transfer, stora-
ge and procurement of human cells and tissues focal theme. Particular attention 
was given to ethical and legal aspects of special tissues, such as embryonic stem 
cells, and the issue of commercialisation. The speakers came from law, medicine 
and philosophy backgrounds. 
The workshop began with an overview of the Tiss.EU project by Nils Hoppe, a 
project partner from the University of Hannover. In his presentation, Hoppe went 
over the issues at stake in the project, the project objectives and deliverables, and 
the work accomplished thus far.  
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2 Country Report: Ireland 
Elizabeth Yuko from Dublin City University presented Ireland’s country report, 
which focused on the current state of bioethics regulation. At present, Ireland’s 
only legal regulation of human tissues for research purposes comes via two statuto-
ry instruments implementing the three EU Directives.  
The Irish Minister for Health and Children adopted the European Communi-
ties) Regulations (the “Quality and Safety of Human Tissues and Cells Regula-
tions”) in 2006 as a means of implementing Directive 2004/23/EC of the Europe-
an Parliament and of the Council of 31 March 2004 (the “EU Tissue Directive”) 
and Commission Directive 2006/17/EC of 8 February 2006.1 The Quality and 
Safety of Human Tissues and Cells Regulations is a statutory instrument, meaning 
the Minister for Health and Children implemented it directly, unlike primary legis-
lation, which is debated and must pass through the Irish legislature, known as the 
Oireachtas.2 
The Quality and Safety of Human Tissues and Cells Regulations explicitly 
states that it pertains to tissues and cells that are applied to the human body in 
clinical trials.3 It does not otherwise add to the scope of the EU Tissue Directive. 
The Irish Medicines Board is named as the State-designated competent authority, 
as required by the EU Tissue Directive.4 
Another statutory instrument, the European Communities Regulations 2007 
(“Human Tissues and Cells Traceability Requirements”, “Notification of Serious 
Adverse Reactions and Events and Certain Technical Requirements”), implement-
ed Commission Directive 2006/86/EC.5 The Irish Medical Council has published 
the Guide to Professional Conduct and Ethics for Registered Medical Practitioners, which is 
only binding upon medical professionals.6 The guidelines contain regulations of 
clinical trials and research, detailing the rights of the patients and responsibility of 
the medical professionals in research situations.7 
In 2008, the Government proposed a Human Body Organs and Human Tissue 
Bill (“Human Tissue Bill”) that addresses certain elements of tissue regulation. 
This bill regulates the removal, retention, storage, use and disposal of human tissue 
from deceased persons and consent for the use of donated tissue from living per-
                                                     
1  Commission Directive 2006/86/EC is not implemented with this statutory instrument. 
2  See Byrne, Raymond and J Paul McCutcheon. The Irish Legal System, Fourth Edition. Dublin: But-
terworths, 2001, 442-443 for further information on Irish statutory instruments.  
3  European Communities (Quality and Safety of Human Tissues and Cells) Regulations, S.I. No. 
158 of 2006, Art. 3(3). 
4  See supra note 3, Art.4(1). 
5  European Communities (Human Tissues and Cells Traceability Requirements, Notification of 
Serious Adverse Reactions and Events and Certain Technical Requirements) Regulations 2007, 
S.I. No. 598 of 2007.  
6  Irish Medical Council,Guide to Professional Conduct and Ethics for Registered Medical Practitioners. 7th 
Edition, 2009.  
7  See supra note 6, at p. 47. 




sons for the purpose of transplantation and research.8 In April 2009, Minister for 
Health and Children Mary Harney announced that there would be public consulta-
tion on the proposals for the Human Tissue Bill.9 Bodies such as the Department 
of Health and Children submitted proposals, and a revised version of the bill was 
drafted.10 The latest version of the bill was not publicly available at the time of 
writing, but at 200 pages, the Department of Health and Children’s proposals are 
likely to be similar to the final version of the bill.  
Many of the provisions of the bill were recommendations from Dr Deirdre 
Madden’s Report into Post-Mortem Practice and Procedures (“Madden Report”),11 
primarily that no hospital post-mortem examination should be carried out and no 
tissue retained for any purpose whatsoever without authorisation.12 The bill also 
goes into areas not covered by the Madden Report, such as consent procedures for 
the use of tissue from living and deceased donors for the purpose of research.13 
The bill contains several other provisions pertaining to research. First, when 
consent is given for organ and tissue removal and retention as part of the post-
mortem examination process, consent for the purposes other than the diagnosis of 
the cause of death may not be presumed, but must be specifically obtained for 
research.14 Tissue from deceased persons may be used for research if the removal, 
retention and use for the purpose in question are authorised either by an advance 
healthcare Directive, by next-of-kin or a nominated proxy.15 The consent for re-
search may be general, or be specific, limited or qualified.16 Furthermore, subse-
quent research on the same tissue must be submitted for separate approval if the 
research is of a substantially different nature to the approval originally given.17  
Tissue may be used without consent for research purposes if it was held before 
the date of enactment of the act, the researchers are not able to identify the person, 
and the research is ethically approved by a research ethics committee; or if the 
tissue has been imported.18 Tissue from living donors for research purposes is 
permitted if it is given with proper consent; freely and without coercion; without 
the promise of benefits likely to result from participation; and on the basis of ap-
propriate information on the nature and purpose of the research.19 If the tissue 
                                                     
8  The Department of Health and Children. “Draft Proposals for General Scheme of the Human 
Tissue Bill 2009.” 9 April 2009, p. 6. 
http://www.dohc.ie/consultations/closed/human_tissue_bill/ 
9  See supra note 8. 
10  See http://www.dohc.ie/consultations/closed/human_tissue_bill/draft_proposals.pdf?direct=1 
11  http://www.dohc.ie/publications/madden.html 
12  See supra note 8, at p. 6.  
13  See supra note 8, at p. 6-7. 
14  See supra note 8, at p. 81. 
15  See supra note 8, at p. 89-97. 
16  See supra note 8, at p. 129. 
17  See supra note 8, at p. 129.  
18  See supra note 8, at p. 129. 
19  See supra note 8, at p. 132. 
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from a living person was donated as a by-product of a medical procedure, it is also 
acceptable to obtain general consent to future unspecified uses.20 The donor may 
freely withdraw authorisation or consent at any time.21 
The Human Tissue Bill does not include any regulation of assisted human re-
production, and neither gametes nor embryos are considered to be “tissue” under 
the bill.22 In Ireland there is currently no legal regulation on spare embryos created 
during IVF treatment for research or other purposes. The Irish Medical Council 
provides The Guide to Professional Conduct and Ethics for Registered Medical Practitioners, 
which contains provisions on IVF treatment, but only regulates the actions of the 
physicians. The only part relevant to using IVF embryos for research purposes 
states that physicians should not participate in creating new forms of life solely for 
experimental purposes, nor engage in human reproductive cloning.23 
A recent case before the Supreme Court found that frozen embryos which 
have not yet been implanted do not enjoy the protection of the guarantees provid-
ed to the right to life of the unborn in the Constitution.24 The case involved a 
woman who wished to become pregnant using frozen embryos created with her 
husband prior to their separation, despite his opposition to becoming a father 
again.25 The primary issue in the case was to determine whether the constitutional 
protection afforded to the life of the unborn26 extends to fertilised embryos which 
had been frozen and stored in a clinic.27 Mr Justice Murray stated that that it was 
not for a court of law to determine when life begins.28 Mr Justice Hardiman stated 
that although frozen embryos may not fall under the relevant sub-article of the 
Constitution, it does not mean that they should not be treated with respect as enti-
ties that have the potential to become a human life.29 Mr Justice Geoghegan stated 
that it is up to the Oireachtas to provide regulation on spare embryos.30 Mr Justice 
Fennelly did, however, state that although there may be a constitutional obligation 
on the State to give a concrete form to the respect due to an embryo, if neither the 
executive or legislative organs of the State take action, it may be open to the courts 
to consider the legal status of an embryo in a future case.31 
The underlying reason behind the scarce regulation of human tissue in Ireland 
is a lack of political will. As explained previously, Ireland’s regulation has all been 
                                                     
20  See supra note 8, at p. 132. 
21  See supra note 8, at p. 132. 
22  See supra note 8, at p. 14. 
23  See supra note 6, at section 20.4. 
24  Roche -v- Roche & ors, Judgment of Mr Justice Fennelly. [2009] IESC 82, 15 December 2009. 
25  Roche -v- Roche & ors, Judgment of Mr Justice Hardiman. [2009] IESC 82, 15 December 2009. 
26  Constitution of Ireland, Article 40.3.3. 
27  Roche -v- Roche & ors, Judgment of Mr Justice Murray. [2009] IESC 82, 15 December 2009. 
28  See supra note 27. 
29  See supra note 25. 
30  Roche -v- Roche & ors, Judgment of Mr Justice Geoghegan. [2009] IESC 82, 15 December 2009. 
31  See supra note 24. 




reactive, and a direct result of the EU mandate for the adoption of the Tissue Di-
rective and the accompanying technical directives. No existing human tissue regu-
lation in Ireland has originated in the Oireachtas, nor has gone through the legisla-
tive process or debates. As a result, from an Irish standpoint, the regulations in 
place are not specifically tailored for Irish needs.  
The saying that “all politics is local” truly applies in Ireland. Many politicians 
do not see the merit in initiating or supporting any sort of bioethics-related regula-
tion, for fear that it may harm their electability. While there may be a few votes to 
be gained supporting human tissue regulation, there are far more to be lost. It also 
may be difficult to make distinctions between regulations for research on human 
tissues, and embryonic stem cell research – a highly controversial topic. Along the 
same lines, following long and bitter debates surrounding various abortion refer-
enda and high profile court cases, both politicians and members of the public may 
be weary of approaching any areas that may require revisiting that debate. Howev-
er, the results of a small public opinion survey indicate that the Irish public may 
not be as conservative as politicians think. For example, 82% of people surveyed 
said that surplus embryos should be used for medical research into disease, even if 
that means they will be destroyed.32 Furthermore, 53% of those surveyed either 
agree or strongly agree that the Irish Government should provide funding for em-
bryonic stem cell research.33 
Another possible reason for the lack of regulation is that with the fluctuating 
economy in Ireland over the past two decades, there have been other issues seen to 
be more urgent to legislate on than the regulation of human tissues. While every 
country does have economic matters to contend with, Ireland has experienced 
drastic changes in its economy over recent years, which necessitated rapidly im-
plementing new legislation. Matters relating to the economy may have been viewed 
as being more important than human tissue regulation. 
3 Other presentations relating to Ireland 
Eoin Gaffney, a pathologist and founder of Biobank Ireland Trust gave a presenta-
tion entitled, “An Irish Biobank Network for Patient-Focused Translational Re-
search and Improved Global Healthcare”. He cited the importance of developing a 
cancer biobank network as a bridge between research and care. Gaffney stated that 
biobanks are important because fresh or frozen samples are better than traditional 
ones, which could ultimately lead to better patient care. The Biobank Ireland Trust 
was established in 2004, with a primary objective of creating an all-Ireland biobank 
network. The Biobank Ireland Trust would specialize in patient-focused research, 
better treatment, and biomarkers. He noted that it is important for the public to 
                                                     
32 Irish Council for Bioethics. Bioethics Research. September 2005, p. 34.  
http://www.bioethics.ie/uploads/docs/129171-Bioethics%20Research.pdf. 
33 See supra note 33, at p. 36. 
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understand that biobanks are the way to research disease and that biobanks should 
be government funded.  
According to Gaffney, the tipping point for the Biobank Ireland Trust came in 
2008 with the Vodafone Award given to Blanaid Mee to work with Biobank Ire-
land Trust for one year at St. James’s Hospital in Dublin. In August 2008 the St. 
James’s Hospital Cancer Biobank commenced biobanking breast and colon cancer 
samples. It is also collaborating with the biobank at Beaumont Hospital in Dublin. 
Gaffney noted that there is a large team of people required to operate a biobank, 
including the patients, surgeons, pathologists, researchers, nurses, medical scien-
tists and porters. There are breast and colon cancer samples from 172 patients in 
St. James’s Hospital, and 472 samples from Beaumont Hospital and the Royal 
College of Surgeons Ireland over the past four years. The funding comes from 
fundraisers, the National Lottery and 10 pharmaceutical companies. The govern-
ance of a biobank involves the management and protection of those who are vul-
nerable. Gaffney stated that a biobank network must maximise the use of the tis-
sue. It also must be accompanied by a better understanding of the early stages of 
disease by physicians. He said that in Biobank Ireland, 94% favour once-off con-
sent. 
Adam McAuley from Dublin City University gave a presentation entitled, “Tis-
sue and cell transfers: the regulatory framework and the impact on trust”. McAuley 
examined the EU Tissue Directive 2004/23/EC and its two accompanying tech-
nical Directives in order to identify the issues surrounding the transfer of human 
cells and tissues. He noted that the word “transfer” is not used in the Directive at 
all. It does, however, talk about distribution, imports and exports. According to 
McAuley, it is not simply a matter of transport under the framework of the Direc-
tives; rather, it is a transfer of tissues and cells, in addition to legal duties and re-
sponsibilities. Such responsibilities include obtaining a license, record keeping, 
traceability and the inspection of tissue establishments and third-party facilities. 
Imports and exports from non-European Economic Area (EEA) States require 
having an agreement in place between the research establishment and laboratory. 
The agreement is in relation to ensuring that the safety standards and technical 
directives are adhered to, and that the establishment has the capacity to fulfil func-
tions set out by the Directive. This is essentially delegating the monitoring func-
tions to a private individual.  
McAuley questioned how detailed the regulations should be, and noted that 
the EU Tissue Directives were extremely comprehensive and contained several 
annexes. He indicated that the EU Tissue Directive may contain too many specif-
ics. This may subject individuals working with tissues and cells who previously may 
not have been regulated, or were regulated with a soft touch, to a significant degree 
of regulation. In Ireland, the regulator is the Irish Medicines Board. There are cur-
rently 19 tissue establishments in Ireland, mostly in the area of assisted human 
reproduction. Twenty-five serious adverse events and reactions were reported in 
Ireland, but fewer in the UK. McAuley noted that Ireland does have a tendency to 




mirror the UK from a regulatory perspective. He said that the amount of regula-
tion in the UK has been overwhelming for scientists. The Human Tissue Authority 
issues Codes of Practice and also has the power to issue directions to the 176 tis-
sue establishments – a figure that is high in Europe. The large amount of regula-
tion is a clear indication of noncompliance. The organ retention scandals in the 
UK caused mistrust in science and scientists. Reviewing steps that States had taken 
to solve problems with noncompliance – particularly in relation to the organ reten-
tion scandals – resulted in the implementation of regulation. However, according 
to McAuley, this has not led to an increase in public confidence in science, but has 
led to more mistrust. It is impeding the professions rather than helping them. In 
his view, we are moving from a system of non-regulation or limited regulation, to 
an overarching all-encompassing regulation.  
Against this background, McAuley asked whether we were in a transition peri-
od, and whether in the future, everyone will be used to the processes brought 
about by the regulation. He also asked whether the design of the EU regulatory 
system is appropriate and whether whoever designed the system looked at how 
tissues and cells are moved and processed. McAuley is also concerned that when-
ever licensed tissue establishments give material to a non-licensed tissue establish-
ment, they must ensure that they abide by the rules, thereby making them mini-
regulators. He noted that international imports from outside the EEA into the 
EEA must meet quality and safety standards of the Directives, but there is no rule 
with regard to consent. He suggested using another mechanism – potentially simi-
lar to a safe harbour agreement. 
Maureen Smyth from the Forensic Science Laboratory (FSL) in Dublin spoke 
about forensic DNA databases. She noted that there is very little transfer of sam-
ples in Ireland, but there is a lot of data transfer from those samples. Most crime in 
Ireland is local, and most of the transnational crime is between the Republic of 
Ireland and Northern Ireland. Forensic service in Ireland is a public service, and 
has a simpler setup than in most countries. In England and Wales, for example, 
forensic science is commercial (but that has changed in her time in service). From 
Smyth’s perspective, a complete change in atmosphere occurred once privatisation 
of the laboratories was established; she doubted however that privatisation in Ire-
land will happen in the near future. Forensic science operates between science and 
law, using different languages and concepts, and is not confined to DNA and bio-
logy. The end result of the work in the FSL is court cases, and Smyth explained 
that those working in the lab often may end up defending their work in court. She 
said that interaction with lawyers is interesting since they either want the scientists 
to be vague or narrowly black and white with their explanations in court – but 
science is very rarely black and white.  
Smyth explained the importance of transparency in the FSL, promoting a very 
open setup and often receiving visits. Moreover, the FSL is used to maintaining 
records and having internal audits. There is, for example, a peer review of every file 
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since 1981 and audits are no problem because so much of the information is pub-
lic.  
The use of DNA in crime investigation started in mid-1980s with the drive to 
make it more sensitive and discriminating. Nowadays, DNA is used in a greater 
range of cases than it ever was, and there are strengths and weakness of testing. 
Currently, emphasis is not only placed on whether or not DNA matches other 
DNA found in a crime scene, but other factors such as how long it had been there 
are also taken into account. 1989 saw the first case using DNA in Ireland, but 
there were transfer issues at that time because the samples were transferred to the 
UK. Lastly in 1994, profiling began in the Irish FSL. Unlike in most EU countries 
there is currently no national DNA database in Ireland, nor is there any legislation 
to establish one, which leads to DNA work being done on a case-by-case basis. 
Smyth questioned whether samples should be stored in a database, or only 
their profiles (the digital piece of information), and whether the profiles from uni-
dentified bodies or the deceased should be stored. The EU Data Retention Di-
rective from 2006 must be implemented by 2011, although Ireland and many other 
States may not comply and will have to pay a fine.  
Smyth went through the timeline of events leading up to the introduction of a 
bill establishing a DNA database. Under a current proposal, people will only be 
sampled for crimes that carry a sentence of five years or more, in addition to bur-
glary. The samples will remain in the database for three years and there is a detailed 
appeals system. In two cases, the European Court of Human Rights has ruled that 
indefinite retention of samples violated Article 8 of the European Charter of Hu-
man Rights. Legislation enacted by the new UK government may mirror that in 
Scotland, which has been approved by the European Court of Human Rights. 
Smyth is of the opinion that any new legislation should offer increased protection 
to many people. A vast majority of samples are taken under common law and 
therefore there is no onus on anyone to destroy them, as well as no legal protec-
tion. Now all samples taken in criminal work will come under the legislation. 
Smyth stated that forensic science prefers regulation to open-endedness, and that 
the FSL would be very willing to work with a piece of legislation with clear provi-
sions and regulations. 
4 Special tissues 
Kris Dierickx from the Catholic University Leuven gave a presentation on the ethi-
cal considerations on use of stored samples from minors for non-clinical research. 
Before World War II there was a history of abuse of children in research, with 
some researchers using their own children as objects for research. The Council for 
International Organisations of Medical Science (CIOMS) 2002 presented the gui-
delines for children’s participation in research. Dierickx explained that the reasons 
for paediatric biobanks include studying interaction between genes and the en-




vironment in childhood and adolescence; genetic factors of disease; and studying 
genetic aspects of childhood occurrences. He is of the opinion that research must 
occur in order to have better insight into what is happening with children. More 
than 75% of drugs developed and used for children are not being tested on them, 
and only 18 of the 29 biobank guidelines examined mention children. A recurring 
theme in the ethical discourse is who should consent to the storage of material 
from children. Dierickx asked if consent from both parents is feasible, and then 
stated that he thought that consent from one parent was enough. Other themes 
dealt with risk, benefit, return of result, anonymisation, and ownership. Issues 
surrounding consent include who should grant consent, whether consent is nee-
ded, the scope of consent, and the right to withdraw.  
Dierickx said that children should be exposed only to minimal risk. Risks in 
this context include physical as well as emotional aspects, discrimination and priva-
cy issues. There are also dangers associated with returning results, and Dierickx 
wondered if this is good practice, and whether parents should be able to opt-out 
from receiving such results, especially concerning information for early-onset dis-
eases. He concluded that there should not be opt-out information for early-onset, 
preventable or treatable diseases. However, other types of information should not 
be accessible to parents. Children can contribute to research if there is direct bene-
fit to them, and/or benefit to persons of the same age or with the same condition. 
Dierickx also questioned whether anonymisation removes all privacy risks, and 
who owns the tissue and data taken from children and stored in biobanks. He also 
presented research from a focus group study, which looked at burden and benefit, 
parental responsibility and growing autonomy of the child. He included the results 
of interviews with professionals in the areas of bureaucracy and good research, the 
process of decision making, and burden and benefit. Dierickx noted that children 
can be asked to participate in research, but have a restricted duty to solidarity and 
the limitations of their participation is based on the risk involved. In terms of con-
sent, Dierickx stated that parents can give consent within limited scope, and chil-
dren themselves should be asked to re-consent at age 18 if possible (this should be 
done on a best-effort basis).  
Sorcha Uí Chonnachtaigh of Keele University spoke about the ethical, legal and 
socio-cultural challenges of embryonic stem cell research (ESCR) in Ireland. She 
stated that ESCR faces a number of obstacles including a lack of regulation, the 
socio-cultural dominance of the conservative view of the embryo/foetus, and the 
moral issue of the embryo’s status. Uí Chonnachtaigh contends that the ambiguity 
of Article 40.3.3 of the Irish Constitution’s protection of the unborn makes it diffi-
cult to legislate on any aspect of assisted human reproduction. In the “frozen em-
bryos” case from 2009, the High Court ruled that there was no evidence of specific 
consent of what to do with the embryos when they were created, and that Article 
40.3.3 did not apply to embryos ex utero. Accordingly, the Supreme Court decided 
that the embryos are not “unborn” for the purposes of Article 40.3.3 and are not 
guaranteed the right to life under the Constitution. Uí Chonnachtaigh noted that 
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Ireland’s Catholic past was a reason behind the lack of regulation of ESCR. She 
explained that the economic prosperity of the 1990s brought liberalism, and polls 
indicate that indeed Irish people nowadays disagree with the Catholic stance on 
many issues. However, the polls also indicated that with regard to abortion and 
embryo destruction, the Irish appear to defer to the authority of the Catholic 
Church. She also noted that being anti-abortion is an “Irish thing,” as opposed to a 
“Catholic thing.” As a result of the extremely divisive abortion debates in the early 
1980s, people have been reluctant to approach the issue – or related topics – again.  
In addition, both legally and socio-culturally, the “unborn” has a special status 
in Ireland, which makes the debates on the moral value of embryos/foetuses high-
ly divisive. Uí Chonnachtaigh stated that since those in favour of ESCR must bear 
the “burden of proof”, a socially-acceptable liberal alternative would be very diffi-
cult to create. The Commission on Assisted Human Reproduction published a 
report in 2005 recommending that ESCR be permitted on surplus IVF embryos up 
to Day 14, and a 2008 report from the Irish Council for Bioethics recommended 
the same. University College Cork furthermore passed a resolution in 2008 allow-
ing ESCR on imported lines. Uí Chonnachtaigh said that even though there is 
discussion of using induced pluripotent stem cells (iPS cells) as an alternative, since 
99% of somatic cells are not reprogrammable, comparative studies are necessary 
for progress in iPS cell research. Uí Chonnachtaigh concluded by arguing that a 
lack of ESCR regulation does not mean that it is legal.  
Dónal O’Mathúna from Dublin City University gave a presentation on the ethi-
cal issues in the procurement, storage and transfer of human embryos and foetuses 
for research. In terms of procurement, O’Mathúna explained that foetal tissue can 
come from spontaneous abortions (in which case it is similar to other human tis-
sues); embryos from assisted reproductive therapy; and embryos and foetal tissue 
from elective abortions. He noted that in research, the live human foetus should be 
treated with the same principles that apply to treatment and research conducted 
with children and adults. O’Mathúna also mentioned the importance of maternal 
consent and the separation of the decision for abortion from the decision for re-
search donation.  
Not only is there no consensus on the regulation in Ireland, but according to 
O’Mathúna, there is none to be found within the EU either. The general consensus 
in the EU Working Party is that no matter whether directly or indirectly applied, 
embryonic and foetal research should be directed towards health purposes. The 
Party said, “There is a well-established principle that a person cannot be bought or 
sold. In the same way that people are not generally regarded as goods it is difficult 
to see why an embryo should be so regarded.” O’Mathúna then discussed the “pa-
rental project” – the problem of what happens to unused embryos when the pa-
rental project ends. He also questioned what should be done with the “fruit” of 
research acquired through research involving embryos and foetuses if it is believed 
that the research itself is unethical. All of the criteria set out in the Oviedo Con-
vention apply to embryos and foetuses as well as born persons, which is the crux 




of much of this debate. O’Mathúna ended his presentation by asking the attendees 
whether there is a legitimate reason to say that the moral status of the embryo 
changes at a certain point.  
5 Commercialisation 
Sarah Wilson from the University of Central Lancashire gave a presentation on 
biobanks, justice and benefit sharing. She said that benefit-sharing is important 
because the Human Genome Organisation (HUGO) and the UNESCO Universal 
Declaration on Bioethics and Human Rights both address the need for benefit 
sharing, given there is not automatic access to benefits through property rights and 
furthermore to encourage participation. She cites other reasons benefit-sharing is 
important for, including reciprocity, fairness, equity, beneficence and global justice. 
The specific benefits are advantages or profits derived from the use of human 
genetic resources. Wilson explained that there often already is an implicit assump-
tion of benefit sharing, even when it is not explicitly mentioned. In addition, there 
are certain other advantages to be gained by benefit-sharing, including increased 
health, better science, specific treatment options, the good feeling of altruism and 
financial reward. Wilson indicated that the sharing of benefits differs within huma-
nity, population groups (developed countries tend to benefit more than less deve-
loped countries), genetically interesting groups and participants.  
Wilson explained that the public good model is used by the UK Biobank to de-
termine how the benefits are to be shared. These include the publication of find-
ings, the dissemination and sharing of data, increased health, better science, the 
positive feeling of altruism, et cetera. Benefits can be shared with specific groups 
through financial gains, provision of treatment and feedback of results. Wilson 
asserted the importance of motivation because it constitutes commutative justice, 
distributive justice, compensatory justice and global justice/social justice. Commu-
tative justice means giving a portion of the advantages/profits derived from the 
use of human genetic resources to the resource providers in order to achieve jus-
tice in exchange. Distributive justice is justice in the distribution of benefits and 
burdens and not to increase existing inequalities. The burdens/risks of benefit 
sharing include unauthorised access, “unauthorised” use, genetic label and restrict-
ed access. Wilson also noted that there should be no exploitation of vulnerable 
groups and no “unjust enrichment,” but instead shared vulnerabilities and altruistic 
participation. She ended by asking the attendees whether the sharing is more im-
portant than the benefit itself, but withheld a definite answer.  
The final portion of the workshop was comprised of a debate over whether or 
not the human body should be commercialised. Siobhán O’Sullivan was asked to 
argue in favour of commercialisation, whilst Mark Cutter was given the anti-
commercialisation position. Their positions in this debate do not necessarily reflect 
their own views on the subject.  
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Siobhán O’Sullivan from the Irish Council for Bioethics spoke in favour of the 
commercialisation of the human body. She noted that commercialisation of the 
human body is nothing new and has become increasingly prominent with advances 
in biotechnology, with a general acceptance of intellectual property rights based on 
human tissue. According to the Moore case before the U.S. Supreme Court, if mate-
rial is voluntarily donated, it is considered to be a gift once it leaves the body. 
O’Sullivan asked why, if a person does not own his/her body, can donating mate-
rial from it be acceptable, but at the same time selling be prohibited? She also em-
phasized the obtuseness of the “human dignity-concept”.  
In terms of commodification and the loss of human dignity, O’Sullivan said 
that the end result – a healthier person – is more important than the process of 
getting there, and compensating a person for his/her donation does not lessen 
his/her dignity, nor the dignity of the recipient. She noted that the concept of 
human dignity is selectively applied, depending on the type of human biological 
material in question: selling blood, sperm and eggs for example is acceptable, but 
selling other materials is not. In terms of coercion, she said that when someone is 
paid for their donation, it ensures that they are not being coerced into giving it, and 
it cannot be called “coercion” if a person is not worse off declining the offer. Soci-
ety routinely allows people from lower-income backgrounds to take high-risk jobs 
– such as firefighters and soldiers – voluntarily which is not seen as coercion ei-
ther. In order to further promote this point she explained about Iran being the 
only country in the world that has a State-sponsored system facilitating the buying 
and selling of human biological material. Although most people who sell are poor, 
they do get some sort of long-term care. There is therefore no place for a black 
market in the Iranian system. O’Sullivan also discussed the autonomy paradox – 
i.e. that a high value is placed on autonomy as a legal right, yet this right is not 
upheld with regard to autonomous decisions to sell biological material.  
She also counteracted the notion that commercialisation undermines the rela-
tionship between donors and recipients, which will lead to a decrease in altruistic 
donations, by claiming that offering financial incentives will increase rates of re-
search participation. O’Sullivan mentioned reciprocal altruism, or the fact that gifts 
are never “free”, but tend to give rise to reciprocal exchanges. She also argued that 
commercialisation will not undermine the public trust in research and professional 
scientists because research is already becoming increasingly commercially-based at 
this point in time. O’Sullivan concluded that with proper regulation in place, the 
body can be legitimately viewed as a useful and exploitable resource, which can 
advance scientific research and potentially provide life-saving benefits to others. 
Furthermore, it would appear that deriving profits from biological material is ac-
ceptable as long as the source of the material (the donor) does not share the prof-
its. Lastly, many of the arguments against commercialisation are primarily based on 
emotions such as revulsion – which heavily reduces their acceptability, since the 
very reason we have ethical discourse is so that value-based reasoning becomes the 
basis of accepted behaviour rather than emotions.  




Mark Cutter from the University of Central Lancashire spoke against the com-
mercialisation of human cells, tissues and organs. However, he is personally in 
favour of commercialisation of any part of the research project, except the parts 
that deal with the human body itself. He noted that selling the human body is dif-
ferent than selling other types of inventions since according to Cutter, we should 
not consider ourselves as having property in our own bodies in order to prevent us 
from having property in other people’s bodies. He said that you cannot sell parts 
of the body that you want to use in research, but did not deny that there is a value 
in being able to sell organs. Cutter is also against commercialisation because he 
does not think it should be necessary; people should not participate in research for 
monetary reasons but out of solidarity.  
Cutter is in favour of a whole population biobank without compensating the 
participants, because everyone will benefit from the research results and the 
healthcare system in general. The samples could belong to the research communi-
ties as a whole. He believes that such a model would be the most useful way of 
moving forward with these kinds of debates, so we would have access to the best 
possible research outputs without worrying about property rights. Cutter said that 
one of the problems arising in commercial settings is that it is so difficult to get a 
product market in large-scale biobanks. He predicted that this debate will become 
even more important with new technologies, such as synthetic biology. Cutter 
concluded by saying that rather than fear commercialisation, people should envis-
age the many benefits they will get from the results of the research. 
6 Results 
 There is a distinct lack of legislation and regulation of anything to do with 
human material or assisted human reproduction. The only existing human 
tissue law is a statutory instrument that merely incorporates the EU Tissue 
Directive into Irish law, but does not in any way add to the scope of the 
legislation, or add anything uniquely Irish. 
 In 2008, the Human Tissue Bill was introduced in Ireland, but the Gov-
ernment has yet to even publish the latest version of the bill, following 
public consultation, let alone take further action. 
 The lack of bioethics-related legislation in Ireland is a result of a lack of 
political will and a reluctance to address anything that may in some way re-
late to the definition of “unborn”. In this context, Ireland’s Catholic back-
ground was brought up frequently, as was the divisive abortion debates of 
the 1980s, from which the country has yet to fully recover. In addition, the 
Irish Government may view other issues – such as those relating to the 
struggling economy – as more urgent to legislate on than human tissue. 
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 Biobanks – an integral part of the transfer, storage and procurement of 
human tissues and cells – were mentioned in several presentations and 
discussions. While they are invaluable to the research and scientific com-
munity, a lack of funding and opportunities for collaboration may hinder 
their development. Other types of biobanks – such as DNA databases – 
were also treated. 
 Consent was another overall theme of the workshop. The subject arose 
within the topics of patients’ willingness to donate their samples to bio-
banks, and who should consent to the biobanking of material from chil-
dren. 
 Research on embryonic stem cells, embryos and foetuses was also dis-
cussed in several presentations. Positions vary on these issues, depending 
on the conception at which point a person considers human life to begin. 
Consequently, it is very difficult to regulate these areas of research, par-
ticularly for countries like Ireland that has difficulty reaching a consensus 
on issues dealing with the beginning of human life. 
 Benefit-sharing is an important and necessary part of biobanks, but there 
must not be any exploitation of vulnerable groups and the benefits should 
be shared as fairly as possible. 
 With all the talk of regulation and lack thereof, the question of whether a 
large amount of (or any) regulation is necessary, was asked frequently. 
There was discussion of the implications for scientists and researchers 
from being overregulated, and whether that would impede their research. 
Most participants agreed that whilst some level of regulation is required, 
the regulation should not be so detailed that it hinders research. Further-
more, in the context of the EU, regulation should be in place that encour-
ages the monetary economy and the knowledge economy, as well as ensur-
ing the protection of the human rights of citizens. 
 In addition to the usual issues surrounding property and ownership of the 
human body, the commercialisation debate also saw a discussion on 
whether altruism exists and the extent of its importance, enlarging upon 
the difference between solidarity and altruism. Several participants con-
cluded that a certain level of commercialisation is acceptable and neces-
sary, but that it must be harnessed within well defined limits in order to 
foreclose any coercion or violation of human rights. 
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The Eighth International Workshop of the Tiss.EU Project was organized by pro-
ject partners Heather Widdows and Sean Cordell from the University of Birmingham. 
The workshop dealt with the fourth focal theme of the project (Focal Theme D: 
Biobanking), comprising presentations on the ethics, governance and regulation of 
Biobanking practices given from a broad range of perspectives. Topics discussed 
included: the state of current legislation in the UK; models of relationship and 
consultation between biobanks and the public; participants’ withdrawal from  
biobanks; the conditions for participants’ autonomy; fledgling legislation concern-
ing transfer of genetic materials in Belgium; and the effectiveness or otherwise of 
ethics committees regarding biobanks. To reflect and accommodate this wide 
scope, the two days’ sessions were divided under three sub themes: “Biobanking, 
Community and Society”; “The Individual and Biobanking”; and “Regulation, 
Governance and Law”. Accordingly, a number of distinguished experts in the 
fields of medical and bioethics, law, philosophy, social sciences and politics attend-
ed the workshop. 
The meeting began with a brief introduction and welcome from Heather 
Widdows, who outlined the theme of the workshop and its place in the project. The 
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first formal presentation was “A Short Introduction to the Tiss.EU Project” given 
by lead partner Christian Lenk from the University of Goettingen (Germany). He 
explained that the project consists of a number of thematic workshops, of which 
Birmingham is one and that together, these aim at assessing the legal and ethical 
regulation of research using human tissue in the EU countries. Regarding the Bir-
mingham workshop more specifically, Lenk linked it to the previous Paris meeting 
(June 2009) on the same focal theme and outlined the key issues raised there: ques-
tions of informed, “specific” and “broad” consent in biobanking; privacy and con-
fidentiality; forensic use of biobanks; feedback and disclosure of medical infor-
mation to participants; access to donated genetic material and whether or not such 
access is construed as a right to one’s “property”. The talk ended with a look ahead 
to the Tiss.EU workshop in Vilnius, Lithuania (September 2010). 
2 Country Report: United Kingdom 
David Price (Leicester De Monfort University, UK) delivered his report on the state 
of current UK legislation and practices relating to biobanking. The report initially 
offered an interesting overview of current regulation, which reflected the relatively 
new and developing nature of biobanking itself: “an incomplete patchwork, with a 
plethora of sources and rules and guidance yet simultaneously replete with gaps 
and interfaces”.  It began by identifying the key issues as: 
 How biological materials are entered into the bank 
 Research biobanks as institutions 
 Under what conditions researchers can access materials in the bank; prob-
lems concerning ownership of biological materials and of intellectual 
property 
 How information is collected and stored 
With regard to the adequacy or inadequacy of the existing legal framework in ad-
dressing these issues, the report went on to note that the removal of tissue from 
living persons is governed by the common law and specific statutory provisions 
such as the Mental Capacity Act 2005; and that all research involving NHS re-
sources de facto requires NHS Research Ethics Committee approval (mandatory re: 
clinical trials), data protection and confidentiality and human rights laws.  
At the same time, there are several areas on which laws and guidelines are rele-
vant but less than clear on the challenges raised by biobanking specifically. On 
“consent” for example, the Human Tissue Act cites “appropriate consent” and 
“qualifying consent” as required for research projects, where the appropriateness 
or the qualification for biobanking is not, as yet, clearly distinguished or tailored to 
large scale collections of material that contain DNA and other genetic information. 
A further problem identified here regards how Research Ethics Committees and 
regulatory bodies are to act concerning consent. A predominant view is that the 




relatively low risks involved in biobanking research (as opposed to medical re-
search on living patients, for example) favours a “biobanking exceptionalism” 
which need not adhere to the strict informed consent condition. This in turn has 
led to a focus on broad consent, where, as stated in the Human Tissue Authority 
Code of Practice on Consent, “if conducting research on samples of tissue, it is 
good practice to request generic consent because this avoids the need to obtain 
further consent in the future.” Implicit in the last part of this statement, however, 
is the assumption that broad consent is a “one off” act, but as has been noted 
elsewhere, this need not be the case.   
It was also noted that anonymity of a tissue sample (such that the researcher 
could not discern the identity of the donor), in conjunction with approval by a 
Research Ethics Committee, is sufficient to provide exemption from the consent 
condition. Lastly, Price’s presentation dealt with the issue of commercialization, 
which to a large extent stands on the question of property in the body. Here too, 
there was a possible tension between UK law and biobanking regulations and prac-
tices. For example the UK’s EGF (Ethical Governance Framework) is clear that 
“UK Biobank Limited will be the legal owner of the database and the sample col-
lection… Participants will not have property rights in the samples”; whilst the 
judgment given in the Yearworth sperm storage case was that the men – whose 
sperm was inadvertently destroyed – had a valid claim on the grounds of “proper-
ty”. The upshot of the report was that the emerging challenges of biobanking are 
themselves shaping legal and regulatory practices as much as, or more than, they 
are responding to laws and regulations. To quote Elizabeth Rynning, “The regula-
tion of research biobanking should be perceived as an ongoing step-by-step pro-
cess, rather than a problem that will soon be solved once and for all.” 
3 Biobanks, communities and society 
Mairi Levitt’s paper “Biobanks, Rights, and the Regulatory Environment: Relating 
to participants: how close do biobanks and donors really want to be?” considered 
the relationship between biobanks and participants, contributors and beneficiaries. 
The philosopher from Lancaster University began her talk with the claim that pub-
lic engagement was crucial to the success of biobanking projects in three ways: to 
ensure that the biobank is constructed and run in ways acceptable to the public; to 
be best placed to secure funding; and to invite participation and instill confidence 
in those participants. After detailing the ways in which such consultation was car-
ried out in the case of UK biobank (e.g. face to face Q and A sessions, postal cor-
respondence), the main public concerns about biobanking were outlined as: the 
potential harm to individual donors and their interests; the possibly commercial or 
nefarious motivations of “big Pharma”; the attendant issue of trust; and the wider 
societal implications of relinquishing one’s genetic material to research (how is 
benefit sharing assured, who will be doing research to which ends?).  
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In light of these concerns, different kinds of inter-personal relationships were 
considered as candidates as those which the biobank might do well to cultivate as a 
model for its own relationship with the public. These were acquaintances; partner-
ships (i.e. business or collaborative task-based partnerships); colleagues or neigh-
bours; and friends.  With reference to an actual project – The Avon Longitudinal 
Study of Parents and Children (ALSPAC) – which is also known as Children of the 90s – 
it was suggested that elements of all four kinds of relationship were salient, and 
that the prevalence, or otherwise, of one or of these features would depend on the 
nature of the project: for example on how much ongoing commitment would be 
needed (more of a partnership and possibly friendship in the case of ALSPAC; 
more of an acquaintance relationship in a shorter term clinical trial, perhaps).  In 
discussion, the issue was then raised of whether a biobanking institution needs to 
be responsive to different participants’ expectations. Perhaps, for example, one 
person is happy to see themselves as engaged in a friend-type relationship, whilst 
another is on a “strictly business” footing. Thus, some interesting points were 
raised about the essentially social structure of biobanking and how this is best in-
terpreted and embodied in the construction and ongoing practices of biobanks.   
Continuing with this last point about structure and practices, in his presenta-
tion on “The Function of the Institution and its Place in Biobanking Ethics”, Sean 
Cordell from the University of Birmingham argued that in the ethics of biobanking, 
there is a place for considering the biobank itself as an “ethical subject”, i.e. an 
institution that can do better or worse according to how well or badly it operates as 
a thing of its kind: a thing that is “fit for purpose” just as we might think that a 
tool or artefact is (a good pen writes well, a good knife is sharp, and so on). He 
began by motivating such an account: explaining that much of the ethical debate 
about biobanking has been framed in terms of the relationship between individual 
agents on one hand and larger groups, social benefits or legislative agencies on the 
other. In such debates the question of the “purpose” or the “function” of the  
biobank is often implicitly or explicitly raised but, equally often, left unaddressed 
or simply assumed to be broad or vague – for example in terms of “public health”, 
with which all sorts of institutions are concerned in some way or other. 
Cordell went on to suggest that a more specific conception of biobank’s func-
tion – its “characteristic activity” – could usefully inform its professional practi-
tioners; its participants (e.g. as to what kind of venture they are giving their con-
sent); and its advisors (e.g. which of its projects are essential and non-essential) as 
to how a biobanking institution should best be structured.  It was claimed that the 
appropriate view of such an institution was that it is socially constructed for the 
human goods of medical research and that it realizes these goods in distinct and 
defining ways – i.e. through large scale data collection and long term research into 
disease prevention – where these aims may be analysed further according to speci-
ficity of function (e.g. the Irish biobank for cancer research). 




The ensuing discussion raised, among other things, the questions of whether a 
biobank’s purpose can be understood as unchanging from its outset, and whether 
that purpose can be construed as singular. That is, as biobanks develop as institu-
tions, so might their function(s). Notwithstanding these pertinent critical points, 
the role of the institution’s function in biobanking ethics, for example in construct-
ing codes of practice and mission statements, was highlighted and constructively 
considered. 
4 The individual and biobanking 
In his presentation on “Biobanking: The Requirements of Respect for Autonomy” 
Iain Law (University of Birmingham) set out 1) to clarify some ways in which “au-
tonomy” and “respect for autonomy” might be understood and what conditions 
they might include; and 2) argued that such an understanding is needed to clarify 
what’s at stake when we talk of respecting autonomy in the biobanking context. He 
started by claiming that to say that someone is, or is not, “autonomous” is rarely, if 
ever, merely to make a purely descriptive claim about an attribute that person has 
or fails to have – such as we might when we say they are “tall” or “outgoing”. Ra-
ther, “autonomy” is value-laden, and this means that claims about the conditions 
for autonomy will at least partly depend on certain values that motivate the claims. 
So for example, a primacy on the value of non-interference – an emphasis on so 
called “negative” liberty – will beget a similar conception of what autonomy consists 
in, namely the individual’s freedom from external constraints on their choices and 
actions.  However, a quite different construal of autonomy can be made in terms 
of the instantiation of an individual’s capacities to make certain kinds of choices 
and then act upon them. On a version of this view, for example, there can be cir-
cumstances in which intervening in an individual’s life could be increasing, rather 
than constraining, their autonomy. (An example would be enforced rehabilitation 
for drug addicts.) Law illustrated this diversity of autonomy by briefly surveying 
some of the vast philosophical and ethical literature on the subject, and the varying 
numbers of different conditions for autonomy that the authors have cited in their 
accounts.   
Given this background, the question for biobanking ethics is how autonomy is 
to be understood, figuring importantly as it does in the rationale for the require-
ment of participants’ informed consent. More specifically it concerns what is owed 
to donors in order to respect their autonomy. Law suggested a strategy of examin-
ing cases in which persons are clearly wronged in a way that involves violating their 
autonomy.  By distinguishing these cases from other ways in which people may be 
wronged (by being harmed, or having their privacy invaded, etc.) it is possible to 
identify more easily what respect for autonomy per se demands.  In other cases in 
which someone lends, gives or sells some of their possessions (including infor-
mation about themselves) to someone else the only constraints imposed by the 
 Sean Cordell 
 
124 
need to respect autonomy appear to be avoiding coercion and deception.  These 
constraints are not in themselves minimal or easy to meet in all circumstances, but 
they are less extensive than the demands created by respecting autonomy are often 
stated or implied to be.  For instance, the constraints of autonomy themselves, on 
Law’s view, entail only that a consenting person is not deceived, so will not include 
or entail any requirement of actively supplying full information at every stage of a 
biobank’s activity involving participants. (Although again, there may well be con-
vincing arguments, separate from appeals to autonomy, for such information being 
supplied.)   
In conclusion, an interesting implication of the paper is that the talk of auton-
omy is often quite loose, and there is no reason to think that it is generally any 
more careful in bioethics. If we are to make respect for donor autonomy a corner-
stone of biobanking ethics, then we need to be clear about what it is we mean by 
autonomy and what a requirement to respect it does and does not entail.  
Søren Holm (Centre for Social Ethics and Policy, University of Manchester) 
opened his talk on “Withdrawal from Biobanking Research – Justification and 
Problems” with a pithy observation: whilst it would be impossible to account for 
everything that has been written on the conditions for participation in research, it 
might prove similarly difficult to find literature on the conditions for withdrawal. 
Holm took off from what he called the “established view” of the right to with-
drawal. On that view the right is: absolute; unconditional; immediate; complete 
(i.e., includes withdrawal of already collected data); and non-tradable (“inaliena-
ble”). Having granted that there are some good historical reasons and principles 
for this view, the argument put forward was, that there may be cases in which 
components of this right should be relaxed, so on this view the right to withdraw is 
not inalienable, nor is it necessarily unconditional.  
In support of the argument, some grounds for denying the unconditional and 
inalienable status of the right to withdraw were presented. Firstly, consent to bio-
bank research involves a commitment, such that granting a right to renege on it for 
any reason – or indeed for no reason at all – may undermine the obligating force of 
active consent, i.e. the commitment in agreeing to participate.  Secondly, there is 
the right of participants to waive their right to withdrawal; where this denial could 
itself be seen as a violation of participants’ autonomy and a constraining of their 
choices. As to the aspects of immediacy and completeness in the biobanking con-
text, whilst immediate withdrawal of genetic samples might be possible, the com-
plete withdrawal of all the data gathered from those samples may not be. This 
underlines the way in which the process of “withdrawal” is not a one-off act, but 
may comprise more than one action. In light of these considerations, some sugges-
tions were made as to how biobanking research might best proceed with respect to 
the right to withdrawal. For example, in the case of a mass withdrawal due to an 
emerging media scandal over a biobank project, it could be that the right to imme-
diate withdrawal of material is maintained, whilst the right to complete withdrawal 




of data is denied for at least a “cooling off period” until the full information is 
discovered and made available.  
A further suggestion, arising from the challenge to unconditional status of the 
withdrawal right, was that participants should have, and give, good reasons for 
their withdrawal in order to withdraw. Such good reasons would include the fact 
that they were deceived or misled, or less than fully informed about the project(s); 
that harm to them or others would result from continued participation; and that 
the overall purpose of a project had changed (such that one would not have con-
sented if this had been the stated purpose at the time of initial donation or partici-
pation). Accordingly, insufficient reasons included mere whim or a fit of pique. 
Hence a person’s change of mind can be an acceptable reason, but only if there is a 
good reason for them changing their mind, or so it was proposed.  
5 Regulation, governance and law 
In her presentation “Biobanks: Comments on the New Belgian Law from an Ethi-
cal Perspective” Sigrid Sterckx (Bioethics Institute, Genth University) looked at 
Belgium’s Law regarding the procurement and use of human body material des-
tined for human medical applications or for scientific research purposes, which 
due to a one-year delay, was just about to be implemented at the time of her 
presentation. As stated, the act is intended to cover “every biological body materi-
al, including human tissues and cells, gametes, embryos, foetuses, as well as sub-
stances extracted therefrom, whatever the degree to which they have been pro-
cessed” (Art 2 (1)).  Nevertheless, the act distinguishes between a “bank for human 
body material”, which has “the sole responsibility to decide on the allocation of 
human body material” and a biobank, which “stores and provides human body 
material, exclusively for scientific research”. A further distinction is between “pri-
mary use” – any use of the human body material to which the donor has explicitly 
and specifically consented in the context of the removal, and “secondary use” – 
any other use of human body material than that to which the donor has consented 
in the context of the removal. There are actions that are excluded from its scope – 
e.g. “the donation and the actions performed with a merely diagnostic purpose for 
the benefit of the person from whom the body material is removed (e.g. a biopsy), 
provided that the body material is not destined for another use”. There are also 
certain bodily materials exempted: the law does not apply to hair, body hair, nails, 
urine, mother’s milk, stools, tears and sweat (a non-exhaustive list). The act is ex-
plicit in its prohibition of financial payment for bodily materials (“No benefit 
whatsoever may be offered in exchange for the donation of human body materi-
al”), though compensation for costs or loss of income may be provided. 
One issue raised was the issue of donor information and its availability. The act 
states that “If in case of an action performed on human body material or the use 
of human body material, analyses provide relevant information regarding the 
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health status of the donor, the donor has a right to this information” and that  “the 
physicians who learn such information in the context of an action with or use of 
the material, the governors of the human body material and the chief physician of 
the hospital where the removal took place are, each in the context of their function 
and role, responsible for the application of [this provision]”. Sterckx asked the 
questions: “What counts as relevant information?”; “What if there are diverging 
interpretations of the relevance (which is likely)?”; and “What if the donor does 
not want to know?”.  In response, she discussed the possibility of the risk of a 
“diffusion” of responsibility – whereby a number of individuals pass on such re-
sponsibility or assume that others have taken it on – could result in nobody 
providing the information to the donor. This possibility can be seen as especially 
important when we consider that the right to be informed also applies to cases of 
“secondary use” outlined above.   
Another related issue concerns the role and status of the ethics committee in 
relation to the law. The act states that in cases where gaining consent to secondary 
use is impossible, such usage can be permitted by the positive approval of an ethics 
committee. Thus the ethics committee is, in effect, deemed to be more than advi-
sory. It is also, in a sense, extra-legal, as in this case it acts in the absence of the 
consenting party normally required by the law. 
Roger Brownsword (School of Law, King’s College London) opened his presenta-
tion on “Biobanks, Law and the Regulatory Environment” with what he sees as 
the main legal and regulatory challenges for biobanking. Currently, these are (1) the 
terms and conditions for participation; (2) the terms and conditions for access; (3) 
interoperability; and (4) effective regulation. For future consideration, he offered the 
following points as central: (1) the application of an improved understanding of 
the conditions for public health (articulating State stewardship); and (2) the impli-
cations of a risk-focused technology-based regulatory environment.  As to the 
current concerns, the question was initially posed as to whether we have a right – 
or an absolute right – to opt not to participate in public health projects. We do not, 
for example, cite such a right in the case of vaccinations or jury service. This 
mapped on to a wider question of whether, and why, we prioritize public goods or 
individual rights. And the perspective we take on this question – or “where we 
stand on the bioethical triangle” (of rights, public goods and regulatory/legislative 
bodies) directly affects the answers we give to questions about e.g. respecting the 
informational interests of participants; privacy; confidentiality; data protection; and 
clinically relevant information that is fed back to participants. 
Within this framework, Brownsword identified the need for the right kind of 
regulatory environment that recognizes the “gap between background legal provi-
sions and foreground practice”. Moving to future challenges, he pinpointed the 
crucial area of State stewardship, i.e. competence and responsibility in relation to 
the conditions for public health. UK Biobank delivers an improved understanding 
of the causes of serious diseases, and the State is the agent responsible for the ap-
plication of such new intelligence. On this crucial point, it was argued that stew-




ardship in this area can be affected, and is in fact hampered, by a general trajectory 
of society: in particular the tendency to frame issues in terms of risk assessment 
and risk management, and to commit regulatory resources to prevention. UK  
Biobank, it was claimed, is a token of this trajectory in the field of public health; 
and the national DNA database is a token in relation to criminal justice. These 
developments can be damaging to the regulatory environment, and in addition to 
risk and risk prevention, the stewardship role must include the provision of condi-
tions essential to life (public health being one instance) which are necessary for the 
development and sustenance of a moral community. 
The question of the role and effectiveness of the Ethics committee in biobank-
ing was dealt with by Jean McHale (Birmingham Law School), whose aim in her 
presentation “Accountability, Governance and Biobanks: The Ethics Committee as 
Guardian or ‘Toothless Tiger’?” was to explore whether it is correct to regard such 
ethics committees as “toothless tigers”, and consider alternative structures which 
may provide a more appropriate regulatory paradigm for the future. The first kind 
of problem she identified was in definition and scope of a biobank’s activities. In 
the words of Susan Gibbons, the subject of legal constraint as described in recent 
(2001) legislation (“collections of genetic sequence information or of human tissue 
from which such information might be derived that are or could be linked to 
named individuals”) is a broad  statutory definition, but in an important sense it is 
also too narrow. For in referring only to “genetic sequence information”, it omits 
collections of personal, medical or genealogical data” (Legal Studies 2007). Partly in 
relation to this vagueness and to the fact that biobanking essentially always deals 
with such materials, there has been an increasing emphasis on the place of ethics 
committees to decide upon and approve particular projects and practices, and has 
for example been reflected in the Implementation of the Clinical Trials Directive 
(2004).  
This raised the question of whether the ethics committee serves as “legitima-
tor” of research or as a means of ensuring accountability (or both).  Acknowledg-
ing good reasons of objectivity and independent perspectives, for ethics commit-
tees to exist, the worry outlined was that the ethics committee is nevertheless all 
too “toothless”. So for example, there is the concern that the sanctions available to 
them in the UK – such as reporting ethical concerns to UK Biobank Funders; 
making their concerns public or resigning en masse – were insufficient to effect 
genuine prevention or change to a project or practice it might deem unethical. A 
further concern was whether the power of ethics committee was weakened by, 
rather than supported by, the complex legal framework in which it operates. For 
instance the data protection act; the ECHR; and the aforementioned lack of defini-
tive definitions in the case of “appropriate consent” and uncertainty of the Codes 
of Practice of the Human Tissue Authority, alongside “Common law consent” as 
employed in legal cases. In the context of these problems, the question of “who 
watches the watchers” also becomes relevant: not least because if ethics commit-
tees are to have regulatory leverage and possibly even de facto legislative power, 
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then these bodies themselves would require regulation. In response, Professor 
McHale tentatively put forward some positive recommendations for facilitating 
good regulatory bodies and their effective regulation as a whole, as follows:    
 A National Bioethics Council with e.g. sub-groups to advise on biobanks. 
 Placing the Human Genetics Commission on a statutory footing and ex-
panding its powers. 
 A broadening of the role of the Human Tissue Authority. 
After an explanation of how they would help achieve a regulatory environment 
that overcomes the problems outlined earlier in the presentation, the final – also 
tentative but no less thought-provoking – idea was that we might well benefit from 
a “Regulation of Research Act 2011”. 
In their paper “Involving Publics in Biobank Governance: Moving beyond ex-
isting approaches” Graeme Laurie and Kathryn Hunter (both from the University of 
Edinburgh) identified as crucial the question of how to involve people well in  
biobank governance.  In addressing this question it focused on ways to effect 
greater participant involvement in the management and oversight of UK Biobank 
as a means to secure public trust and support.  
After setting up the issues via the perceived failures of the UK Biobank con-
sultations, the paper examined David Winickoff’s proposed “shareholder model” 
of governance, which seeks to move beyond public consultation to embrace repre-
sentational forms of participation for the donor collective in biobanking. Such a 
model, Winickoff argues, in which the donor collective has “real representative 
power”, could close the “agency gap” between public expectations and biobank 
managers, thereby enhancing participation rate, participant trust, and project sus-
tainability. Laurie and Hunter claimed that while Winickoff’s proposal has contrib-
uted greatly to the discussion of biobank governance, the shareholder model is 
problematic both practically and conceptually. They argued that not only the very 
notion of “shareholding” is antithetical to the structure and purpose of UK  
Biobank (UKB), which is aimed at benefiting the wider community or society and 
not the happy few, but also that the model raises questions about whether a form 
of representation based on a shareholder analogy is appropriate as a means of en-
gagement.  
Whilst Laurie and Hunter agreed that there is much value in models from the 
corporate sphere, they urged a “stakeholder model” of governance, which goes 
beyond representation to more deliberative and inclusive processes of participa-
tion, as more fitting.  Unlike the shareholder model, the stakeholder model of gov-
ernance resonates with democratic notions of “participation”, “involvement” and 
“inclusion”, which not only reflects the growing trend towards more deliberative 
and participatory mechanisms for involving publics/citizens in decision-making 
processes generally,  but also with UK Biobanks’s own commitment to engage 
with a wide variety of stakeholders. The stakeholder model requires not only a 
commitment on the part of biobank management to engage frequently and sys-




tematically with all relevant stakeholders, but also a willingness to respond and 
adapt to stakeholder concerns over time. Furthermore, the wider scope of stake-
holder view involves corporate responsibilities that extend beyond immediate con-
sideration of participants. For example “to perform in a manner consistent with 
expectations of social mores and ethical norms; to recognize and respect new or 
evolving ethical/moral norms adopted by society; and to prevent ethical norms 
from being compromised in order to achieve corporate goals.” 
In the second part of the presentation,  Laurie reported on a recent workshop 
held by the UK Biobank Ethics and Governance Council (EGC) and discussed the 
extent to which the preliminary conclusions of the Council do, or do not, support 
the stakeholder approach. In light of the workshop, it was found, among other 
things, that there is no obvious and natural single model for best communicating 
and involving the public, and hence that a “mixed methods” approach, consistent 
with the stakeholder model, is required. Both UKB and the EGC, whose roles 
need to be clearly distinguished, need to be open to the possibility of change with 
respect to consultation. For example a consultative committee may be useful, but 
must avoid being “too cozy” if it is to represent the appropriate range of parties 
and interests. 
6 Results 
As the issues and implications of collecting large scale bases of genetic information 
continue to develop, so does the need to identify and clarify them. In focusing on 
both the ethical questions and the actual regulation of biobanking, the workshop 
significantly advanced overlapping conceptual, socio-political, moral, and legal 
debates about the appropriate ethical and legal framework for biobanking practices 
and governance. The upshot of these debates is summarized below. 
Conceptually, the ways in which we think about biobanking practices,  
biobanks themselves, and their relation to participants as well as to the wider pub-
lic and society, shapes the normative perspective from which the ethics and regula-
tion of biobanking is developing. From this angle the discussion opened up some 
crucial lines of inquiry. One was the need for thinking clearly about what individual 
autonomy means, what it does and does not encompass in terms of donors’ con-
sent and privacy and, therefore, the work it can and cannot do in prescribing  
biobanking regulations. Another theme was how best to envisage the way in which 
the public stands in relation to biobanking projects which rely on their participa-
tion and support, and then how such a model would be best cultivated in consulta-
tion and communication. Similarly, the importance of the purpose and aims for 
which a biobanking institution is constructed was discussed.  
The accompanying ethical, social and political issues aired concerned the struc-
tural relationship between biobanks, individuals, and the state, within which an 
exclusive appeal either to individual rights or to public goods will not do all the 
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work in deciding how to regulate biobanks. Here the part the State plays its part in 
both protecting rights and facilitating biobank research and, as such, its directives 
should guide regulation positively towards these goals and away from instilling a 
risk-avoidance culture. In keeping with this suggestion, the question of the legiti-
macy of donor’s withdrawal from biobanking is at least open for discussion. That 
is, whether the individual’s right of withdrawal is unconditional, inalienable and 
immediate in the case of biobanking, is open to question (immediate withdrawal 
may be possible for material but not data); and interrogation (should we be able to 
withdraw participation for no good reason when doing so might compromise ben-
eficial research? Can and should we be able to waive the right to withdraw?)  
Legally, there clearly remains a lack of consistency in UK law, and this is mir-
rored in at least one other European country, i.e. Belgium. In the UK case, the key 
areas in which biobanking legislation could benefit from clarity and precision are a) 
what constitutes “appropriate consent” in which cases, and why; and b) whether 
genetic material is ever in some sense the “property” of the donor – and, if so, 
what sense and under what circumstances – and whether such material is the prop-
erty of UK Biobank. One positive recommendation for more effective regulation 
here was a strengthening of the powers and remits of ethics committees, standing 
as they do at the cusp of extant legal provisions and the new challenges of  
biobanks. In the Belgian case, there are additional concerns about providing do-
nors with information: whether this is what should always be done regardless of a 
particular donor’s wishes as to being informed, for example; and how this commu-








Procurement, Storage and Transfer of Tissues and 
Cells for Non-Clinical Research Purposes 
 
Ninth International Workshop of the Tiss.EU Project 
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Vilius Dranseika, Eugenijus Gefenas 
1 Introduction 
The last international workshop within the Tiss.EU project was organized by the 
Department of Medical History and Ethics, Medical Faculty, Vilnius University in 
cooperation with the Lithuanian Bioethics Committee. It was focused on the Focal 
Theme A, “Procurement, Storage and Transfer of Tissues and Cells for Non-
Clinical Research Purposes”. The workshop’s regional focus was on human tissue 
research regulations in Poland, Estonia, Latvia and Lithuania. In addition, the situ-
ation in Belarus was addressed. Beyond this, the programme included several 
presentations on more general issues of research on human biological materials.  
2 The contributions 
The workshop started with a general introduction to the Tiss.EU project given by 
its coordinator Christian Lenk (Dept. for Medical Ethics and History of Medicine, 
Goettingen). After summarizing the results of the two previous workshops on the 
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same focal theme (Padova and Dublin), Lenk identified some areas in need of 
further work and discussion: 
 contradictions in official EU documents (for example: secondary use of 
tissue samples); 
 different interpretations of the no-property rule; 
 a tendency to broad or blanket consent in the area of biobank research; 
 rather homogenous guidelines and expectations in the field of privacy and 
confidentiality within the EU; 
 differences regarding the right to feedback for health findings of therapeu-
tic relevance. 
2.1 Country report: Estonia 
The first panel started with a presentation by  Aime Keis (Estonian Genome Center) 
who reported on the history, legal framework and day-to-day operations of the 
Estonian Genome Center, a large-scale population-based biobank currently affili-
ated to the University of Tartu. The main document regulating this biobank (the 
Human Genes Research Act) contains provisions on the procedures of data collec-
tion, storage and use (including consent requirements: the biobank has an official 
broad consent form); the rights of the participants (withdrawal of consent, the 
right to know and not to know; the right to be informed of incidental findings); the 
role of the ethics review; and the ownership of the data and samples. The main 
challenges yet to be addressed were identified as: 
 feedback of genetic information to the donors; 
 establishing a genetic consultation network; 
 establishing a follow-up system for the collected data. 
Andres Soosaar (Estonian Medical Journal/Eesti Arst) discussed the status of small 
project-based biobanks in the Estonian biomedical research environment. He 
claimed that small biobanks are underregulated in comparison to the biobank at 
the Estonian Genome Center, which is governed by a special law. This underregu-
lation follows from both a loose moral framework (neither researchers nor RECs 
are adequately trained in research ethics; scientific, technological and economical 
challenges sometimes override moral requirements of biobanking) and a fragmen-
tary legal framework (the Human Genes Research Act can be used by analogy only 
in some situations; there is no general tissue law, some issues are regulated by other 
legal acts, e.g. the Personal Data Protection Act). Soosaar concluded that RECs 
have a crucial role in improving the moral climate around biobanks. The estab-
lishment of regulatory frameworks, education and mutual exchange of information 
about biobanks are the main tools for improving the situation. 
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2.2 Use of human biological material for research 
Arvydas Laurinavičius (Lithuanian National Centre of Pathology) presented the pa-
thologist’s perspective on the use of human biological material for research. Coll-
ections of biological materials removed for diagnostic or therapeutic purposes may 
also function as disease-oriented research biobanks. In such cases it is crucial to 
find the right balance between the interests of the physician and the individual on 
the one hand and interests of the researcher and the public on the other. Laurina-
vičius argued that from the pathologist’s point of view, collection and storage re-
quirements should be relatively liberal while the requirements for research release 
should be rather strict. 
2.3 Country report: Latvia 
Solvita Olsena and Signe Mezinska (Riga Stradins University) reported on the situation 
in Latvia, starting off with a presentation on the legal, ethical and practical aspects 
of sample collections in the Latvian Human Genome Project. Establishment and 
operation of the Latvian Human Genome Project is regulated by the Human Ge-
nome Research Law and a number of cabinet regulations. These regulations define 
the voluntary nature of participation;  the prohibition of any discrimination on the 
basis of the genetic data; the rights of the donors (to become acquainted or to 
refuse to become acquainted with the data; to prohibit the supplementation, rene-
wal or verification of the description of their state of health in the genome data-
base; to revoke their consent at any time); consent requirements (the donor shall 
receive written information regarding the purpose, content and duration of the 
research project; potential risks; the right to freely express his or her consent and 
to revoke it at any time; and the possibility to perform genetic research outside of 
Latvia); the possibilities to include children and incapacitated adults; REC review; 
coding, storage and restrictions of use (it is only permitted to use the genome 
database for scientific research, research and treatment of the diseases of a gene 
donor, research of the health of society and for statistical purposes). A number of 
legal shortcomings were identified including the unclarity of the text of the provi-
sions; contradictions within the law and with other laws; no proper provisions for 
the inclusion of vulnerable donors; no proper way of handling possible damage. 
One challenge among others was the fact that most of the information is available 
in Latvian only, which is problematic in face of the fact that there are populous 
ethnical minorities whose members may lack proficiency in Latvian. During the 
following discussion the problems of broad consent were addressed as well as the 
cultural background of the Latvian Human Genome Project, which initially – at 
least in the public mind – was closely related to the issues of national identity. 
In the second part of their talk, Mezinska and Olsena stressed the need for a 
coherent national regulation on human tissue research in Latvia. In Latvia there are 
no specific national regulations regarding ethical review of biomedical research 
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except clinical drug trials, research on medical devices and research on the Latvian 
population genetic database. In particular, there are no specific legal requirements 
regarding ethical review of research on archived biological materials removed for 
diagnostic purposes. Thus the main practical reason in such circumstances to apply 
for ethical review is participation in the international projects or requirements of 
scientific journals. Mezinska reported that recently there has been a discussion to 
pass a general biobanking law. 
2.4 Country Report: Belarus 
The last presentation on the first day of the workshop was given by Andrei Famen-
ka (Belarusian Medical University). Famenka reported that Belarusian legislation 
governing biomedical research is patchy and fragmentary except in the case of 
clinical drug trials. For example, no consent is legally required for the secondary 
use of biological materials removed for purposes other than research. European 
legal acts pertaining to the field of biomedical research have made almost no im-
pact on the situation in Belarus since the country is neither a member of the Euro-
pean Union nor is it a member of the Council of Europe. The Russian law in con-
trast to the European law has had much more significant influence. The current 
research ethics infrastructure is not sufficiently strong and efficient and ethical 
regulations are currently not considered a priority by the health care authorities. 
2.5 Results from the PRIVILEGED project 
The first speech on the second day was delivered by Claudia Pitz and co-authored 
by David Townend (Dept. of Health, Ethics and Society, Maastricht University). Pitz 
summarized the main results from another European project, PRIVILEGED (De-
termining the Ethical and Legal Interests in Privacy and Data Protection for Re-
search Involving the Use of Genetic Databases and Bio-banks). At first the simila-
rity between samples and data in genetic research was discussed. Is a sample to be 
perceived as “data“ for data protection purposes, or is it a vehicle for data? There 
seems to be no coherent approach in the EU Data Protection Directive. Ingrained 
in the Directive itself is a lack of clarity around research, particularly research on 
data (and samples) that is a secondary purpose to the initial collection of the data. 
There is also a harmonization problem: the Directive leaves the decision as to how 
the secondary use should be regulated to the discretion of the Member States, 
which leads to a wide divergence in the differing ways of implementation. Se-
condly, Pitz discussed the nature of the harms involved in dealing with the genetic 
information in samples and data, which are informational when it comes to the 
secondary use of human biological materials and result primarily from the use of 
the data. As her third main point, Pitz considered the nature of consent in genetic 
research and the ways the Directive copes with the possibility of secondary proces-
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sing. In her opinion, there is still a need for discussion as to whether there is a need 
for a new Directive on data protection in the field of research.   
2.6 Country report: Poland 
Krzysztof Marczewski (Dept. of Bioethics, Anthropology and General Theory of 
Medicine, College of Management and Public Administration, Zamosc, Poland) 
presented a survey on Polish tissue banks he conducted together with Jakub Pawli-
kowski and Jarosław Sak (Dept. of Ethics and Philosophical Anthropology, Medi-
cal University of Lublin, Poland) in 2008. The survey shows that Polish tissue 
banks differ significantly in the ways they handle such issues as coding of the 
samples (almost 25% of the banks do not code the samples) and consent to 
conduct research (written consent is being secured in 92% of the banks; only in 
half of the biobanks an additional talk with the professional staff was possible; only 
70% of the biobanks acquire the consent for future investigations or other use of 
samples). The problem of the comprehensibility of the consent forms was also 
mentioned. Marczewski emphasized the need for a harmonization of legal regula-
tion of human tissue research in both Poland and Europe. 
The current legal situation in Poland in relation to biobanks was surveyed by 
Joanna Rozynska (Dept. of Ethics, University of Warsaw). At the moment, a new 
law on biobanks is being drafted. However, it is not clear when it will enter into 
force. Currently Poland has detailed regulations on clinical trials of medicinal 
products and medical devices (implementation of the EU Directives). Regulations 
on other types of biomedical research involving human subjects are scattered in 
different documents, poorly written (unclear, messy, incoherent) and often incon-
sistent with international standards. There are no specific regulations in such areas 
as research on human biological materials and associated data; collection, storage, 
processing, and utilization of biological samples and data collected for research 
purposes; research biobanks; usage of residual or archived biological material for a 
purpose other than that for which it was removed (e.g. for research). However, this 
does not mean that there is a total normative vacuum since general principles from 
the Constitution, the Criminal Code etc. can usually be applied.  
2.7 Country report: Lithuania 
Vilius Dranseika (Dept. of Medical History and Ethics, Vilnius University) present-
ed a paper on regulations of human tissue research in Lithuania. Even though 
Lithuania has a specific law regulating biomedical research (Law on Ethics of Bio-
medical Research) a number of issues remain unclear. First, it is not clear whether 
broad consent is compatible with the consent provisions in the said law. Second, 
only very general regulations exist in relation to anonymization. There are no spe-
cific regulations for different levels of anonymization. Third, there are no regula-
tions concerning the ownership of biological samples. Fourth, it is not clear 
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whether obtaining samples from the deceased for scientific purposes is possible at 
all. Fifth, broad definition of research covers all types of biomedical research but 
activities not directly falling within a particular research project (procurement in 
case of secondary use, transfer and storage) are not addressed. 
2.8 Research on the deceased  
Jūratė Šerepkaitė and Asta Čekanauskaitė (Dept. of Medical History and Ethics, Vilni-
us University) discussed whether consent is always required in research on human 
post mortem samples. Different European countries follow very different regulati-
ons on research with samples removed from the deceased, ranging from no 
consent to written consent obtained when the donor was still alive. The latter is the 
case in Lithuania. This makes research on post mortem samples virtually impossible. 
The analysis of legislation from different European countries suggests two possible 
approaches to the consent problem: (a) to obtain consent from the relatives; or (b) 
to set the conditions under which the waiver of the requirement of consent would 
be possible. 
2.9 How does ethical review of research on biological materials compare to 
other types of human research? 
Eugenijus Gefenas (Dept. of Medical History and Ethics, Vilnius University) posed 
the question how ethical review of research on biological materials compares to 
other types of human research in the Baltic States. First, in Lithuania, the same 
rigid requirements as those applied to clinical research (e.g. specific consent, REC 
approval of every project, third party insurance of the PI and the sponsor) are also 
pertinent to prospective studies on human tissue samples, even though the latter 
type of research seems to present fewer risks. Second, there seems to be an asym-
metry between the stringency of regulations for the national genome projects and 
other types of research on human biological materials. In Latvia and Estonia, na-
tional genome projects are regulated by specific legislation which defines clear 
standards for the collection, storage and research use of biological samples. In 
addition, these biobanks have been assigned specific ethics bodies that supervise 
their activities. At the same time there is no specific national legislation to deal with 
research on other collections. Third, regulations are often vague and unspecific. 
For example, there are no clear criteria under which conditions the waiver from 
the requirement of informed consent can be granted; the strategy to re-contact the 
donor seems not to be defined in any national documents; there seem to be no 
specific provisions to use discarded pathological specimens without personal iden-
tifiers or pathological specimens after the required period of their storage is over. 
Christian Lenk concluded the workshop by emphasizing the fact that many 
non-specific regulations hamper the work of RECs, which in many cases do not 
have proper guidelines. However, it is not clear whether the introduction of  
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another European guideline would be helpful in this situation. Perhaps it would be 
better to stick to the current principles and try to make them more concrete. Ac-
cording to Lenk, more work is needed to clarify current contradictions before pro-
ceeding with new legal developments. 
3 Results 
Most of the workshop was devoted to the country reports (four countries and a 
special report on the situation in Belarus) with a special emphasis on the large-scale 
population biobanks and the secondary use of human biological materials for rese-
arch. The main results are the following: 
 The legal developments in the field of human tissue research in Poland 
and the Baltic States were shaped to a large degree by the integration into 
the European structures (EU and CoE). 
 The only countries that have specific laws regulating activities of biobanks 
are the ones that have implemented national genome programmes (Esto-
nia and Latvia). However, these laws do not cover other types of bi-
obanks. 
 In most cases of research on human biological materials that does not fall 
within the remit of the national genome projects there is either a lack of 
regulation, or regulations are not sufficiently specific in relation to differ-
ent types of biomedical research. In Lithuania, for example, the regulations 
on prospective research on human biological materials are rather strict, 
since they mirror those applicable to clinical research. The lack of specific 
regulations may also result in insufficiently nuanced systems which do not 
provide a possibility for any type of expedited review for research that in-
volves only a minimal risk. This is the case in both, Poland and the Baltic 
States. Finally, research on human biological material may not be reviewed 
by the RECs at all, as is usually the case in Belarus. 
 The lack of specific regulations in the field of human tissue research in 
contrast to the presence of legally-binding regulations of research involv-
ing physical or psychological interventions in humans seems to mirror the 
development of the Council of Europe guidelines where human tissue re-
search is regulated by a recommendation instead of a legally-binding doc-
ument. 
 Research on biological materials removed from the deceased follows very 
different regimes in this country group. In Estonia, Latvia and Poland it is 
possible to remove materials from the deceased without consent for the 
purposes of scientific research, while in Lithuania consent must be secured 
while the donor is still alive. 
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To sum up the mentioned particular points in the context of the Focal Theme A, 
two more general observations can be made: 
 First, the situation in Poland, Belarus and the Baltic States encourages to 
pay more attention to the possibility of situations where very different le-
gal regimes in terms of their content and stringency are applied within a 
single country in relation to different types of human biological materials 
obtained and used in research, e.g. very detailed regulations with regard to 
population biobanks as compared to non-specific or even absent norma-
tive framework in other types of tissue research.  
 Second, having only very general legal documents may lead to the situation 
where discrepancies and ambiguities emerge as soon as there are any di-
gressions from the most common scenarios for which the legislation was 
put together, e.g. when the normative framework developed for clinical 
trials is applied to the research procurement of biological materials which 
otherwise would be discarded, or legal documents dealing with procure-
ment  of and research on tissues from the living are applied to the tissues 
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1 Introduction 
Whilst in the course of the Tiss.EU project the major ethical and legal challenges 
have been outlined, the Final Status Conference aimed at providing answers to the 
most outstanding issues in human tissue research, as there are issues of informed 
consent, privacy protection and the balancing of individual and public interests by 
adequate governance mechanisms. The conference was organized by the project 
coordinator Christian Lenk and Katharina Beier in cooperation with the project part-
ner Nils Hoppe from the University of Hannover.  
In order to do justice to the ambitious goal of the conference, the organizers 
targeted invitations to seven keynote speakers being known as legal and ethical 
experts in this field. In addition, the conference was enriched by contributions that 
have been accepted due to a call for papers that was announced in the European 
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research community. Except for the keynote talks which were held in plenary ses-
sions, the other papers have been presented in parallel sessions focussing on the 
topics “Trust, privacy and data protection”, “Rights of donors”, “Vulnerable 
Populations”, “Biobank Governance” and “Informed consent”. The scientific 
discussions were additionally enriched by the participation of several biobanking 
practitioners – mostly from Germany and a panel discussion with four stakehold-
ers at the first evening of the conference. In total, almost 80 participants, speakers 
included, from all over Europe took part in the Final International Tiss.EU con-
ference at the venue “Paulinerkirche” in Goettingen from 19-21 January 2011.   
2 The Contributions 
The conference commenced with a general introduction into the Tiss.EU’s major 
topics and research questions by the representative of the coordinating institution 
in Goettingen, Christian Lenk. In his talk he emphasised the importance of biobank 
research by pointing out to a variety of existing biobank projects on different levels 
(transnational, national, local, small-size biobanks) and gave an outline of the most 
pressing ethical and legal questions in this field. In particular, as regards patients’ 
rights and participation in the context of large-scale biobank research, he asked 
whether it is still acceptable to capture patient participation in terms of an individ-
ual right or whether a governance model might be more suitable to tackle this is-
sue. Another problem relates to informed consent in biobank research. According 
to Lenk, we are not only confronted with different concepts (specific, broad, open, 
blanket consent) and contexts (epidemiological vs. disease-related biobanks), but 
also with the more general question whether informed consent might be dispensa-
ble at all in biobank research. Thirdly, there is the issue of trust and data protection 
in biobanking. Given that trust is an inevitable precondition for the enrolment of 
healthy volunteers, there is the need to balance the participants’ rights to infor-
mation as well as the researchers’ interest in accessing samples and data on the one 
hand, and the maintenance of secrecy of personal information on the other. In 
addition, it seems most appropriate to establish special safeguards regarding vul-
nerable populations, including amongst others, children, mentally handicapped 
people or patients with severe psychiatric disorders. Finally, Lenk addressed the 
question of property rights in human tissue samples. Starting from the fact that 
there is no common perception of this issue across the European Member states, 
Lenk questioned the relevance of property rights in this context and asked whether 
we should not rather be concerned with the establishment of adequate rights of 
control. In his conclusion, he stressed that the ethical and legal issues of human 
tissue research are already tackled by a number of national and also EU docu-
ments. However, as there are diverging national traditions it is up to debate wheth-
er we need a more homogeneous regulation of biobank research in Europe.     




In the first key-note talk Judit Sándor, Professor and Director of the Centre for 
Ethics and Law in Biomedicine at the Central European University in Budapest, 
went into the genesis of the biobank concept. In her analysis she interpreted  
biobanks as a “benevolent legal fiction”. Although a biobank clearly does not func-
tion as a bank, Judit Sándor argued that our fiction to call it a bank serves an im-
portant benevolent purpose, e.g. the generation of trust and the idea of personal 
benefits which in the long run will enhance participation rates. The same is true for 
the quite common practice of handling samples as data. Although the underlying 
assumption is clearly false, the fictional equation of samples with data serves an 
important purpose: it enhances the rights of the individual on her samples. Against 
this background, Sándor stressed the necessity of different dimensions of privacy 
protection due to different potential harms, as there are: loss of control on person-
al data; exposure to unwanted observation; misuse of data or potential human 
error. In particular, she argued for a project-specific assessment of privacy issues: 
whilst genetic tests and commercial or forensic uses are undoubtedly of substantial 
interest to the individual, this is less true for population or epidemiologic research. 
However, besides different practical contexts, privacy rights are also strongly 
shaped by cultural norms and expectations. According to Sándor, we should thus 
perceive of privacy as an important, though a limited and culturally contextual 
right.  
The second key-note speech by Graeme Laurie, Professor of Medical Jurispru-
dence in the School of Law at University of Edinburgh and Director of the 
SCRIPT research centre, focused on the protection and promotion of public and 
private interests in biobank research. Whilst it is often argued that there is an inevi-
table tension between public and private interests in this field, according to Laurie, 
their reconciliation is possible. He fleshed out his thesis by pointing out to the 
special governance model of UK Biobank. As it builds on an “Ethics+” approach, 
it exhibits several advantageous features for meeting the ethical challenges related 
to UK biobank as a national resource. In particular, Graeme Laurie argued, the 
Ethics and Governance Framework (EGF) of UK Biobank appears as a “living 
instrument” due to its reflective and anticipatory governance mechanisms, e.g., an 
in-tandem development of project and ethical oversight and the implementation of 
revisions in the EGF due to unforeseen developments. In addition, the UK Bio-
bank Ethics and Governance Council succeeded in engendering a form of “institu-
tional distrust” by holding a mirror to UK biobank on a regular basis. Coming to 
the reconciliation of public and private interests, Laurie argued that it is indispen-
sable to make these interests explicit. In addition, whilst exclusive access is not 
desirable, access should at least be limited to health benefits and an overt commit-
ment to benefit-sharing should be made. Furthermore, Laurie admitted that public 
consultation is not sufficient anymore and has to be replaced by more active partic-
ipation in governance mechanisms. In particular, a stakeholder model that builds 
on a partnership between stakeholders and the management of the biobank ap-
pears as a promising road for establishing a dynamic process of dialogue. Laurie 
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concluded his talk by summarizing some requirements for ensuring that a biobank 
is in line with the public interest, i.e. to protect proportionally individual rights to 
privacy and confidentiality, to actively promote access to the resource on sound, 
scientific, ethical and legal principles and to commit responsibility to benefit shar-
ing. 
In the third and final keynote talk of the first day, Anne Cambon-Thomsen, Direc-
tor of research at the French National Centre for Scientific Research (CNRS), 
outlined the European approach to the ethics of biobanking from different per-
spectives. She started at a more general level by highlighting specific tensions of 
values in the field of biobank research and also gave an overview on the regulatory 
landscape of ethical issues in the European Union. She concluded from this that 
partial aspects are approached in different ways. For example, whilst therapeutic 
use of biological materials is covered by a European Directive, other fields where 
safety and public health aspects are concerned are subject to much stronger regula-
tion. Given the variety of activities in the field of biobank research, their coordina-
tion remains an important task in future. In this context, Cambon-Thomsen identi-
fied several “switches” in the landscape of biobank research – from biological 
material issues to challenges about data generated; from time-defined use to unlim-
ited timeframes, from defined uses to undefined uses; from team related research 
to international sharing; from separation of clinical and scientific research use to 
blurring limits; from research teams to research infrastructures, from a biobank to 
a network of biobanks, from prior ethics committee opinions to sustainable gov-
ernance structures. Following Cambon-Thomsen, these changed dimensions in 
time and organization can be labelled as “biobank-omics”. Coming to the ethical 
regulation of this field, she identified amongst others tendencies towards larger 
consent the possibility of follow-up, more sophisticated data security control, em-
powerment of Research Ethics Committees and specifications of what will be 
done after death. Beyond internal government mechanisms, Anne Cambon-
Thomsen finally described the aims of the Biobanking and Biomolecular Re-
sources Research Infrastructure (BBMRI) as a platform for harmonising ethical, 
legal and societal issues of biobank research on European level. Therefore, the 
BBMRI has set up an ELSI working group for designing a framework for such an 
infrastructure. In particular, it should include a methodology to address public 
perceptions, a coordinated review process and a data protection policy for cross 
border data transfer and tools that can facilitate harmonisation. Although empirical 
studies document general positive attitudes across the European population to-
wards biobank research, Cambon-Thomsen stressed that this support is neither 
unconditional nor irreversible. For the future of biobanking she thus argued to “go 
ahead, but proceed with caution” by making trust as a key-matter in this regard.      
The first day ended with a panel discussion moderated by Christian Lenk on the 
question whether there is a need for a more homogeneous framework for human 
tissue research. The four invited discussants – Graeme Laurie, representing the per-
spective of the UK Biobank Ethics and Governance Council, Judit Sándor as repre-




sentative of the human rights and international law perspective, Anne Cambon-
Thomsen representing the European Group on Ethics and finally Georges Dagher as 
representative of the BBMRI – elaborated their position on different aspects in 
regard to this general question. During the discussion it became apparent that all 
four speakers seemed to be in favour of at least some form of harmonization. 
However, beyond this general consensus they were also very much aware of exist-
ing obstacles. For example, it was stressed by Judit Sándor that people in Europe 
are concerned about different things. Even the quantity and quality of samples 
does matter in their assessment of biobank research. In addition, she suspected 
that a harmonization of the ethical and legal conditions for biobanking might cre-
ate a stricter regime of regulation. As a consequence, there might be a preference 
to use samples under the former framework rather than the new, harmonized one. 
Despite these obstacles, the representative of BBMRI, Georges Dagher, argued 
clearly in favour of some form of harmonization. According to his judgment, the 
BBMRI might even function as an independent driving force on European level. 
According to Graeme Laurie, another pathway towards harmonization in the field 
of biobanking could emerge by sharing best practices on a global level. Finally the 
panel discussion was opened for questions from the audience. The questions were 
related to the four discussants’ statements in the panel discussion but also to the 
three key-note talks presented before. 
The first talk of the second day was given by David Townend, Associate Profes-
sor of the Law of Public Health and Care at Maastricht University, who presented 
a co-authored paper by Knut Ruyter on the issue of consent in biobank research. 
For explicating the particular challenges, he employed the analogy of medicine as a 
road. Whilst we have been travelling the road of autonomy, individual patient 
rights in the context of clinical research, this road is not applicable to biobank 
research in the same manner. According to Townend, the reason can be found in 
the different nature of harm. In biobank research we are not concerned with the 
risk of the first intervention, but rather with risks connected to secondary pro-
cessing of samples and data. For dealing with this different kind of harm he ex-
plored the possibility of choosing another road, i.e. turning to alternative consent 
forms, as there are broad, open or blanket consent. However, Townend dismissed 
this option on the account that it is still “thinking” in the mechanisms of consent. 
In fact, Townend argued that since information on sample usage can never be 
definite due to the open-ended nature of biobank research, this might not be ac-
ceptable to many people. In his further talk, he discussed two alternatives to in-
formed consent. For example, the European Data Protection Directive allows for 
a waiver of consent provided that the research is in the public interest. Although 
this entails the difficulty of deciding when the public interest should apply and who 
has the right to make this decision, Townend argued that the “public interest” is 
not substantially different from other competing interests since the former still 
consists of individuals rather than an abstract mass. Consequently, there are situa-
tions in biobank research where the rights of others might legitimately override 
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individual interests. As another alternative, Townend pointed out to the “register 
of sensitivities” as it became established with the Norwegian Health Research Act 
(§28). According to this provision, material collected by the health service may be 
used for research purposes without the patient’s explicit consent, provided that the 
research is of significant interest to society and the participant’s welfare and integri-
ty are ensured. In addition, all patients have to be informed on the possibility of 
opting-out and researchers are obliged to check their research project with the 
register in advance. Townend concluded his talk by admitting that the opt-out 
scheme is based on a rather passive citizen model; however, according to him there 
is no substantial reason, why opting-in mechanisms would be per se superior to opt-
out models. Notwithstanding this, there is good reason to search for more interac-
tive forms of participation. In particular, Townend envisioned a portal where peo-
ple can upload their particular sensitivities and inform themselves about ongoing 
research activities. 
After David Townend’s presentation the conference went into parallel ses-
sions. Panel A (chaired by Judit Sándor) focused on trust, privacy and data protec-
tion, whilst panel B (chaired by Renzo Pegoraro) dealt with the issue of donor rights. 
2.1 Trust, Privacy and Data Protection 
Liam Curren, researcher in law at the HeLEX Centre for Health, Law and Emerg-
ing Technologies at the University of Oxford, presented a paper co-authored by 
Nadja Kanellopolou, Jane Kaye, Prodromos Tsiavos and Edgar Whitley. In his 
talk, Curren outlined the aims of the EnCoRe project, a multidisciplinary UK re-
search project between academic and industrial partners. The primary goal of the 
project is to facilitate the giving and revoking of consent for participants in  
biobank research, thus accrediting participants with a higher level of control over 
their own information and promoting trust in the biobank. For this purpose, the 
EnCoRe project works closely together with a local biobank in Oxford. In the 
beginning of his talk, Curren gave an overview over how the informational land-
scape presents itself in our time: data subjects give away their information to a 
variety of contexts while relinquishing all control over said information. This prac-
tice holds particularly true for the internet; users usually do not know who controls 
their data given to websites such as Google or Amazon, or what is going to happen 
to their information. Curren then introduced the notion of user-centric systems of 
dealing with personal information, which are in line with the discussion about a 
possible revision of the European Data Protection Directive. The aim of the Di-
rective, according to Curren, is to promote participants’ control over their data and 
to improve information privacy rights for data subjects. In this context, Curren 
spoke out in favor of a model of “dynamic consent”. Consent in this view is seen 
as a dynamic process, as opposed to “static” consent that is given once, with the 
participants relinquishing all future control over their information. In order to put 
the theory of dynamic consent into practice, Curren referred to “participant-centric 




technology”. In the case of the EnCoRe project, the plan is to set up a simple and 
usable interactive website where participants can enter their preferences for the 
whole duration of the research project. These preferences are then fed to the re-
searchers and clinicians involved, ensuring an ongoing dialogue between all parties 
concerned as well as transparency of the research done on the participants’ data. A 
prototype of the website is scheduled for July 2011. 
Eugenijus Gefenas, Associated Professor and Head of the Department of Medi-
cal History and Ethics at the Medical Facility of Vilnius University, presented a 
paper co-authored by Vilius Dranseika and Jurate Serepkâite. Gefenas started his 
talk by identifying three different types of residual human biological materials: 
leftover materials, materials archived during the compulsory storage period, and 
materials archived after the compulsory storage period. Each of these types re-
quires a different type of consent: While for archived residual materials, “tradition-
al” re-consent is sufficient for their secondary use, with leftover materials, more 
“flexible” modes of consent are needed, like broad or presumed consent. Further 
regulatory asymmetries result from the divergent implementation of these modes 
of consent in different countries and the varying treatment of population- and 
disease-based biobanks respectively. Whereas population biobanks usually require 
additional measures like special laws, assigned research ethics or governance bod-
ies, or clear operational procedures for data safety, the research on residual materi-
als, in most cases, is less stringently regulated. There is however no difference to be 
found between population- and disease-based biobanks when it comes to the ques-
tion of the donors’ privacy and autonomy. So where does this contrast in stringen-
cy stem from, and is it realistic to strive for equal stringency of ethical regulations 
regarding the research use of both leftover and archived residual materials within a 
country? Gefenas thinks it is. In his conclusion, he thus argued for a stringency of 
regulatory oversight, referring to the principle that “research projects imposing 
equal risks on research participants should be subjected to equally stringent over-
sight procedures”. 
The final presentation in this session was given by Shawn Harmon, a research 
fellow in Medical Law & Technologies at Imogen and SCRIPT, and Kuan-Hsun 
Chen, a PhD research student at the School of Law, both at the University of Ed-
inburgh. Harmon started his part of the talk by stating his objective: to discuss 
competing interests in the biobank and genomic research settings focusing on the 
substantive issue of data-sharing. To illustrate, Harmon went on to describe the 
new research model in biobanking that is, among other things, interdisciplinary, 
collaborative and segmented, and relies on new and quickly evolving technologies. 
With this new model in mind, it is essential that bioscience is based on certain 
values such as solidarity, justice, and honesty in order to retain public trust. Data-
sharing is another key feature for advancing values within the new research model, 
but it is weighed down by the fact that science culture often acts as a counter to 
sharing achievements. In Harmon’s view, the key is to identify to what extent sci-
ence-relevant laws and policies recognize the new model, and what they say about 
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data-sharing and about the competing interests at stake. In the second part of the 
presentation, Kuan-Hsun Chen went on to talk about the governance legal frame-
work, which is both complex and contradictory. Although there are a number of 
governance instruments that promote sharing, they also recognize limiting con-
cepts such as consent, confidentiality and privacy. Chen gave a few examples 
where these instruments can be found at the highest level of law, like the CoE’s 
Additional Protocol on Biomedical Research (2005) and the UNESCO Interna-
tional Declaration on Human Genetic Data (2003). He then went on to present 
possible solutions to the complexity found in the regulation of conducting re-
search. After identifying some key problems, he outlined a possible way to strike a 
balance between public and private interests. Possible solutions, according to 
Chen, include public participation in science/biobank governance and harmoniz-
ing practices regarding data-sharing. To sum up their presentation, Chen posed a 
number of key questions for this new approach, for instance how important it is to 
get all relevant stakeholders to agree on standard principles and harmonized prac-
tices across borders, and how to find the appropriate balance between pro-data-
sharing and countervailing policies and mechanisms. 
2.2 Rights of donors 
Jasper Bovenberg, a Dutch lawyer and director of Legal Pathways Institute for Health 
and Bio-law, introduced a novel model of how the donors’ inequity in biobank 
research could be remedied. By talking about inequity, he particularly referred to 
the problem of commercialization and the donors’ “cash and control inequity” 
resulting from this. Whilst people usually give their bodily materials for free and 
are even prevented from any remuneration, biomedical research enterprises are in 
the position of making profits of it. Bovenberg criticised this as an inacceptable 
double-standard. In fact, donors might either receive direct control through prop-
erty rights, or through indirect governance mechanisms, such as benefit sharing. As 
Bovenberg’s preference is with the latter, he argued for a “shares for sample-
sharing” model. This is not without precedent, as the Dutch company Johnson & 
Johnson offered shares on the Crucell PER.C6 cell line. Following Bovenberg’s 
suggestion, the share of donors does not necessarily represent a financial gain, but 
might rather allow for rights that are proportionate to their shareholding. Being 
aware of the fact that commercialization on the one hand often appears as stum-
bling block to biobank research, but on the other hand is inevitable, e.g. for the 
development of vaccines, Bovenberg argued that by assigning donors a share in 
their samples they might obtain a say in both, the governance and the gains of their 
samples. In the following discussion it was, however, questioned whether this 
model is suitable on a practical level given that people ask for benefit sharing on a 
collective rather than an individual level.  
Miguel Ruiz-Canela, Associate Professor at the Department of Biomedical Hu-
manities at the University of Navarra in Spain, presented a paper co-authored by 




Marta Saénz de Tejada on the impact of the Spanish Biomedical law on the con-
tent of consent forms in pharmacogenetic studies. They presented results of an 
empirical study that particularly examined whether the new law contributed to an 
increase of information in the consent forms regarding the donor’s right to disclo-
sure of his genetic results. As a general result, Ruiz-Canela and his colleague ob-
served an increase in information about the right to disclosure. In particular, im-
provements were found concerning the donor’s general right to ask for their ge-
netic data and the information about the right not to know. In total, however, 
information on disclosure is still scarce. In addition, there is also a gap between 
providing information on disclosure of results and an explicit offer for proving 
access to results. According to Ruiz-Canela these findings might indicate that re-
searchers are more interested in fulfilling legal requirements than in really acting in 
the interest of donors. In this light, the inclusion of information in consent forms 
appears as a rather formalistic act, leading to an oversimplification of research 
ethics. In fact, given that 48% of the research participants, but only 17% of re-
searchers support the disclosure of results to individuals, Ruiz-Canela stressed the 
necessity of increased research in this field in order to show more respect for par-
ticipants, but also for applying the rule of disclosure in the donor’s best interest. 
The final presentation in this session was given by Allane Madanamoothoo, a 
PhD student in Private Comparative Law at the University of Toulouse in France. 
She discussed the ethical, medical and legal aspects of cord blood banks. After 
outlining some basic organisational and medical facts on cord blood banks, 
Madanamoothoo went into the discussion of some ethical and legal challenges that 
apply to both, public and private cord blood banks. In particular, Madanamoothoo 
addressed the issue of property – who is the owner of the cord blood? A second 
concern relates to the safety of the cord blood and the question which require-
ments for consent should apply. As a particular concern for public cord blood 
banks, she further pointed out to the issue of sustainable funding and the fact, that 
cord blood in public banks is not necessarily available to the donating child/the 
family. Private cord blood banking, however, is very expensive and it could be seen 
as discrimination in health matters since not all can afford it. Another issue derives 
from the fact that the ability to use cord blood from a private bank depends on its 
economic viability. Finally, there is also criticism on the way of advertising cord 
blood banks as it might pressure couples to donate cord blood just for the profits 
of private companies. In the last part of her talk, Madanamoothoo described the 
current legal situation for cord blood banking in France. At present, there is no 
legal provision in place; however, in 2010 a bill was introduced to promote the 
organisation of umbilical cord blood banks in the country. In summary, Mada-
namoothoo argued that cord blood banks should be allowed for the sake of the 
individual’s autonomy, but should be subject to thorough regulation. 
After the first parallel session, the conference proceeded in plenum with the 
fourth keynote talk. Margit Sutrop, Professor of Practical Philosophy at the Univer-
sity of Tartu (Estonia), approached the issue of informed consent in biobank re-
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search from a philosophical point of view. She started her talk with the observa-
tion of a growing dissatisfaction with the prevalent individual rights-centred ethical 
framework and asked whether the protection of individual interests might have 
gone too far. In particular, given that the limits of informed consent, but also the 
principles of autonomy and privacy can hamper research, Sutrop argued that there 
is reason for re-thinking the current ethical framework. In fact, there are examples 
of alternative consent requirements in the case of human genetic databases (open 
consent). Furthermore, the Estonian Electronic Health Record system does not 
foresee consent at all but rests on an opt-out system and if it comes to forensic and 
biometric databases there is neither a consent required nor an opt-out rule fore-
seen. Sutrop pointed out the different justifications behind these approaches. In 
the case of genetic databases the establishment of a broad consent rule can either 
be explained by an instrumental argument (i.e. “impossible to obtain informed 
consent”) or a substantial argument (“genetic information is by nature shared by 
others”). According to Sutrop, the Estonian Electronic Health Record system can 
be interpreted as “soft paternalism” approach as it rests upon a restricted right to 
autonomy: whilst participants cannot make a decision to drop in, they can at least 
refuse the disclosure of their data. The rationale of this system can be explained by 
the expectation that the electronic health record will support the public interest. 
However, Margit Sutrop admitted that these arguments in favour of the public 
interest or the common good are somewhat vague and can easily become manipu-
lated. She thus argued for a less dichotomised understanding of the public-/private 
interest divide. In fact, so-called conflicts between public and private interests can 
often be reconceptualised simply as conflicts between two individuals. Further-
more, Sutrop criticized the prevailing understanding of autonomy as a too narrow 
one. Rather than focussing merely on autonomous decisions, we should take the 
deeper implications of moral autonomy into account, for example, by respecting 
the will of demented people. In addition, the public debate might contribute the 
promotion of individual autonomy as it may enable people to express their person-
al interests and even to understand public interests as their personal ones. Accord-
ing to this ideal of deliberative democracy, individual autonomy is respected by 
allowing the individual to engage in meaningful public debates on values and their 
respective balancing. In her conclusion, Margit Sutrop argued that it is not justified 
to abandon the individual right of autonomy, but we also should not perceive of it 
as an absolute right. In addition, she stressed that the concepts of public or com-
mon good should not be manipulated in order to promote particular interests in 
the guise of common ones. 
The fifth keynote talk of this conference was given by the Danish doctor and 
philosopher Søren Holm who currently works as a Professor of Bioethics at the 
University of Manchester. In his presentation he discussed the issue of using mate-
rial from children. By looking at the age statistics of the PG3 project, Holm 
showed that besides the obtainment of material from newborns, there are several 
large studies with children and even children-parent cohorts across the countries of 




the European Union. He thus raised the question whether parents can validly con-
sent to the biobanking of their childrens’ tissue. On the one hand it could be ar-
gued that this is not in the best interest of the child; but on the other hand, the 
contrary argument might also be applicable. The parents’ decision to biobank their 
childrens’ biological material could then be compared to other things parents are 
usually allowed to give proxy consent to. A rather strict reading of article 17 of the 
Council of Europe’s Convention on Human Rights and Biomedicine does not yet 
support this latter suggestion. However, while it prescribes the protection of per-
sons not being able to consent due to a state of illness or disability, following 
Søren Holm’s analysis this is not applicable to children since childhood is no dis-
order but rather a human condition. Given this rather negative finding, he thus 
approached the issue from another perspective. In particular, he asked whether the 
fact that we all have an interest in research might matter here. Although we might 
have a prima facie obligation to contribute to research, Holm conceded that this 
obligation does not only have to be balanced against other obligations and interests 
but that the personal costs of participation can even outweigh this obligation. In 
the remaining part of his talk, he went into the question what rights children 
should have in relation to their banked tissues and information at the time when 
they become competent decision makers. According to his analysis the most ac-
ceptable model would be to make the biobank visible, the withdrawal option clear 
and communication easy to the matured child. This issue appears as somewhat 
more complicated if there is a commingling of samples in parent-child cohorts or 
twin-studies. Notwithstanding this, Holm concluded that biobanks storing material 
from children have an obligation to organize the bank in such way that there is a 
real possibility to withdraw and to carefully and clearly set out and signpost the 
withdrawal options rather than “hiding” the bank. In the following discussion the 
Danish philosopher clarified that – since the child is the main stakeholder of the 
respective material – even children at the age of 14 may have a right to withdrawal 
if they are capable of reasonable decisions.  
After Holm’s presentation the conference went again into parallel sessions. 
Panel A (chaired by Jasper Bovenberg) focused on biobank governance, whilst panel 
B (chaired by Katharina Beier) dealt with vulnerable populations. 
 
2.3 Biobank Governance (I) 
Sean Cordell, a Tiss.EU research fellow at the Department of Philosophy at the 
University of Birmingham, started his talk by distinguishing two kinds of interests 
to be addressed by biobank ethics: individual interests like privacy, autonomy or 
protection, and socio-political interests like public health or the well-being of fu-
ture generations. Purely individual models are not adequate, according to Cordell, 
so he went on to outline two alternative models: broad or future consent, which 
has the potential to do justice to the multiple purposes of biomedical research; and 
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the “stakeholder” model, with its wider scope including participants like the board 
of directors, ethics committees, funders and the wider public or society. Cordell 
went on to distinguish two kinds of biobanking communities and their goods: the 
participant community with its aggregative goods (i.e. goods of individual persons 
which add up into community goods, like “rights”, “interests”, “needs”) and the 
public community with its corporate goods (i.e. goods attached to a community 
itself and distinct from those of the particular individuals within the group, like 
“heritage”, “culture”, “cohesion”). In his conclusion, Cordell argued that it is vital 
to distinguish the relevant communities of biobank ethics and their ethically im-
portant goods. He suggested that goods such as public health, research and pre-
serving genetic heritage are best understood as corporate, as aggregative models 
fail to capture the ethical features of these goods. 
Jane Kaye, Director at the HeLEX Centre for Health, Law and Emerging Tech-
nologies at the University of Oxford, focused on feedback to participants in ge-
nomics. To start off her talk, Kaye remarked on the nature of genomic information 
in our time: it is increasingly difficult to make information anonymous, and the 
increased amount of information on individuals also increases the likelihood of 
identifying serious treatable conditions and incidental findings. Kaye posed the 
question whether there is an obligation to feedback to participants in genomic 
research, and if, what kind of data should be fed back. To illustrate her theoretical 
findings, Kaye quoted the UK10K project as an example. This (Wellcome Trust 
funded) project’s aim is to better understand the link between low-frequency and 
rare genetic changes by studying 10,000 genome sequences.  The project is super-
vised by an Ethical Advisory Group, of which Kaye is a member, and whose remit 
it is to provide guidance for investigators on consent and feedback issues. Kaye 
went on to distinguish two types of findings in the project: findings that pertain to 
the disease being studied – with this type, feedback to participants is generally en-
couraged – and findings that are incidental to the research aims, but not necessarily 
of lower clinical validity or significance. As laid down in the project’s policy docu-
ment, UK10K researchers have no obligation to search for potentially significant 
findings; they do, however, have an obligation to establish management pathways 
to find out if the participants in question have consented for feedback. Kaye made 
it clear that she understands the obligation to feedback as a moral rather than a 
legal one. In concluding, she outlined some possible ramifications of the UK10K 
project: it challenges the clinical/research divide and raises questions about how 
the project fits in with National Health Service financial resource allocation, but it 
also has the potential to enable the translation of results to the participants. 
The session closed with a joint presentation by Matteo Macilotti, a post-doc re-
searcher in Comparative Private Law at the University of Trento, and Simone 
Penasa, a fellow researcher at the Department of Legal Studies, also at the Universi-
ty of Trento. Macilotti started his talk by referring to the distinction between the 
legal treatment of research on the human body and of research on human tissue. 
Whereas the human body falls under the “no proprietary principle”, human tissue, 




once it is removed from the body, is considered an autonomous and independent 
entity. Therefore bodily integrity rights cannot automatically be applied to human 
tissue. In fact, there are two dimensions to be considered when it comes to the 
legal status of human tissue: the material and the informational. While the material 
dimension implies property rights (the owner and the owned object are two sepa-
rate identities), the informational dimension implies rights of personality (though 
the speakers identify the supposed correspondence between owner and owned 
object as a legal fictio). In the actual regulatory framework both in the EU and in 
Italy, there is an overlap between the bundle of property rights and the bundle of 
personality rights. Macilotti pointed out that complete anonymization is impossible 
to achieve, as the material and the informational dimensions are not completely 
separable. As a consequence, Macilotti argued, there is a traceability liability within 
the biobank’s proceedings, as well as a new object of rights – the so-called “corpo-
rality rights” – that develops from the overlap of property rights and rights of per-
sonality. Simone Penasa, in the second half of the talk, elaborated further on the 
aforementioned distinction. In his point of view, there is another multidimensional 
relationship to be found: the individual or personal, and the social-communitarian 
dimension (which belongs to society as a whole). As “corporality rights” involve a 
plurality of subjects and inter-subjective relationships, regulators will have to deal 
with this plurality. Penasa went on to introduce three important questions for a 
possible legal framework: Who is entitled to achieve a reasonable balancing?; 
Should the link between sources be exclusive or mutual?; and: Could the Italian 
legal system act as a virtuous example? With regard to the last question, Penasa 
remained skeptical: though there are many advantages to be found in the Italian 
hybrid-mixed legal system – it combines a very limited legislative intervention dedi-
cated to genetic data treatment with an administrative act to which the legislator 
has substantially delegated the systematic regulation –, the disadvantages of such a 
system are just as great. In particular, the Italian system is characterized by a lack of 
legislative regulation, regulatory particularism, and a “supply function” developed 
by the National Authority for Personal Data Protection. 
2.4 Vulnerable Populations 
The issue of disclosing individual genetic data to research participants was ad-
dressed by Annelien Bredenoord, an Assistant Professor of Medical Ethics at the Uni-
versity Medical Centre in Utrecht (The Netherlands). She started her argumenta-
tion with a sketch of two extreme positions, either full disclosure or no disclosure 
at all. Since neither of these arguments is defended in its pure form, Bredenoord’s 
further argumentation focused on the moral landscape “in-between”. In particular, 
she went into the question whether researchers should disclose genetic research 
results when these are other than or beyond life-saving data. Following her thor-
ough analysis, there are several arguments in favour of disclosure, amongst others a 
positive account of autonomy, arguments of beneficence or the promotion of 
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donor engagement. Although there are also several objections against these argu-
ments, Bredenoord dismissed them by presenting respective counter arguments. 
As an interim conclusion of her analysis she arrived at a prima facie moral duty to 
disclose individual genetic research results; however, this duty has to be considered 
in light of competing values. In the remaining part of her talk, Bredenoord envi-
sioned different practical models of disclosure. After dismissing again two extreme 
positions – either the researcher selects which information will be subject to dis-
closure, or the patient himself decides – she argued for an intermediate approach 
by offering “packages of menu options”. The first package would include standard 
default options, such as disclosure of live-saving data. People would receive this 
information unless they had explicitly indicated that they do not want this infor-
mation. The second additional package would reveal data of potential or moderate 
clinical utility, but compared to the default package it would involve lower benefit 
but higher risks for the participants. The third package would include data of per-
sonal or only recreational significance. According to Bredenoord’s model, all addi-
tional packages that go beyond the default package would follow an opt-in proce-
dure. In addition, the researcher’s obligation to disclosure is rather context-specific. 
According to this qualified disclosure policy the general rule should be: the less 
significant the finding, the looser the duty to return results to the participant. 
Kristof van Assche, a philosopher from the Free University of Brussels, presented 
a paper co-authored by Sigrid Sterckx on the Havasupai case as an example of 
severe misconduct in biobank research. Whilst this native American tribe was orig-
inally approached for the examination of the causes of diabetes amongst its mem-
bers, the research leader gave priority to his own research interests. In addition, a 
consent form was used that was deliberately vague. Moreover, towards the tribe 
only the study on diabetes was mentioned. In truth, however, the samples were 
used for studies on schizophrenia, inbreeding and population migration. Assche 
interpreted this case as an instructive example as it reveals some obvious short-
comings of the present ethical and legal safeguards. In particular, he argued that 
there are factors beyond commonly anticipated risks that must be taken into ac-
count. The Havasupai case reveals that – beyond obvious tangible harms – there 
are also intangible, dignitary harms, e.g. psychological and cultural harms. Conse-
quently Assche argued for a revision of the existing biobank research guidelines in 
order to extend the rights of research participants and to prevent the occurrence of 
dignitary harms in future.  
The last talk of this session was given by Sylwia Maria Olejarz, a PhD candidate 
from Warsaw University (Poland). She focused on the question of how vulnerable 
populations can be protected in the context of pan-European biobank research. 
For answering this question, she applied the concept of “biocitizenship” to this 
field and argued that research participants from vulnerable or stigmatized popula-
tions should ex ante be provided with a “biocitizenship” (that encompasses par-
ticular rights and duties) as a means of empowerment. Olejarz argued that this 
might not only strengthen the rights of vulnerable populations, but could help in 




overcoming the so-called “agency gap” (Winickoff) between the collective of the 
donors and the managers and supervisors of biobanks. In the long run, Olejarz 
argued, this might also encourage participants from stigmatized populations in the 
Eastern European countries to join the project of a pan-European biobanking 
initiative. In the discussion, however, some doubts where raised whether the con-
cept of “biocitizenship” provides for an adequate tool of empowerment as it might 
rather reinforce than remove existing stigmatisations. 
The second conference day ended with the keynote talk of the Norwegian phi-
losopher Bjørn Hofmann, Professor at the University College of Gjøvik, who ad-
dressed once more the issue of informed consent in biobank research. In his analy-
sis he explored twelve arguments that can be found in support of the application 
of a broad consent rule in the literature and dismissed them. For example, by 
pointing out the genuine function of informed consent, i.e. the justification or 
legitimization of otherwise unacceptable or illegitimate actions, he argued that 
broad consent cannot fulfil this task of protection in a comparable way. He also 
criticized current tendencies to adopt consent rules to the specific nature of  
biobank research. In this regard, he dismissed the proposal to answer the issue of 
unpredictability of research by the introduction of broad consent as this would be 
an inacceptable confusion of the motivation for and the justification of biobank 
research. As, according to Hofmann’s further analysis, the premises underlying 
broad consent are also flawed, he cautioned against an easy replacement of in-
formed consent by broad consent rules. Apart from the fact that the current “hype 
of hope” regarding the benefits of biobank research might prove false, Hofmann 
showed himself concerned that something of the genuine function of informed 
consent might be lost throughout this debate.  
The next day started with parallel sessions. Panel A (chaired by Claudio Tambur-
rini) focused on informed consent, whilst panel B (chaired by Nils Hoppe) dealt with 
the issue of biobank governance. 
2.5 Informed Consent 
The Portuguese lawyer Rafael Vale e Reis, Assistant Professor at the Faculty of Law 
at the University of Coimbra, addressed the rather provocative question whether 
we have to boost our concept of informed consent. He started from the assump-
tion that broad consent could be interpreted as an opt-out from informed consent 
for the sake of autonomy. For fleshing out his thesis, he compared the existing 
regulations on biobanking in Portugal and Spain, but also took a look at the Euro-
pean level. In particular, Vale e Reis pointed out the differences between the Span-
ish and the Portuguese regulations which already start at the level of defining  
biobanks. While the Portuguese law employs a rather broad definition (all samples 
whether anonymized or not, whether obtained for research or therapy are per-
ceived of as biobank), the Spanish law adopted a more restrictive interpretation by 
defining biobanks as a collection of samples for diagnosis or research only. Given 
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these differences Vale e Reis recalled the tradition of harmonising biobanking by 
soft law. However, whilst the Council of Europe’s Recommendation 2006(4) re-
quires consent to be as specific as possible, the Portuguese law even stipulates 
informed consent as a rule and interprets the Recommendation as a prohibition of 
broad consent. According to Vale e Reis’ analysis, this is no stringent conclusion as 
of yet. Given that informed consent is usually seen as an instrument of fighting 
paternalism, the imposition of informed consent in the Portuguese law could be 
interpreted as a new form of paternalism. From this perspective, the prohibition of 
broad consent results in a kind of “hyper-protection” of the individual. However, 
Vale e Reis also acknowledged the objections to broad consent; in particular the 
issue that consent in biobank research cannot be informed in the original sense. 
Against the background of this conflict he showed himself in favour of a pragmatic 
solution on this aspect. In any case, Vale e Reis argued that biobanking requires us 
to leave the “comfort zone” of theorizing about informed consent. 
Mark Sheehan, Research Fellow at the Ethox Centre and the Faculty of Philos-
ophy at the University of Oxford, elaborated further on the issue of consent by 
asking whether a broad consent can also be a valid consent and answered this 
question clearly with “yes”. For the justification of his thesis he started from the 
question of what makes consent a valid one. According to his analysis, the most 
important preconditions are the ability of making decisions with understanding and 
by having an amount of information that is material to the decision in question (i.e. 
not all information that is possible). In addition, Mark Sheehan reminded the audi-
ence to the primary justification for the obtainment of informed consent, i.e. the 
respect for autonomy and self-governance which does not include any restriction 
on the range or content of choices or decisions. He illustrated this fact by employ-
ing an analogy of broad consent, i.e. asking a friend for choosing a menu for you in 
a restaurant after having been informed about some general ideas of your likes and 
dislikes. Although Sheehan admitted that there are clearly choices that cannot be 
made autonomously (e.g. giving up all one’s future choices, selling oneself into 
slavery etc.), the general argument that decisions without information are not au-
tonomous decisions is not sound. Moreover, as it can be seen in the restaurant 
example, it would even have absurd consequences. Sheehan thus concluded by 
arguing for a qualified understanding of a valid consent. In practice this would 
mean that patients should be provided with an appropriate level of information in 
order to function as rational choosers. 
As the talk of Luciana Caenazzo, a Research Professor at the Department of 
Environmental Health at the University of Padua, revealed, informed consent is 
also an issue in the context of residual tissue application. In her co-authored paper 
by Renzo Pegoraro she started with a distinction between tissue archives for diag-
nostic purposes and tissue biobanks for research purposes and also described dif-
ferent ways how residual tissue emerges. As Caenazzo made clear, we must distin-
guish between different types of residual materials for deciding whether informed 
consent is necessary or not. For example in case of irreversible anonymized sam-




ples their obtainment might be perceived of as a donation from the donor, whereas 
in case of reversible anonymization the consent should be clear and obtained in an 
opt-in form. In the final part of her talk, Caenazzo outlined some positive effects 
of applying the donation framework to residual tissues: the promotion of solidari-
ty. In fact, studies have shown that participants express an overwhelming readiness 
to donate their leftover tissues for research because of the good it might bring to 
others (their family, friends, or even community members). The likelihood of this 
scenario is strengthened by the fact that residual tissues would otherwise be dis-
carded. In addition, the unease that is related to other forms of donations is not 
the case with residual tissues. Taking these facts into account, Caenazzo concluded 
that a system built on solidarity is likely to increase the credibility and trust of the 
overall biobanking system. 
The session closed with Giorgio Stanta’s presentation of some general ethical 
considerations on residual tissues. The Italian Professor of Pathology from the 
University of Trieste stressed that one major ethical challenge derives from the fact 
that residual tissues are related to clinical records. The pathologists who run the 
respective archives thus have access to all information; however, they are bound by 
the professional obligation of secrecy. From the patients’ perspective it has to be 
stressed that their consent comprises merely the drawing of samples in the course 
of a biopsy or autopsy, whilst the further treatment of obtained tissues is rather 
implicit. In addition, there are several sensitive information related to archived 
tissues; e.g. personal, clinical and pathological data. Whilst the former must be 
anonymized, the latter ones can but must not be coded. In the remaining part of 
his talk, Stanta outlined the basic conditions for a Pan-European archive tissue-
banks network (PatB-network) which will help to collect very large numbers of 
samples in well defined sub-types and promote the collection of sufficient samples 
of rare entities. In this context he pointed out to the necessity of large financed 
studies and voluntary and collaborative participation. As regards the question of 
conflicting public and private interests, Stanta argued that there is a considerable 
alignment of interests in this field. For all actors in transnational clinical research – 
the patient as donor, the researcher as operator, clinicians as users, and patients as 
beneficiaries – it is ethical that tissues are used in the best way and with the most 
efficient results. However, he also admitted that the time for clinical results is very 
limited – often no longer than one year. In particular, there are problems for ob-
taining consent since many patients are already dead after one year (for example 
due to cancer). Stanta further explained that most retrospective studies in adjuvant 
therapy are preliminary researches, in which hypotheses are often tested for the 
first time and expected results are badly defined. Consequently, there is no possi-
bility to give correct information to the patient and in addition, it is difficult to re-
contact patients due to death. In his conclusion, Stanta once more stressed the 
ethical value of clinical research for patients and society.   
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2.6 Biobank Governance (II) 
Mária Šulekovà, a PhD fellow at the Institute of Bioethics of the “Agostino Ge-
melli” School of Medicine at the Catholic University of Sacred Heart in Rome, 
presented a paper co-authored by her colleagues Dario Sacchini and Antonio G. 
Spagnolo. Šulekovà started her talk by giving an overview over the biobank con-
text in Italy. As of now, there is no binding regulatory framework for genetic bio-
banks in Italy, but a network of by-laws and non-binding instruments to govern 
the collection and use of DNA and human tissue. After naming some essential 
ethical principles with regard to donors in biobank research (like autonomy, soli-
darity and the intangibility of the human person), Šulekovà identified five condi-
tions how to govern a research biorepository in the best interest of donors: in-
forming them about the biobank project, informing them about future research, 
guaranteeing privacy protection, offering individual benefits, and guaranteeing 
interdisciplinary counseling. She then went on to outline possible strategies to ful-
fill these conditions, using the “Moli-Sani” project as an example. Moli-Sani con-
ducts an epidemiological study on 25,000 donor samples to evaluate cardiovascular 
and cancer risk factors and its prevention in the adult population of the Molise 
Region in Italy. The project launched a large-scale communication campaign to 
fulfill its aim of creating a “community” for Moli-Sani, where already recruited 
people are meant to keep in constant touch with the project. Šulekovà strongly 
argued in support of a policy for information about future research where the op-
erator of the biobank expresses which kind of research will be excluded in the 
future, if no other prediction can be made. In order to guarantee privacy protec-
tion, biobank projects should use double coding and make it clear whether and 
under which conditions they refuse access to or disclosure of the participants’ 
biological materials or data to third parties. When it comes to individual benefits, 
Šulekovà proposed benefit sharing in biobank research. Patients and healthy do-
nors should be guaranteed high quality sample storage for future autologous use. 
They should also have the possibility to make use of interdisciplinary counseling 
(genetic, psychological, ethical, legal, social) when it comes to the disclosure of 
incidental health findings. 
Virginie Commin, a Jurist at the Centre National de la Recherche Scientifique 
(CNRS) at the Université Paris I Panthéon-Sorbonne, presented a paper on  
biobanks’ financial sustainability and a concept from the European Union Law, the 
SGEI (Service of General Economic Interest). The SGEI concept is laid down in 
Art. 16 and 86(2) of the Treaty of the European Union, where the term is used but 
not defined, and the White book of the European Commission COM (2004)374 
final of 12 May 2004. The SGEI refers to services of an economic nature which 
subject the Member State or the community to specific public service obligations. 
Regarding biobanks, Commin argued, the criteria of the SGEI concept seem to be 
fulfilled: they serve the general interest and are economically active. Commin then 
outlined how the SGEI concept could be applied to biobanks in compliance with 




the European regulation, using a two-tiered approach: on the one hand, a “mini-
mum service” for storage activities at the cost price for access to collections could 
be claimed from academics (dispensatory rules from the rules on competition 
would apply), whereas for industrial partners, there would be an “added-value ser-
vice” for access to collections charged the market price (which would fall under 
the rules on competition). These provisions, according to Commin, could also be 
based upon the EU Tissue Directive (2004/23/EC), or the rules on competition 
(Art. 95) of the aforementioned Treaty of the European Union. In practice, she 
concluded, the SGEI could either fall under the principle of social justice (distribu-
tive justice), be set up as a non-profit storage (a guarantee for sustainable collec-
tions), or as a modification of the biobank entity (a dichotomous functioning 
“non-profit/for-profit”). 
Kristi Lõuk, Project Manager at the Centre for Ethics at the University of Tartu, 
presented a paper on a new ethical framework for non-interventional research. 
Lõuk started her talk by posing some basic questions about consent, governance 
and informational autonomy, then went on to outline her argument. She clearly 
distinguished between interventional and non-interventional research: whereas 
interventional research (diagnostic, preventive or therapeutic) is marked by a risk 
of physical harm, in non-interventional research (for collections or databases), it is 
values like privacy, confidentiality and integrity that are at stake. In the latter case, 
it is impossible for the participants to have meaningful control over their data, 
whereas explicit consent is an essential condition for interventional research. Ac-
cording to Lõuk, research on human tissue samples should be seen as non-
interventional, but there is no reason to presuppose that one ethical framework is 
suitable for all types of biomedical research on humans. Lõuk went on to talk 
about a possible new framework, which should cause neither a relaxation of rules 
nor a slippery slope effect. An important question for Lõuk was if the research 
subjects should be able to control and decide about every possible use of their 
information, leading to a choice between a “rules of the game” (where participants 
give a general consent) or a “tick of the box” (where consent is given to specific 
procedures) approach. Out of all the possible solutions available (like broad or no 
consent, reflexive governance or written authorization), Lõuk prefers having trust-
worthy institutions and giving consent to governance. Trustworthy institutions in 
this sense are defined by a democratic public sphere and technical, procedural and 
control mechanisms. They are institutions in a broad sense, with the general public 
accepting the role they will have. Lõuk closed her talk with a reference to the Es-
tonian Human Genes Research Act (2000), which is currently under debate.  
The final talk of the session was held by Reinhard Thasler, Project Manager at 
BioM GmbH in Munich, who presented a paper co-authored by Isabel Hackl, 
Horst Domdey, Karl-Walter Jauch and Wolfgang Thasler. In the beginning, 
Thasler described how the m4 Munich Biobank Alliance fits into the context of 
current biobanking initiatives with public funding. He then went on to discuss the 
key aspects of their sustainability: market orientation, functionality and public ac-
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ceptance, the latter being highly relevant when it comes to the participation of 
patients in biobanking efforts. In Thasler’s opinion, the milestones towards achiev-
ing public acceptance are respect for the donor, transparency, access and benefit 
sharing, secrecy and functionality. He outlined the perceived balancing act between 
the demand that biobanking has to be self-financing on the one hand, and ban on 
commercialization of body parts on the other hand. Whereas the call for self-
financing leads to a vendor-customer relationship between the biobank and its 
participants, the ban on commercialization points towards a model of trusteeship. 
This model is at the root of HTCR (Human Tissue and Cell Research), a non-
profit foundation under civil law located in Regensburg, Germany. The HTCR 
foundation acts as the patients’ trustee and allocates a minimum of 51% of its re-
sources to academic use and a maximum of 49% to commercial use. Within the 
ten years since its formation, the focus within the existing HTCR ethical frame-
work has shifted from obtaining informed consent to ensuring public benefit and 
trusting the biobank “in general”. In addition, data is no longer transferred anony-
mously, but anonymized yet identifiable. HTCR has also made great progress when 
it comes to transparency, with continuous PR work and evaluation of research and 
algorithms for government within a quality management system. Despite all these 
efforts, Thasler pointed out that it is still an open question whether the HTCR 
model can be applied to existing biobanking networks. 
The conference closed with a last keynote talk given by Georges Dagher, a senior 
investigator at Inserm (Institut National de la Santé et de la Recherche Médicale) 
and representative of the Biomolecular and Biobanking Research Infrastructure 
(BBMRI). He started his talk by outlining the potential of the genetics of diseases. 
In the long run it might help explaining why some become sick whilst others do 
not. This can be seen as main motivation behind all initiatives for the development 
of personalized medicine. According to Dagher, however, there are several bottle-
necks in this context, such as sample shortage, fragmentation of research on na-
tional level, and also ELSI issues. The development of a pan-European and broad-
ly accessible network of existing and de novo biobanks and biomolecular resources 
needs to be seen against this background. About 290 biobanks coming from 51 
institutions and 30 countries expressed their interest in BBMRI. BBMRI will be 
implemented under the ERIC (European Research Infrastructure Consortium) 
legal entity. As a possible legal structure, Dagher envisioned the model of a distrib-
uted hub and spoke structure where one centre is in charge of the coordination of 
this entity. The BBMRI-ERIC headquarter will provide a common access portal to 
resources available in Member states as well as appropriate facilities and expertise. 
The national hubs are also established under the ERIC legal entity and will link the 
national scientific community (e.g., universities, hospitals, research institutions, 
resource centres) to BBMRI-ERIC. Following Dagher, the incentive for Member 
States to join this infrastructure would be an improved quality and interoperability 
of national biobanks and biomolecular resources. Additionally however, there are 
several challenges to deal with in order to start this infrastructure, e.g., amongst 




others the necessity of harmonized processes, incentives for contributors, access 
rules, and the need of a sustainable funding for the next 15 years. According to 
Dagher, there are already some good starting points for a future integration of 
existing biobanking activities – the OECD best practice guidelines for biobanks 
and the P3G international harmonization of biobanks. Looking at the existing 
biobanks, Dagher showed himself in favour of an “adaptor approach”, i.e. rather 
than standardizing everything, criteria should be defined by which samples from 
different biobanks can be collected. In addition, tools should be developed that 
allow for data exchange and cross-border transfer of samples. In the remainder of 
his talk, Dagher described the main features of BBMRI’s policy: the primacy of 
national legislation; no data on individuals will be made publicly available and fair 
access in the context of specific research. In the long run, he expects BBMRI 
working as an “incubator” for regional development (e.g. the establishment of 
biotech and pharma clusters and the opportunity for joint ventures with industry) 
and the accomplishment of cheaper and faster projects.  
3 Results 
In his concluding remarks, Christian Lenk pointed out that the regulation of human 
tissue research is not in its infancy anymore; however, more initiatives in harmo-
nizing this field are needed. On a more general level, the most important insights 
from this conference can be summarized as follows: 
 The third status conference revealed once more that there is European-
wide attention to the scientific potentials, but also to the ethical and legal 
bottlenecks of human tissue and biobank research.  
 One major focus of this conference was on the reconciliation of public 
and private interests. Several speakers thereby argued for a re-
conceptualised and less dichotomized understanding of public and private 
interests in the field of human tissue research. In addition, on a more 
practical level, several suggestions were made for the realization of such 
an alignment of interests. 
 Another point at issue was the conceptualisation of informed consent. 
Whilst the majority of speakers – though from different perspectives – 
argued that a broad consent would be acceptable in the context of human 
tissue research, others were rather reluctant to approve broad consent as a 
valid alternative to informed consent.  
 The issue of biobank governance was addressed in several talks. In 
general, all speakers pointed out already existing governance models, 
guidelines and legislations that can be seen as a step towards 
harmonization in this field. However, it was widely agreed that this is not 
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sufficient yet. In particular, there are pan-European initiatives, such as 
BBMRI, that are still under way. 
 On the other hand, most of the speakers but also the audience were 
rather reluctant to accept a “one size fits all approach” to the governance 
of biobanks. The same result could be found in terms of particular ethical 
and legal provisions, for example the protection of privacy or the 
disclosure of genetic results to individuals. Beyond the two extreme poles 
of full or non disclosure, reasonable arguments for a more nuanced step 
model of disclosure have been brought forward. 
 That regulations should be context-sensitive was an additional insight that 
derived from the discussion on residual tissue application. Whilst these 
materials are expected to make an important contribution to research, the 
burdens for donors are comparably low. For this reason donation might 
be encouraged by a notion of solidarity. 
 Finally, it was almost consent amongst the speakers and the audience that 
there should be more forms of genuine donor participation in biobank 
research. These participation rights should include more rights of control 
and shareholding for the participants. Thereby it was stressed that these 
participation rights should not be confounded with material gains. The 
underlying aim of this democratic approach is rather to give donors a say 
in the application of their samples. In addition, when it comes to 
vulnerable populations, it turned out that beyond these participation 





As outlined in the introduction to these proceedings, the Tiss.EU project’s work-
shops and conferences followed a two-layer structure. Conclusions can thus be 
derived from both perspectives: the analyses of the European Member States’ 
regulation on human tissue and biobank research and the more theoretical exami-
nation of the four Focal Themes.1  Given that the first perspective is at the focus 
of several other project publications (see Beier/Lenk 2011), at this place the pro-
ject results will be mainly summarized along the four Focal Themes, giving the 
country reports a rather explanatory character.  
2 Focal Theme A: 
Procurement, storage and transfer of tissues and cells for 
non-clinical research purposes 
As a general insight from the Tiss.EU project’s workshop and conferences emerg-
es the fact, that in almost every country clinicians and clinical researchers procure, 
obtain and store human tissue samples for present but also future research purpos-
es. In this regard the most crucial ethical concerns relate to the donors’ protection 
                                                     
1  The conclusions in this volume are an extended version of a formerly published article in 
SCRIPTed (2001), 8:1, http://www.law.ed.ac.uk/ahrc/script-ed/issue8-1.asp 
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of autonomy and privacy. Whilst the importance of these issues is acknowledged 
by all European Member States, the means of protection and the type of regulation 
differ not only across the countries, but are also divergent at the level of institu-
tions. In particular, there is a spectrum of regulations ranging from the UK (which 
has a discrete law and other reference Acts on human tissue), over countries like 
Greece or Italy (which make at least reference to some national Acts or Guide-
lines), to countries like Malta or Bulgaria (being only bound by EU legislation in 
this field).  
Notwithstanding this regulative diversity, there is no evidence that countries 
with a discrete tissue or biobank law have necessarily a “better” or more compre-
hensive regulation. Rather, the different approaches tend to have their own 
strengths and weaknesses.2 Whilst Estonia and Latvia, one the one hand, issued 
particular Acts for the regulation of their national genome programs, other types of 
biobank research are left to a legal grey zone. In Cyprus, on the other hand, where 
no national human tissue or biobank law exists, the opinion of the National Bio-
ethics Committee on the establishment and use of biobanks has gained importance 
in the regulation of sample collections. Due to its comprehensive and sophisticated 
evaluation, the Cyprian approach is perceived as a successful example of soft regu-
lation.  
Despite the divergent and multilayered legal landscape in the field of human 
tissue and biobank research, some common practical standards have emerged. For 
example, for the transfer of samples and data it is usually required that the receiv-
ing institution or country adheres to the domestic rules of the sender country. Giv-
en that the value of biobank research increases the more samples and data can be 
consolidated, this provision might promote the incremental legal harmonization of 
the ethical and legal rules in this field.  
Furthermore, the reports gathered in this volume support the impression that 
the obtainment of the donor’s consent is regarded the default condition also for 
research applications of human tissue, but the type of consent (open, specific, 
broad, or blanket) that is required in this context is contested.3 For example, ac-
cording to the Declaration of Helsinki the informed consent of the donor is oblig-
atory (art. 24). However, given the peculiarities of human tissue and biobank re-
search – e.g. its open character regarding research purposes and time, the unknown 
extend of gathered information due to new analysis methods, the collective dimen-
sion due to the involvement of healthy volunteers in long-time studies with poten-
tial impact on future generations etc. – it seems that this requirement is not equally 
                                                     
2  However, it has to be noted that countries with only very general provisions run the risk of legal 
vagueness as soon as deviations from the most frequently occurring scenarios emerge; for exam-
ple, if legal documents that deal with the procurement of human tissues of the living are applied to 
research with tissues from the deceased (see report from the Vilnius Workshop in this volume). 
3  The removal of material from deceased persons follows for example very different regulative 
regimes: whilst in Poland, Estonia or Latvia no consent of the deceased is required for scientific 





applicable to the different kinds of human tissue research. In contrast to epidemio-
logical research projects where donors can be provided with quite detailed infor-
mation, population-based studies are prone to the application of a broad consent 
rule. However, it has been argued by the members of the Tiss.EU project (see 
Lenk et al. 2011 forthcoming), that a broad consent is not inevitably detrimental to 
the protection of the donor’s rights provided that it still allows for a range of in-
formation and individual protection guarantees. Notwithstanding this, it is quite 
likely that the regulation of informed consent remains subject to changes. In par-
ticular, a trend towards less strict interpretations of informed consent can be ob-
served which is triggered by the endeavor to adopt this concept to the field of 
human tissue and biobank research, rather than to abolish it.  
Another issue arises from secondary research purposes that are not covered by 
the donor’s original consent. Whilst the Oviedo Convention requires the informed 
consent of the donor if the removed material is “stored and used for a purpose 
other than that for which it was removed” (art. 22), the Council of Europe’s Rec-
ommendation 2006(4) does allow for a waiver of secondary consent provided cer-
tain conditions are met (art. 22). Against this background some EU Member States 
allow for exemptions if the obtainment of secondary consent is too burdensome 
compared to the high value and low risk of the respective research (e.g. Portugal, 
Spain) or if the research has been approved by a Research Ethics Committee (e.g. 
Denmark, Lithuania).  
Another challenge in the context of procurement, storage and transfer of hu-
man tissue samples and data results from its potential forensic use. For example, it 
turned out that in some countries in the Mediterranean area, but also in at least two 
reported cases in Sweden, the aim of criminal persecution has been given prece-
dence over the protection of individual rights, i.e. the request for an informed con-
sent to the procurement, storage and transfer of samples and data. From the per-
spective of privacy and data protection this might be a startling result which evokes 
the general question of whether the ends justify the means or more practically 
speaking: where to draw the line between high ranking public interests and indi-
vidual interests worthy of protection. This question touches a particular sensitive 
issue because the success of biobank research depends heavily on the donors’ par-





 Katharina Beier 
 
164 
3 Focal Theme B:  
Rights, interests and entitlements in human tissues and 
cells 
Human tissue and biobank research also raises questions regarding the legal status 
of human bodily material. In line with the European Convention on Human 
Rights and Biomedicine (1997, art. 21) and the Council of Europe’s Recommenda-
tion 2006(4) on research on biological materials of human origin (art. 7)4 provision 
that “the human body and its parts shall not, as such, give raise to financial gain” 
almost all EU Member States perceive the human body as res extra commercium. 
However, divergent positions regarding the question of whether donors can be 
granted property rights in their tissue samples can be found across the European 
Member States. According to a strict interpretation of the so-called “no property-
principle” (e.g. in France and the UK) donors do not hold proprietary rights in 
their biological materials. In contrast, other countries’ jurisdictions grant donors a 
property right in their tissues after its extraction from their body. For example, in 
the German-speaking countries the “source” of the removed tissue can still claim a 
de facto property-right for the reason that removed human materials are perceived 
as “continued personality”. Donors do thus not only keep the material disposal of 
their samples, but retain also further rights of control, e.g. the right to decide on 
their tissues’ use for research. Following this approach, an automatic transfer of 
property in human tissues is excluded since donors have to transfer their rights by 
an explicit consent.  
Despite the existence of different approaches to the issue of property rights in 
human tissues and cells, both of the aforementioned accounts seem to be compat-
ible with the above cited EU documents’ provision “the human body and its parts 
shall not, as such, give raise to financial gain”. Taken literally, this wording seems 
neither to exclude proprietary rights in human tissues and cells nor their trading as 
long as this does not amount to financial gains. In fact, a closer look at current 
applications of human tissue samples reveals rather different levels than a strict 
prohibition of commercial practices in this field (see Lenk/Beier 2011). For exam-
ple, the non-commercialisation principle no longer applies if human body materials 
are turned into products (e.g. in Germany); and in Belgium, according to a Royal 
decree of 2009, separated human biological materials become even a “good” with a 
fixed price that can be owned by a not-for-profit biobank. However, the degree of 
sample procession that is needed to convert it into a product is still an open ques-
tion in most national jurisdictions. The same is true regarding the question who 
might then become the rightful owner of the processed material.   
                                                     
4 See for example the European Convention on Human Rights and Biomedicine (1997, art. 21) or the 
Council of Europe’s Recommendation 2006(4) on research on biological materials of human origin 





Against this background, it does not come as a surprise that human tissue re-
search raises also questions of justice: Given that donors on the one hand are 
mostly barred from any property rights in their tissue samples and – in the majority 
of countries – may not receive any remuneration for their donated tissues, re-
searchers or companies on the other hand may derive profits thereof. For this 
reason the interests of various stakeholders involved (e.g. the participants, re-
searchers, biobanks, enterprises) need to be taken more thoroughly into account. 
For example, whilst it might be justified that the operator of a biobank demands a 
fee for covering the maintenance costs of the biobank, this has to be distinguished 
from the obtainment of real profits as they can be made by private enterprises. As 
regards the latter, there are serious doubts that this should be permissible without 
having any benefit sharing procedures with the donors in place. In order to pro-
vide fair shares to all actors involved, practices of indirect benefit-sharing become 
increasingly important in the field of human tissue and biobank research. In fact, 
several empirical studies document that the public is predominantly positive to-
wards participation in this strand of research provided that the benefits of research 
are not for the economic benefit of an industrial enterprise only. This attitude is 
mostly explained by the wish to help those who suffer from a presently incurable 
disease and to prevent future illnesses. In light of this motivation, remunerating 
donors directly in financial terms seems to be beside the point. Participants are 
rather interested in getting a say about the potential research purposes of their 
samples and in being informed of incidental health findings. In some countries, 
such as Austria or Estonia, it is thus obligatory that biobanks provide patients with 
results being of relevance for their health. Moreover, given that biobank research 
involves the participation of healthy volunteers the provision of feedback displays 
an important tool of strengthening the trust between biobank research and its 
potential participants.     
If it is true that donors are mostly interested in maintaining some control over 
their samples it can be doubted whether the concept of property rights is an ade-
quate framework for meeting this rather participation-oriented attitude. As an al-
ternative account, the so-called “bundle theory of rights” suggests that human 
biological materials should not be regulated across the board by the same category 
of rights but rather by a more nuanced perception (Björkmann 2007). In this re-
gard it is also conceivable that property issues become displaced by more urgent 
questions, such as how equal access and efficient usage of human biological mate-
rials for research can be assured, while maintaining the donors’ privacy at the same 
time. 
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4 Focal Theme C:  
Anonymization and pseudonymization as means of privacy 
protection 
The protection of the donor’s privacy is another important issue in the context of 
human tissue and biobank research. As regards the protection of human samples 
and data derived thereof, most Member States refer to their national Data Protec-
tion Laws (implementing the European Data Protection Directive 1995/46/EC). 
The Directive allows for several exemptions for the use of health data “for reasons 
of substantial public interest” (art. 8, §4). However, amongst legal experts there is 
disagreement whether these exceptions are also meant to apply to research (Pöttgen 
2007). In addition, there is considerable disagreement about the provisions of 
anonymization and pseudonymisation of samples and data across the EU Member 
States. 
Although the anonymization of samples and data might be the most effective 
means in protecting donors’ privacy, in the context of human tissue and biobank 
research outright anonymization might neither be desirable, nor obtainable. Its 
desirability is questioned by the fact that only with the donors’ traceability signifi-
cant research results regarding the development of certain diseases can be ob-
tained. On the other hand, the practical realization of full anonymization is chal-
lenged by the possibility of genetic analysis which – at least theoretically – allows 
for univocal individual identification. Taking these limitations of anonymization 
into account as well as the fact that the re-identification of donors is indispensable 
for many research projects, the coding of samples (i.e the code-key is not accessi-
ble for the researchers who work with the samples, but kept separately by an au-
thorized person or body) emerged as the most important means of privacy protec-
tion in the field of human tissue and biobank research.  
As another common feature, several countries (e.g. France, Sweden) are in fa-
vor of exempting anonymised samples and data (i.e. materials that are not easily re-
traceable) from the protection measures which normally apply for sensitive data. 
This implies that there is often no other available safeguard for anonymized sam-
ples than to respect the donor’s explicitly stated restrictions at the time of sample 
donation. However, as it has been stressed in the Swedish country report, there is 
no guarantee that this will be done. In addition, there are doubts that the means of 
anonymization by de-identifying samples might not be a sufficient safeguard, but 
needs to be complemented by options for withdrawal or sample destruction. Fur-
thermore, a balance needs to be found between informing donors of incidental 
health findings, whilst at the same time respecting a donor’s wish of not being 
informed in such a case.  
It was also argued at several workshops that the fragmented terminology in 
this field results in a considerable lack of transparency regarding the effective pro-





terms in the current debate are often overlapping or even contradictory, a point of 
convergence can be found in Recommendation 2006(4) of the Council of Europe 
(see art. 3). By distinguishing between identifiable and non-identifiable materials, it 
avoids looming misconceptions of “anonymity” in this context.  
Taken together, the analyses of the workshops on this Focal Theme suggest 
that the issue of data protection displays as a highly context-sensitive matter; i.e. 
whether the safeguards for the donor’s privacy are sufficient can only be decided 
by taking the goal of the respective biobank as well as the kind of samples which it 
stores into account. Beyond the necessity of a context-specific assessment of pri-
vacy protection measures, however, there still remain a number of ethical, legal and 
technical issues in this field to be solved in future.  
5 Focal Theme D:  
Biobanks 
In the context of human tissue research, biobanking deserves particular attention 
from an ethical and legal point of view. In the last two decades, several countries, 
for example the UK, Sweden or Estonia, have established national biobanks, but 
also the number of local and small-scale biobanks is growing. For this reason,  
biobanks increasingly become the object of ethical and legal regulation. The anal-
yses of the Tiss.EU project group bears on the insight that the public perception of 
biobanks, their practices and their relations to the participants, have a considerable 
impact on the emergence of ethical and legal frameworks in this field. Given the 
different national experiences with biobank-based research in the European arena 
(for example, the Scandinavian countries hold different registries already for centu-
ries, whilst other countries are about establishing their first systematic large-scale 
collections) it does not come as a surprise that also the regulation of biobank re-
search varies across the Member States. The current legislative activities are also 
shaped by aberrations in this field that are to be prevented in future (see for exam-
ple the release of the British Human Tissue Act in 2004 as consequence of organ 
retention scandals).  
At the current stage only few countries feature discrete laws on biobank re-
search or guidelines on particular biobank projects (e.g. Sweden, Estonia, UK). 
There are also countries that have adopted a somewhat wider framework which 
entails research with humans in general (e.g. the Swiss draft for a Human Research 
Law). Still other countries have made biobank research subject to more general 
provisions on public health or biomedical research (e.g. France, Portugal), whereas 
some European Member States have no national regulation in this field at all. It is 
important to note that although countries with national biobanks might be more 
prone to release biobank-specific regulations, according to the Tiss.EU project’s 
country analyses it is neither justified to speak of a general overlap between these 
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two features, nor is it right to conclude vice versa that countries with scattered and 
small-scale collections tend to adopt more general legal frameworks in this field.  
Despite this diversity regarding the scope, type and level of biobank regulation, 
also in this field some common standards have emerged. For example, participants 
in biobank research are usually assigned a right to be informed about the use of 
their samples and data. In particular, if material is stored in a disease-specific  
biobank, the aim and purpose of the collection are well-known to the researchers 
and can thus be communicated to the potential participants. In this context, the 
requirement for obtaining the donor’s informed consent is still applicable. In con-
trast, in the case of population-based biobanks there is an increasing acceptance of 
broad consent models as it is impossible to foresee all potential future purposes 
the samples might become useful for. As an alternative to the donor’s informed or 
broad consent, some countries prefer an opt-in model for the regulation of tissue 
research. In Sweden, for example, human materials obtained in the context of 
health care can be made available for research unless the patient explicitly rejects 
this. However, as the potential drawbacks of an opt-out model are well-known 
from the discussions on post-mortal organ donation, these concerns cannot be 
ignored in the context of human tissue and biobank research either.    
As another common feature, according to most countries’ legislations, donors 
are also granted a right to withdraw their materials from research. However, what 
this right really entails and how it can be assured is still an open question. For ex-
ample, the UK biobank provides for a sliding scale of withdrawal options reaching 
from “no further contact” over “no further access” to “no further use”, whereas in 
Sweden researchers may still make use of the data even after the materials’ with-
drawal. As a matter of fact it is contested in the current debate whether a right for 
withdrawal should be granted immediately (samples might be easily destroyed but 
not necessarily the data) and unconditionally (some types of research might lead to 
profound benefits for the public health, but entail only low risks for individual 
participants) or whether this option should only be admitted when the participant 
can present sufficient reasons for his withdrawal (see Eriksson and Helgesson 
2005). 
In this regard a last issue of this Focal Theme which shall be addressed here re-
lates to the organization of the relationship between participants and the biobank. 
Given the fact that the research purposes stored human tissues will be used for are 
often not clearly defined at the time of sample taking and for this reason (particu-
larly in population-based biobanks) the obtainment of broad consent holds sway, 
the success of biobank research is heavily dependent on the donors’ trust in re-
search. On the account of this, in several countries biobanks are run on a non-
commercial basis and work as a public body for the public good. The so-called 
trust model, which has been most famously suggested by Winickoff and Winickoff, 
is largely in line with this approach. According to this model, the tissue donor for-
mally transfers her property interest in the tissue to the trust and also appoints a 





the property for the benefit of a particular party (for example, the general public in 
the case of a charitable trust model). Whilst this latter model is mostly practiced in 
the Anglo-Saxon countries, alternative models which follow a similar impetus are 
emerging in the European arena. For example, the Norwegian HUNT biobank has 
been established as a ‘for-profit-for public company’. Amongst others, this implies 
that economic benefits gained by the HUNT biobank have to be re-invested in 
medical research for the promotion of the public good (see Solum Steinsbekk et al. 
2009: 148). 
Admittedly, the aforementioned conclusions present only a selection of the 
most pertinent issues and debates in the field of human tissue and biobank re-
search, which naturally leave many questions unresolved. However, our analyses 
revealed at least an increasing awareness of the ethical and legal challenges that also 
come to the notice of politicians and law-makers in the countries of the European 
Union. In this regard it is important to note, that there is neither a “one-size-fits-
all” approach at hand, nor a harmonization in all fields needed. While there is no 
doubt that some harmonization of rules is indispensable in the European arena, 
e.g. to assure safe cross-border transfers of samples, the particular means of regula-
tion allow for a considerable leeway. In particular, there is no reason to assume 
that countries featuring particular human tissue or biobank research Acts are per se 
better prepared to protect the donors’ rights and interests in their samples, than 
countries that regulate this field by reference to more general laws and codes of 
conduct. Whilst this might speak in favor of a context-sensitive regulative ap-
proach by taking the countries’ particular legal and ethical traditions into account, 
this does not exclude improvement and “institutional learning”. For example, 
when the Eastern European countries entered the EU in 2004 and 2007 respec-
tively, the transposition of the European acquis communitaire led to the systematic 
introduction of informed consent into the health care system which was formerly 
not constantly referred to in this context. Another tool for future adaptations con-
sists in the initiative for a pan-European framework, the so-called Biobanking and 
Biomolecular Resources Research Infrastructure (BBMRI) which has been joined 
by more than 280 associated organisations (largely biobanks) from over 30 coun-
tries. Given that the value of human tissue and biobank research increases the 
more repositories can be linked and samples and data be transferred across country 
borders, this initiative is an important step in the promotion of comparable and 
transparent rules for human tissue and biobank research. 
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Human tissue and biobank research is of increasing importance for understanding the causes of widespread diseases and developing 
effective therapies. However, while the success of biobank research depends 
on the availability of a large number of samples and the consolidation of 
collections across country borders is very desirable from the perspective 
of researchers, the legal and ethical requirements for the procurement, 
storage and use of human tissue samples are rather heterogeneous across 
different countries. Moreover, the lack of comprehensive supranational 
regulation on human tissue and biobanking can be seen as posing a serious 
threat to transnational biomedical research. Against this background, it was 
one of the aims of the EU-funded Tiss.EU project (“Evaluation of Legislation 
and Related Guidelines on the Procurement, Storage and Transfer of Human 
Tissues and Cells in the European Union – an Evidence-Based Impact Analysis”) 
to analyse the ethical and legal regulation of human tissue and biobank 
research across the 27 European Member States plus Switzerland. The 
results of nine international workshops and three conferences are gathered 
in this volume. While the country reports evaluate the implementation of 
ethical and legal guidelines at a national level, point out their strengths and 
deficits, and, where required, create an evidence base for the revision of 
said legislation, the conference reports address more general ethical and 
legal issues in this field. The volume is completed by a final presentation of 
project’s results. 
